

## European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support

Charles D. Deakin<sup>a,1</sup>, Jerry P. Nolan<sup>b,\*,1</sup>, Jasmeet Soar<sup>c</sup>, Kjetil Sunde<sup>d</sup>, Rudolph W. Koster<sup>e</sup>, Gary B. Smith<sup>f</sup>, Gavin D. Perkins<sup>f</sup>

<sup>a</sup> Cardiothoracic Anaesthesia, Southampton General Hospital, Southampton, UK

<sup>b</sup> Anaesthesia and Intensive Care Medicine, Royal United Hospital, Bath, UK

<sup>c</sup> Anaesthesia and Intensive Care Medicine, Southmead Hospital, Bristol, UK

<sup>d</sup> Surgical Intensive Care Unit, Oslo University Hospital Ullevål, Oslo, Norway

<sup>e</sup> Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands

<sup>f</sup> Critical Care and Resuscitation, University of Warwick, Warwick Medical School, Warwick, UK

### Summary of changes since 2005 Guidelines

The most important changes in the 2010 European Resuscitation Council Advanced Life Support (ALS) Guidelines include:

- Increased emphasis on the importance of minimally interrupted high-quality chest compressions throughout any ALS intervention: chest compressions are paused briefly only to enable specific interventions.
- Increased emphasis on the use of 'track and trigger systems' to detect the deteriorating patient and enable treatment to prevent in-hospital cardiac arrest.
- Increased awareness of the warning signs associated with the potential risk of sudden cardiac death out of hospital.
- Removal of the recommendation for a pre-specified period of cardiopulmonary resuscitation (CPR) before out-of-hospital defibrillation following cardiac arrest unwitnessed by the emergency medical services (EMS).
- Continuation of chest compressions while a defibrillator is charged—this will minimise the preshock pause.
- The role of the precordial thump is de-emphasised.
- The use of up to three quick successive (stacked) shocks for ventricular fibrillation/pulseless ventricular tachycardia (VF/VT) occurring in the cardiac catheterisation laboratory or in the immediate post-operative period following cardiac surgery.
- Delivery of drugs via a tracheal tube is no longer recommended—if intravenous access cannot be achieved, drugs should be given by the intraosseous route.
- When treating VF/VT cardiac arrest, adrenaline 1 mg is given after the third shock once chest compressions have restarted and

then every 3–5 min (during alternate cycles of CPR). Amiodarone 300 mg is also given after the third shock.

- Atropine is no longer recommended for routine use in asystole or pulseless electrical activity.
- Reduced emphasis on early tracheal intubation unless achieved by highly skilled individuals with minimal interruption to chest compressions.
- Increased emphasis on the use of capnography to confirm and continually monitor tracheal tube placement, quality of CPR and to provide an early indication of return of spontaneous circulation (ROSC).
- The potential role of ultrasound imaging during ALS is recognised.
- Recognition of the potential harm caused by hyperoxaemia after ROSC is achieved: once ROSC has been established and the oxygen saturation of arterial blood (SaO<sub>2</sub>) can be monitored reliably (by pulse oximetry and/or arterial blood gas analysis), inspired oxygen is titrated to achieve a SaO<sub>2</sub> of 94–98%.
- Much greater detail and emphasis on the treatment of the post-cardiac arrest syndrome.
- Recognition that implementation of a comprehensive, structured post-resuscitation treatment protocol may improve survival in cardiac arrest victims after ROSC.
- Increased emphasis on the use of primary percutaneous coronary intervention in appropriate, but comatose, patients with sustained ROSC after cardiac arrest.
- Revision of the recommendation for glucose control: in adults with sustained ROSC after cardiac arrest, blood glucose values >10 mmol l<sup>-1</sup> (>180 mg dl<sup>-1</sup>) should be treated but hypoglycaemia must be avoided.
- Use of therapeutic hypothermia to include comatose survivors of cardiac arrest associated initially with non-shockable rhythms as well shockable rhythms. The lower level of evidence for use after cardiac arrest from non-shockable rhythms is acknowledged.
- Recognition that many of the accepted predictors of poor outcome in comatose survivors of cardiac arrest are unreliable,

\* Corresponding author.

E-mail address: [jerry.nolan@btinternet.com](mailto:jerry.nolan@btinternet.com) (J.P. Nolan).

<sup>1</sup> These individuals contributed equally to this manuscript and are equal first co-authors.

especially if the patient has been treated with therapeutic hypothermia.

#### 4a Prevention of in-hospital cardiac arrest

Early recognition of the deteriorating patient and prevention of cardiac arrest is the first link in the chain of survival.<sup>1</sup> Once cardiac arrest occurs, fewer than 20% of patients suffering an in-hospital cardiac arrest will survive to go home.<sup>2–4</sup> Prevention of in-hospital cardiac arrest requires staff education, monitoring of patients, recognition of patient deterioration, a system to call for help and an effective response.<sup>5</sup>

##### The problem

Cardiac arrest in patients in unmonitored ward areas is not usually a sudden unpredictable event, nor is it usually caused by primary cardiac disease.<sup>6</sup> These patients often have slow and progressive physiological deterioration, involving hypoxaemia and hypotension that is unnoticed by staff, or is recognised but treated poorly.<sup>7–9</sup> Many of these patients have unmonitored arrests, and the underlying cardiac arrest rhythm is usually non-shockable.<sup>3,10</sup> Survival to hospital discharge is poor.<sup>2,4,10</sup>

The records of patients who have a cardiac arrest or unanticipated intensive care unit (ICU) admission often contain evidence of unrecognised, or untreated, respiratory and circulation problems.<sup>6,8,11–16</sup> The ACADEMIA study showed antecedents in 79% of cardiac arrests, 55% of deaths and 54% of unanticipated ICU admissions.<sup>8</sup> Early and effective treatment of seriously ill patients might prevent some cardiac arrests, deaths and unanticipated ICU admissions. Several studies show that up to a third of patients who have a false cardiac arrest call subsequently die.<sup>17–19</sup>

##### Nature of the deficiencies in the recognition and response to patient deterioration

These often include: infrequent, late or incomplete vital signs assessments; lack of knowledge of normal vital signs values; poor design of vital signs charts; poor sensitivity and specificity of 'track and trigger' systems; failure of staff to increase monitoring or escalate care, and staff workload.<sup>20–28</sup> There is also often a failure to treat abnormalities of the patient's airway, breathing and circulation, incorrect use of oxygen therapy, poor communication, lack of teamwork and insufficient use of treatment limitation plans.<sup>7,14,29</sup>

##### Education in acute care

Several studies show that medical and nursing staff lack knowledge and skills in acute care,<sup>30</sup> e.g., oxygen therapy,<sup>31</sup> fluid and electrolyte balance,<sup>32</sup> analgesia,<sup>33</sup> issues of consent,<sup>34</sup> pulse oximetry<sup>35,36</sup> and drug doses.<sup>37</sup> Medical school training provides poor preparation for doctors' early careers, and fails to teach them the essential aspects of applied physiology and acute care.<sup>38</sup> There is a need for an increased emphasis on acute care training of undergraduate and newly qualified doctors.<sup>39,40</sup> There is also little to suggest that the acute care training and knowledge of senior medical staff is better.<sup>41,42</sup> Staff often lack confidence when dealing with acute care problems, and rarely use a systematic approach to the assessment of critically ill patients.<sup>43</sup>

Staff education is an essential part of implementing a system to prevent cardiac arrest.<sup>44</sup> However, there are no randomised controlled studies addressing the impact of specific educational interventions on improvements in patient outcomes such as the earlier recognition or rescue of the deteriorating patient at risk of cardiac or respiratory arrest.

In an Australian study, virtually all the improvement in the hospital cardiac arrest rate occurred during the educational phase of implementation of a medical emergency team (MET) system.<sup>45,46</sup> In studies from Australian and American hospitals with established rapid response teams, education about the specific criteria for activating their teams led to proactive ICU admission of patients and a reduction in the number of ward cardiac arrests.<sup>47–49</sup> A UK study found that the number of cardiac arrest calls decreased while pre-arrest calls increased after implementing a standardised educational program in two hospitals; the intervention was associated with a decrease in true arrests, and increase in initial survival after cardiac arrest and survival to discharge.<sup>50,51</sup>

##### Monitoring and recognition of the critically ill patient

In general, the clinical signs of acute illness are similar whatever the underlying process, as they reflect failing respiratory, cardiovascular and neurological systems. Abnormal physiology is common on general wards,<sup>52</sup> yet the measurement and recording of important physiological observations of sick patients occurs less frequently than is desirable.<sup>6,8,13,16,24,53,54</sup>

To assist in the early detection of critical illness, each patient should have a documented plan for vital signs monitoring that identifies which variables need to be measured and the frequency of measurement.<sup>26</sup> Many hospitals now use early warning scores (EWS) or calling criteria to identify the need to escalate monitoring, treatment, or to call for expert help.<sup>13,24,55–57</sup> The use of these systems has been shown to increase the frequency of patient vital signs measurements.<sup>54,58,59</sup>

These calling criteria or 'track-and-trigger' systems include single-parameter systems, multiple-parameter systems, aggregate weighted scoring systems or combination systems.<sup>60</sup> The aggregate weighted track-and-trigger systems offer a graded escalation of care, whereas single parameter track and trigger systems provide an all-or-nothing response.

Most of these systems lack robust data to suggest they have acceptable accuracy for use in the roles for which they are proposed. Low sensitivity of systems means that a significant number of patients at risk of deterioration leading to cardiac arrest are likely to be missed.<sup>61,62</sup> Hospitals should use a system validated for their specific patient population to identify individuals at increased risk of serious clinical deterioration, cardiac arrest, or death, both on admission and during hospital stay.

Alterations in physiological variables, singly or in combination are associated with, or can be used to predict the occurrence of cardiac arrest,<sup>9,13,15,63,64</sup> hospital death<sup>22,23,65–82</sup> and unplanned ICU admission,<sup>15,80,83</sup> with varying sensitivity and specificity. Differing criteria for ICU admission between hospitals make the use of unplanned ICU admission a less useful endpoint to study.

As one would expect, an increased number of derangements increases the likelihood of death.<sup>11,15,20,63,77,84–91</sup> The best combination and cut off values to allow early prediction is not known. For aggregate-weighted scoring systems, inclusion of heart rate (HR), respiratory rate (RR), systolic blood pressure (SBP), AVPU (alert, vocalizing, pain, unresponsive), temperature, age, and oxygen saturation achieve the best predictive value.<sup>22,61</sup> For single parameter track-and-trigger systems, cut-off points of HR <35 and >140 min<sup>-1</sup>; RR <6 and >32 min<sup>-1</sup>; and SBP <80 mm Hg achieved the best positive predictive value.<sup>23</sup> Taking account of the patient's age improves the predictive value of both aggregate and single parameter scoring systems.<sup>77</sup> Aggregate-weighted scoring systems appear to have a rank order of performance that is relatively constant.<sup>92</sup> A newly devised, aggregate-weighted scoring system discriminates better than all others tested using mortality within 24 h of an early warning score as the outcome.<sup>92</sup>

The design of vital signs charts or the use of technology may have an important role in the detection of deterioration and requires further study.<sup>21,93,94</sup>

### Calling for help

The traditional response to cardiac arrest is a reactive one in which hospital staff ('the cardiac arrest team') attend the patient after the cardiac arrest has occurred. Cardiac arrest teams appear to improve survival after cardiac arrest in circumstances where no team has previously existed.<sup>95</sup> However, the role of the cardiac arrest team has been questioned. In one small study, only patients who had return of spontaneous circulation before the cardiac arrest team arrived were discharged from hospital alive.<sup>96</sup> When combined with the poor survival rate after in-hospital cardiac arrest, this emphasises the importance of early recognition and treatment of critically ill patients to prevent cardiac arrest.

Nursing staff and junior doctors often find it difficult to ask for help or escalate treatment as they feel their clinical judgement may be criticised. Hospitals should ensure all staff are empowered to call for help and also trained to use structured communication tools such as RSVP (Reason-Story-Vital Signs-Plan)<sup>97</sup> or SBAR (Situation-Background-Assessment-Recommendation)<sup>98</sup> tools to ensure effective inter-professional communication.

### The response to critical illness

The response to patients who are critically ill or who are at risk of becoming critically ill is usually provided by medical emergency teams (MET), rapid response teams (RRT), or critical care outreach teams (CCOT).<sup>99–101</sup> These teams replace or coexist with traditional cardiac arrest teams, which typically respond to patients already in cardiac arrest. MET/RRT usually comprise medical and nursing staff from intensive care and general medicine and respond to specific calling criteria. CCOT are common in the UK, based predominantly on individual or teams of nurses.<sup>60</sup> Outreach services exist in many forms, ranging from a single nurse to a 24-h, 7 days per week multi-professional team. Any member of the healthcare team can initiate a MET/RRT/CCOT call. In some hospitals, the patient's family and friends are also encouraged to activate the team, if necessary.<sup>102–104</sup> Team interventions often involve simple tasks such as starting oxygen therapy and intravenous fluids.<sup>105–109</sup> However, *post hoc* analysis of the MERIT study data suggests that all nearly all MET calls required 'critical care-type' interventions.<sup>110</sup> A circadian pattern of team activation has been reported, which may suggest that systems for identifying and responding to medical emergencies may not be uniform throughout the 24-h period.<sup>111,112</sup>

Studying the effect of the MET/RRT/CCOT systems on patient outcomes is difficult because of the complex nature of the intervention. During the period of most studies of rapid response teams, there has been a major international focus on improving other aspects of patient safety, e.g., hospital acquired infections, earlier treatment of sepsis and better medication management, all of which have the potential to influence patient deterioration and may have a beneficial impact on reducing cardiac arrests and hospital deaths. Additionally, a greater focus on improving 'end of life' care and the making of 'do not attempt resuscitation' (DNAR) decisions also impact cardiac arrest call rates. The available studies do not correct for these confounding factors.

Nevertheless, numerous single centre studies have reported reduced numbers of cardiac arrests after the implementation of RRT/MET systems.<sup>45,47,107,111,113–125</sup> However, a well-designed, cluster-randomised controlled trial of the MET system (MERIT study) involving 23 hospitals<sup>24</sup> did not show a reduction in cardiac arrest rate after introduction of a MET when analyzed on an intention-to-treat basis. This study was unable to demonstrate a

difference between control and intervention hospitals in reduction in a composite outcome of (a) cardiac arrests without a pre-existing not-for-resuscitation (NFR) order, (b) unplanned ICU admissions, and (c) unexpected deaths (deaths without a pre-existing NFR order) taking place in general wards during the 6-month study MET period. Both the control and MET groups demonstrated improved outcome compared to baseline. *Post hoc* analysis of the MERIT study showed there was a decrease in cardiac arrest and unexpected mortality rate with increased activation of the MET system.<sup>126</sup> Several other studies have also been unable to show a reduction in cardiac arrest rates associated with the introduction of RRT/MET systems.<sup>105,106,108,109,127–130</sup> A single-centre study of the implementation of an early warning scoring system showed an increase in cardiac arrests among patients who had higher early warning scores, compared with similar scored patients before the intervention.<sup>56</sup>

A recent meta-analysis showed RRT/MET systems were associated with a reduction in rates of cardiopulmonary arrest outside the intensive care unit but are not associated with lower hospital mortality rates.<sup>131</sup>

### Appropriate placement of patients

Ideally, the sickest patients should be admitted to an area that can provide the greatest supervision and the highest level of organ support and nursing care. This often occurs, but some patients are placed incorrectly.<sup>132</sup> International organisations have offered definitions of levels of care and produced admission and discharge criteria for high dependency units (HDUs) and ICUs.<sup>133,134</sup>

### Staffing levels

Hospital staffing tends to be at its lowest during the night and at weekends. This may influence patient monitoring, treatment and outcomes. Data from the US National Registry of CPR Investigators shows that survival rates from in-hospital cardiac arrest are lower during nights and weekends.<sup>135</sup> Admission to a general medical ward after 17.00 h<sup>136</sup> or to hospital at weekends<sup>137</sup> is associated with increased mortality. Patients who are discharged from ICUs to general wards at night have an increased risk of in-hospital death compared with those discharged during the day and those discharged to HDUs.<sup>138,139</sup> Several studies show that higher nurse staffing is associated with lower rates of failure-to-rescue, and reductions in rates of cardiac arrest rates, pneumonia, shock and death.<sup>25,140,141</sup>

### Resuscitation decisions

The decision to start, continue and terminate resuscitation efforts is based on the balance between the risks, benefits and burdens these interventions place on patients, family members and healthcare providers. There are circumstances where resuscitation is inappropriate and should not be provided. Consider a 'do not attempt resuscitation' (DNAR) decision when the patient:

- does not wish to have CPR;
- will not survive cardiac arrest even if CPR is attempted.

Hospital staff often fail to consider whether resuscitation attempts are appropriate and resuscitation attempts in futile cases are common.<sup>142</sup> Even when there is clear evidence that cardiac arrest or death is likely, ward staff rarely make decisions about the patient's resuscitation status.<sup>8</sup> Many European countries have no formal policy for recording DNAR decisions and the practice of consulting patients about the decision is variable.<sup>143,144</sup> Improved knowledge, training and DNAR decision-making should improve

patient care and prevent futile CPR attempts (see Section 10).<sup>145</sup> Medical emergency teams may have an important role in improving end-of-life and DNAR decision-making.<sup>142,146–148</sup>

### Guidelines for prevention of in-hospital cardiac arrest

Hospitals should provide a system of care that includes: (a) staff education about the signs of patient deterioration, and the rationale for rapid response to illness, (b) appropriate and regular vital signs monitoring of patients, (c) clear guidance (e.g., via calling criteria or early warning scores) to assist staff in the early detection of patient deterioration, (d) a clear, uniform system of calling for assistance, and (e) an appropriate and timely clinical response to calls for assistance.<sup>5</sup> The following strategies may prevent avoidable in-hospital cardiac arrests.

1. Provide care for patients who are critically ill or at risk of clinical deterioration in appropriate areas, with the level of care provided matched to the level of patient sickness.
2. Critically ill patients need regular observations: each patient should have a documented plan for vital signs monitoring that identifies which variables need to be measured and the frequency of measurement according to the severity of illness or the likelihood of clinical deterioration and cardiopulmonary arrest. Recent guidance suggests monitoring of simple physiological variables including pulse, blood pressure, respiratory rate, conscious level, temperature and arterial blood oxygen saturation by pulse oximetry (SpO<sub>2</sub>).<sup>26,149</sup>
3. Use a track-and-trigger system (either 'calling criteria' or early warning system) to identify patients who are critically ill and, or at risk of clinical deterioration and cardiopulmonary arrest.
4. Use a patient charting system that enables the regular measurement and recording of vital signs and, where used, early warning scores.
5. Have a clear and specific policy that requires a clinical response to abnormal physiology, based on the track and trigger system used. This should include advice on the further clinical management of the patient and the specific responsibilities of medical and nursing staff.
6. The hospital should have a clearly identified response to critical illness. This may include a designated outreach service or resuscitation team (e.g., MET, RRT system) capable of responding in a timely fashion to acute clinical crises identified by the track-and-trigger system or other indicators. This service must be available 24 h per day. The team must include staff with the appropriate acute or critical care skills.
7. Train all clinical staff in the recognition, monitoring and management of the critically ill patient. Include advice on clinical management while awaiting the arrival of more experienced staff. Ensure that staff know their role(s) in the rapid response system.
8. Hospitals must empower staff of all disciplines to call for help when they identify a patient at risk of deterioration or cardiac arrest. Staff should be trained in the use of structured communication tools to ensure effective handover of information between doctors, nurses and other healthcare professions.
9. Identify patients for whom cardiopulmonary arrest is an anticipated terminal event and in whom CPR is inappropriate, and patients who do not wish to be treated with CPR. Hospitals should have a DNAR policy, based on national guidance, which is understood by all clinical staff.
10. Ensure accurate audit of cardiac arrest, "false arrest", unexpected deaths and unanticipated ICU admissions using common datasets. Audit also the antecedents and clinical response to these events.

### Prevention of sudden cardiac death (SCD) out-of-hospital

Coronary artery disease is the commonest cause of SCD. Non-ischaemic cardiomyopathy and valvular disease account for most other SCD events. A small percentage of SCDs are caused by inherited abnormalities (e.g., Brugada syndrome, hypertrophic cardiomyopathy) or congenital heart disease.

Most SCD victims have a history of cardiac disease and warning signs, most commonly chest pain, in the hour before cardiac arrest.<sup>150</sup> In patients with a known diagnosis of cardiac disease, syncope (with or without prodrome—particularly recent or recurrent) is as an independent risk factor for increased risk of death.<sup>151–161</sup> Chest pain on exertion only, and palpitations associated with syncope only, are associated with hypertrophic cardiomyopathy, coronary abnormalities, Wolff–Parkinson–White, and arrhythmogenic right ventricular cardiomyopathy.

Apparently healthy children and young adults who suffer SCD can also have signs and symptoms (e.g., syncope/pre-syncope, chest pain and palpitations) that should alert healthcare professionals to seek expert help to prevent cardiac arrest.<sup>162–170</sup>

Children and young adults presenting with characteristic symptoms of arrhythmic syncope should have a specialist cardiology assessment, which should include an ECG and in most cases an echocardiogram and exercise test. Characteristics of arrhythmic syncope include: syncope in the supine position, occurring during or after exercise, with no or only brief prodromal symptoms, repetitive episodes, or in individuals with a family history of sudden death. In addition, non-pleuritic chest pain, palpitations associated with syncope, seizures (when resistant to treatment, occurring at night or precipitated by exercise, syncope, or loud noise), and drowning in a competent swimmer should raise suspicion of increased risk. Systematic evaluation in a clinic specializing in the care of those at risk for SCD is recommended in family members of young victims of SCD or those with a known cardiac disorder resulting in an increased risk of SCD.<sup>151,171–175</sup> A family history of syncope or SCD, palpitations as a symptom, supine syncope and syncope associated with exercise and emotional stress are more common in patients with long QT syndrome (LQTS).<sup>176</sup> In older adults<sup>177,178</sup> the absence of nausea and vomiting before syncope and ECG abnormalities is an independent predictor of arrhythmic syncope.

Inexplicable drowning and drowning in a strong swimmer may be due to LQTS or catecholaminergic polymorphic ventricular tachycardia (CPVT).<sup>179</sup> There is an association between LQTS and presentation with seizure phenotype.<sup>180,181</sup> Guidance has been published for the screening of competitive athletes to identify those at risk of sudden death.<sup>182</sup>

### 4b Prehospital resuscitation

#### EMS personnel

There is considerable variation across Europe in the structure and process of EMS systems. Some countries have adopted almost exclusively paramedic/emergency medical technician (EMT)-based systems while other incorporate prehospital physicians to a greater or lesser extent. In adult cardiac arrest, physician presence during resuscitation, compared with paramedics alone, has been reported to increase compliance with guidelines<sup>183,184</sup> and physicians in some systems can perform advanced resuscitation procedures more successfully.<sup>183,185–188</sup> When compared within individual systems, there are contradictory findings with some studies suggesting improved survival to hospital discharge when physicians are part of the resuscitation team<sup>189–192</sup> and other studies suggest-



ing no difference in short- or long-term survival.<sup>183,189,191,193–199</sup> In one study, survival of the event was lower when physicians were part of the resuscitation team.<sup>199</sup> Studies indirectly comparing resuscitation outcomes between physician-staffed and other systems are difficult to interpret because of the extremely high variability between systems, independent of physician-staffing.<sup>200</sup> Although some studies have documented higher survival rates after cardiac arrest in EMS systems that include experienced physicians,<sup>186,188,201–203</sup> compared with those that rely on non-physician providers,<sup>201,202,204,205</sup> other comparisons have found no difference in survival between systems using paramedics or physicians as part of the response.<sup>206,207</sup> Well-organised non-physician systems with highly trained paramedics have also reported high survival rates.<sup>200</sup> Given the inconsistent evidence, the inclusion or exclusion of physicians among prehospital personnel responding to cardiac arrests will depend largely on existing local policy.

### Termination of resuscitation rules

One high-quality, prospective study has demonstrated that application of a 'basic life support termination of resuscitation rule' is predictive of death when applied by defibrillation-only emergency medical technicians.<sup>208</sup> The rule recommends termination when there is no return of spontaneous circulation, no shocks are administered, and the arrest is not witnessed by EMS personnel. Of 776 patients with cardiac arrest for whom the rule recommended termination, four survived [0.5% (95% CI 0.2–0.9)]. Implementation of the rule would reduce the transportation rate by almost two thirds. Four studies have shown external generalisability of this rule.<sup>209–212</sup>

Additional studies have shown associations with futility of certain variables such as no ROSC at scene; non-shockable rhythm; unwitnessed arrest; no bystander CPR, call response time and patient demographics.<sup>213–218</sup>

Two in-hospital studies and one emergency department study showed that the reliability of termination of resuscitation rules is limited in these settings.<sup>219–221</sup>

Prospectively validated termination of resuscitation rules such as the 'basic life support termination of resuscitation rule' can be used to guide termination of prehospital CPR in adults; however, these must be validated in an emergency medical services system similar to the one in which implementation is proposed. Other rules for various provider levels, including in-hospital providers, may be helpful to reduce variability in decision-making; however, rules should be prospectively validated prior to implementation.

### CPR versus defibrillation first

There is evidence that performing chest compressions while retrieving and charging a defibrillator improves the probability of survival.<sup>222</sup> EMS personnel should provide good-quality CPR while a defibrillator is retrieved, applied and charged, but routine delivery of a pre-specified period of CPR (e.g., 2 or 3 min) before rhythm analysis and a shock is delivered is not recommended. Some emergency medical services have already fully implemented a pre-specified period of chest compressions before defibrillation; given the lack of convincing data either supporting or refuting this strategy, it is reasonable for them to continue this practice (see Section 3).<sup>223</sup>

### 4c In-hospital resuscitation

After in-hospital cardiac arrest, the division between basic life support and advanced life support is arbitrary; in practice, the resuscitation process is a continuum and is based on common sense. The public expect that clinical staff can undertake cardiopulmonary

resuscitation (CPR). For all in-hospital cardiac arrests, ensure that:

- cardiorespiratory arrest is recognised immediately;
- help is summoned using a standard telephone number;
- CPR is started immediately using airway adjuncts, e.g., a pocket mask and, if indicated, defibrillation attempted as rapidly as possible and certainly within 3 min.

The exact sequence of actions after in-hospital cardiac arrest will depend on many factors, including:

- location (clinical/non-clinical area; monitored/unmonitored area);
- training of the first responders;
- number of responders;
- equipment available;
- hospital response system to cardiac arrest and medical emergencies (e.g., MET, RRT).

### Location

Patients who have monitored arrests are usually diagnosed rapidly. Ward patients may have had a period of deterioration and an unwitnessed arrest.<sup>6,8</sup> Ideally, all patients who are at high risk of cardiac arrest should be cared for in a monitored area where facilities for immediate resuscitation are available.

### Training of first responders

All healthcare professionals should be able to recognise cardiac arrest, call for help and start CPR. Staff should do what they have been trained to do. For example, staff in critical care and emergency medicine will have more advanced resuscitation skills than staff who are not involved regularly in resuscitation in their normal clinical role. Hospital staff who attend a cardiac arrest may have different levels of skill to manage the airway, breathing and circulation. Rescuers must undertake only the skills in which they are trained and competent.

### Number of responders

The single responder must ensure that help is coming. If other staff are nearby, several actions can be undertaken simultaneously.

### Equipment available

All clinical areas should have immediate access to resuscitation equipment and drugs to facilitate rapid resuscitation of the patient in cardiopulmonary arrest. Ideally, the equipment used for CPR (including defibrillators) and the layout of equipment and drugs should be standardised throughout the hospital.<sup>224,225</sup>

### Resuscitation team

The resuscitation team may take the form of a traditional cardiac arrest team, which is called only when cardiac arrest is recognised. Alternatively, hospitals may have strategies to recognise patients at risk of cardiac arrest and summon a team (e.g., MET or RRT) before cardiac arrest occurs. The term 'resuscitation team' reflects the range of response teams. In hospital cardiac arrests are rarely sudden or unexpected. A strategy of recognising patients at risk of cardiac arrest may enable some of these arrests to be prevented, or may prevent futile resuscitation attempts in those who are unlikely to benefit from CPR.

## Immediate actions for a collapsed patient in a hospital

An algorithm for the initial management of in-hospital cardiac arrest is shown in Fig. 4.1.

- Ensure personal safety.
- Check the victim for a response.
- When healthcare professionals see a patient collapse or find a patient apparently unconscious in a clinical area, they should first shout for help, then assess if the patient is responsive. Gently shake the shoulders and ask loudly: 'Are you all right?'
- If other members of staff are nearby, it will be possible to undertake actions simultaneously.

### The responsive patient

Urgent medical assessment is required. Depending on the local protocols, this may take the form of a resuscitation team (e.g., MET, RRT). While awaiting this team, give the patient oxygen, attach monitoring and insert an intravenous cannula.

### The unresponsive patient

The exact sequence will depend on the training of staff and experience in assessment of breathing and circulation. Trained healthcare staff cannot assess the breathing and pulse sufficiently reliably to confirm cardiac arrest.<sup>226–235</sup> Agonal breathing (occasional gasps, slow, laboured or noisy breathing) is common in the early stages of cardiac arrest and is a sign of cardiac arrest and should not be confused as a sign of life/circulation.<sup>236–239</sup> Agonal breathing can also occur during chest compressions as cerebral perfusion improves, but is not indicative of a return of spontaneous circulation.

- Shout for help (if not already)

Turn the victim on to his back and then open the airway:

- Open Airway and check breathing:
  - Open the airway using a head tilt chin lift.
  - Look in the mouth. If a foreign body or debris is visible attempt to remove with a finger sweep, forceps or suction as appropriate.
  - If you suspect that there may have been an injury to the neck, try to open the airway using a jaw thrust. Remember that maintaining an airway and adequate ventilation is the overriding priority in managing a patient with a suspected spinal injury. If this is unsuccessful, use just enough head tilt to clear the airway. Use manual in-line stabilisation to minimise head movement if sufficient rescuers are available. Efforts to protect the cervical spine must not jeopardise oxygenation and ventilation.

Keeping the airway open, look, listen, and feel for normal breathing (an occasional gasp, slow, laboured or noisy breathing is not normal):

- Look for chest movement;
- Listen at the victim's mouth for breath sounds;
- Feel for air on your cheek.

Look, listen, and feel for no more than 10 s to determine if the victim is breathing normally

- Check for signs of a circulation:
  - It may be difficult to be certain that there is no pulse. If the patient has no signs of life (consciousness, purposeful movement, normal breathing, or coughing), start CPR until more experience help arrives or the patient shows signs of life.




Fig. 4.1. Algorithm for the treatment of in-hospital cardiac arrest. © 2010 ERC.

- Those experienced in clinical assessment should assess the carotid pulse whilst simultaneously looking for signs of life for not more than 10 s.
- If the patient appears to have no signs of life, or if there is doubt, start CPR immediately. Delivering chest compressions to a patient with a beating heart is unlikely to cause harm.<sup>240</sup> However, delays in diagnosis of cardiac arrest and starting CPR will adversely effect survival and must be avoided.

If there is a pulse or signs of life, urgent medical assessment is required. Depending on the local protocols, this may take the form of a resuscitation team. While awaiting this team, give the patient oxygen, attach monitoring, and insert an intravenous cannula. When a reliable measurement of oxygen saturation of arterial blood (e.g., pulse oximetry (SpO<sub>2</sub>)) can be achieved, titrate the inspired oxygen concentration to achieve a SpO<sub>2</sub> of 94–98%.

If there is no breathing, but there is a pulse (respiratory arrest), ventilate the patient's lungs and check for a circulation every 10 breaths.

### Starting in-hospital CPR

- One person starts CPR as others call the resuscitation team and collect the resuscitation equipment and a defibrillator. If only one member of staff is present, this will mean leaving the patient.
- Give 30 chest compressions followed by 2 ventilations.
- Minimise interruptions and ensure high-quality compressions.
- Undertaking good-quality chest compressions for a prolonged time is tiring; with minimal interruption, try to change the person doing chest compressions every 2 min.
- Maintain the airway and ventilate the lungs with the most appropriate equipment immediately to hand. A pocket mask, which may be supplemented with an oral airway, is usually readily available. Alternatively, use a supraglottic airway device (SAD) and self-inflating bag, or bag-mask, according to local policy. Tracheal intubation should be attempted only by those who are trained, competent and experienced in this skill. Waveform capnography should be routinely available for confirming tracheal tube placement (in the presence of a cardiac output) and subsequent monitoring of an intubated patient.
- Use an inspiratory time of 1 s and give enough volume to produce a normal chest rise. Add supplemental oxygen as soon as possible.
- Once the patient's trachea has been intubated or a SAD has been inserted, continue chest compressions uninterrupted (except for defibrillation or pulse checks when indicated), at a rate of at least 100 min<sup>-1</sup>, and ventilate the lungs at approximately 10 breaths min<sup>-1</sup>. Avoid hyperventilation (both excessive rate and tidal volume), which may worsen outcome. Mechanical ventilators may free up a rescuer and ensure appropriate ventilation rates and volumes.
- If there is no airway and ventilation equipment available, consider giving mouth-to-mouth ventilation. If there are clinical reasons to avoid mouth-to-mouth contact, or you are unwilling or unable to do this, do chest compressions until help or airway equipment arrives.
- When the defibrillator arrives, apply the paddles to the patient and analyse the rhythm. If self-adhesive defibrillation pads are available, apply these without interrupting chest compressions. The use of adhesive electrode pads or a 'quick-look' paddles technique will enable rapid assessment of heart rhythm compared with attaching ECG electrodes.<sup>241</sup> Pause briefly to assess the heart rhythm. With a manual defibrillator, if the rhythm is VF/VT charge the defibrillator while another rescuer continues chest compressions. Once the defibrillator is charged, pause the chest compressions, ensure that all rescuers are clear of the patient and

then give one shock. If using an automated external defibrillation (AED) follow the AED's audio-visual prompts.

- Restart chest compressions immediately after the defibrillation attempt. Minimise interruptions to chest compressions. Using a manual defibrillator it is possible to reduce the pause between stopping and restarting of chest compressions to less than 5 s.
- Continue resuscitation until the resuscitation team arrives or the patient shows signs of life. Follow the voice prompts if using an AED. If using a manual defibrillator, follow the universal algorithm for advanced life support (Section 4d).
- Once resuscitation is underway, and if there are sufficient staff present, prepare intravenous cannulae and drugs likely to be used by the resuscitation team (e.g., adrenaline).
- Identify one person to be responsible for handover to the resuscitation team leader. Use a structured communication tool for handover (e.g., SBAR, RSVP).<sup>97,98</sup> Locate the patient's records.
- The quality of chest compressions during in-hospital CPR is frequently sub-optimal.<sup>242,243</sup> The importance of uninterrupted chest compressions cannot be over emphasised. Even short interruptions to chest compressions are disastrous for outcome and every effort must be made to ensure that continuous, effective chest compression is maintained throughout the resuscitation attempt. Chest compressions should commence at the beginning of a resuscitation attempt and continue uninterrupted unless they are briefly paused for a specific intervention (e.g., pulse check). The team leader should monitor the quality of CPR and alternate CPR providers if the quality of CPR is poor. Continuous ETCO<sub>2</sub> monitoring can be used to indicate the quality of CPR: although an optimal target for ETCO<sub>2</sub> during CPR has not been established, a value of less than 10 mm Hg (1.4 kPa) is associated with failure to achieve ROSC and may indicate that the quality of chest compressions should be improved. If possible, the person providing chest compressions should be alternated every 2 min, but without causing long pauses in chest compressions.

## 4d ALS treatment algorithm

### Introduction

Heart rhythms associated with cardiac arrest are divided into two groups: shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia (VF/VT)) and non-shockable rhythms (asystole and pulseless electrical activity (PEA)). The principal difference in the treatment of these two groups of arrhythmias is the need for attempted defibrillation in those patients with VF/VT. Subsequent actions, including high-quality chest compressions with minimal interruptions, airway management and ventilation, venous access, administration of adrenaline and the identification and correction of reversible factors, are common to both groups.

Although the ALS cardiac arrest algorithm (Fig. 4.2) is applicable to all cardiac arrests, additional interventions may be indicated for cardiac arrest caused by special circumstances (see Section 8).

The interventions that unquestionably contribute to improved survival after cardiac arrest are prompt and effective bystander basic life support (BLS), uninterrupted, high-quality chest compressions and early defibrillation for VF/VT. The use of adrenaline has been shown to increase return of spontaneous circulation (ROSC), but no resuscitation drugs or advanced airway interventions have been shown to increase survival to hospital discharge after cardiac arrest.<sup>244–247</sup> Thus, although drugs and advanced airways are still included among ALS interventions, they are of secondary importance to early defibrillation and high-quality, uninterrupted chest compressions.

As with previous guidelines, the ALS algorithm distinguishes between shockable and non-shockable rhythms. Each cycle is

broadly similar, with a total of 2 min of CPR being given before assessing the rhythm and where indicated, feeling for a pulse. Adrenaline 1 mg is given every 3–5 min until ROSC is achieved—the timing of the initial dose of adrenaline is described below. In VF/VT, a single dose of amiodarone is indicated after three unsuccessful shocks.

### Shockable rhythms (ventricular fibrillation/pulseless ventricular tachycardia)

The first monitored rhythm is VF/VT in approximately 25% of cardiac arrests, both in-<sup>4</sup> or out-of-hospital.<sup>248–250</sup> VF/VT will also occur at some stage during resuscitation in about 25% of cardiac




Fig. 4.2. Advanced life support cardiac arrest algorithm. © 2010 ERC.



arrests with an initial documented rhythm of asystole or PEA.<sup>4</sup> Having confirmed cardiac arrest, summon help (including the request for a defibrillator) and start CPR, beginning with chest compressions, with a compression:ventilation (CV) ratio of 30:2. When the defibrillator arrives, continue chest compressions while applying the paddles or self-adhesive pads. Identify the rhythm and treat according to the ALS algorithm.

- If VF/VT is confirmed, charge the defibrillator while another rescuer continues chest compressions. Once the defibrillator is charged, pause the chest compressions, quickly ensure that all rescuers are clear of the patient and then give one shock (360-J monophasic or 150–200 J biphasic).
- Minimise the delay between stopping chest compressions and delivery of the shock (the preshock pause); even 5–10 s delay will reduce the chances of the shock being successful.<sup>251,252</sup>
- Without reassessing the rhythm or feeling for a pulse, resume CPR (CV ratio 30:2) immediately after the shock, starting with chest compressions. Even if the defibrillation attempt is successful in restoring a perfusing rhythm, it takes time until the post-shock circulation is established<sup>253</sup> and it is very rare for a pulse to be palpable immediately after defibrillation.<sup>254</sup> Furthermore, the delay in trying to palpate a pulse will further compromise the myocardium if a perfusing rhythm has not been restored.<sup>255</sup>
- Continue CPR for 2 min, then pause briefly to assess the rhythm; if still VF/VT, give a second shock (360-J monophasic or 150–360-J biphasic). Without reassessing the rhythm or feeling for a pulse, resume CPR (CV ratio 30:2) immediately after the shock, starting with chest compressions.
- Continue CPR for 2 min, then pause briefly to assess the rhythm; if still VF/VT, give a third shock (360-J monophasic or 150–360-J biphasic). Without reassessing the rhythm or feeling for a pulse, resume CPR (CV ratio 30:2) immediately after the shock, starting with chest compressions. If IV/IO access has been obtained, give adrenaline 1 mg and amiodarone 300 mg once compressions have resumed. If ROSC has not been achieved with this 3rd shock the adrenaline will improve myocardial blood flow and may increase the chance of successful defibrillation with the next shock. In animal studies, peak plasma concentrations of adrenaline occur at about 90 s after a peripheral injection.<sup>256</sup> If ROSC has been achieved after the 3rd shock it is possible that the bolus dose of adrenaline will cause tachycardia and hypertension and precipitate recurrence of VF. However, naturally occurring adrenaline plasma concentrations are high immediately after ROSC,<sup>257</sup> and any additional harm caused by exogenous adrenaline has not been studied. Interrupting chest compressions to check for a perfusing rhythm midway in the cycle of compressions is also likely to be harmful. The use of waveform capnography may enable ROSC to be detected without pausing chest compressions and may be a way of avoiding a bolus injection of adrenaline after ROSC has been achieved. Two prospective human studies have shown that a significant increase in end-tidal CO<sub>2</sub> occurs when return of spontaneous circulation occurs.<sup>258,259</sup>
- After each 2-min cycle of CPR, if the rhythm changes to asystole or PEA, see 'non-shockable rhythms' below. If a non-shockable rhythm is present and the rhythm is organised (complexes appear regular or narrow), try to palpate a pulse. Rhythm checks should be brief, and pulse checks should be undertaken only if an organised rhythm is observed. If there is any doubt about the presence of a pulse in the presence of an organised rhythm, resume CPR. If ROSC has been achieved, begin post-resuscitation care

During treatment of VF/VT, healthcare providers must practice efficient coordination between CPR and shock delivery. When VF is present for more than a few minutes, the myocardium is

depleted of oxygen and metabolic substrates. A brief period of chest compressions will deliver oxygen and energy substrates and increase the probability of restoring a perfusing rhythm after shock delivery.<sup>260</sup> Analyses of VF waveform characteristics predictive of shock success indicate that the shorter the time between chest compression and shock delivery, the more likely the shock will be successful.<sup>260,261</sup> Reduction in the interval from compression to shock delivery by even a few seconds can increase the probability of shock success.<sup>251,252</sup>

Regardless of the arrest rhythm, give adrenaline 1 mg every 3–5 min until ROSC is achieved; in practice, this will be once every two cycles of the algorithm. If signs of life return during CPR (purposeful movement, normal breathing, or coughing), check the monitor; if an organised rhythm is present, check for a pulse. If a pulse is palpable, continue post-resuscitation care and/or treatment of peri-arrest arrhythmia. If no pulse is present, continue CPR. Providing CPR with a CV ratio of 30:2 is tiring; change the individual undertaking compressions every 2 min, while minimising the interruption in compressions.

#### *Witnessed, monitored VF/VT in the cardiac catheter lab or after cardiac surgery*

If a patient has a monitored and witnessed cardiac arrest in the catheter laboratory or early after cardiac surgery:

- Confirm cardiac arrest and shout for help.
- If the initial rhythm is VF/VT, give up to three quick successive (stacked) shocks. Start chest compressions immediately after the third shock and continue CPR for 2 min.

This three-shock strategy may also be considered for an initial, witnessed VF/VT cardiac arrest if the patient is already connected to a manual defibrillator. Although there are no data supporting a three-shock strategy in any of these circumstances, it is unlikely that chest compressions will improve the already very high chance of return of spontaneous circulation when defibrillation occurs early in the electrical phase, immediately after onset of VF (see Section 3).<sup>223</sup>

#### *Precordial thump*

A single precordial thump has a very low success rate for cardioversion of a shockable rhythm<sup>262–264</sup> and is only likely to succeed if given within the first few seconds of the onset of a shockable rhythm.<sup>265</sup> There is more success with pulseless VT than with VF. Delivery of a precordial thump must not delay calling for help or accessing a defibrillator. It is therefore appropriate therapy only when several clinicians are present at a witnessed, monitored arrest, and when a defibrillator is not immediately to hand (see Section 3).<sup>223,266</sup> In practice, this is only likely to be in a critical care environment such as the emergency department or ICU.<sup>264</sup>

A precordial thump should be undertaken immediately after confirmation of cardiac arrest and only by healthcare professionals trained in the technique. Using the ulnar edge of a tightly clenched fist, deliver a sharp impact to the lower half of the sternum from a height of about 20 cm, then retract the fist immediately to create an impulse-like stimulus. There are very rare reports of a precordial thump converting a perfusing to a non-perfusing rhythm.<sup>267</sup>

#### *Airway and ventilation*

During the treatment of persistent VF, ensure good-quality chest compressions between defibrillation attempts. Consider reversible causes (4 Hs and 4 Ts) and, if identified, correct them. Check the

electrode/defibrillating paddle positions and contacts, and the adequacy of the coupling medium, e.g., gel pads. Tracheal intubation provides the most reliable airway, but should be attempted only if the healthcare provider is properly trained and has regular, ongoing experience with the technique. Personnel skilled in advanced airway management should attempt laryngoscopy and intubation without stopping chest compressions; a brief pause in chest compressions may be required as the tube is passed between the vocal cords, but this pause should not exceed 10 s. Alternatively, to avoid any interruptions in chest compressions, the intubation attempt may be deferred until return of spontaneous circulation. No studies have shown that tracheal intubation increases survival after cardiac arrest. After intubation, confirm correct tube position and secure it adequately. Ventilate the lungs at 10 breaths  $\text{min}^{-1}$ ; do not hyperventilate the patient. Once the patient's trachea has been intubated, continue chest compressions, at a rate of 100  $\text{min}^{-1}$  without pausing during ventilation. A pause in the chest compressions enables the coronary perfusion pressure to fall substantially. On resuming compressions there is some delay before the original coronary perfusion pressure is restored, thus chest compressions that are not interrupted for ventilation (or any reason) result in a substantially higher mean coronary perfusion pressure.

In the absence of personnel skilled in tracheal intubation, a supraglottic airway device (e.g., laryngeal mask airway) is an acceptable alternative (Section 4e). Once a supraglottic airway device has been inserted, attempt to deliver continuous chest compressions, uninterrupted during ventilation. If excessive gas leakage causes inadequate ventilation of the patient's lungs, chest compressions will have to be interrupted to enable ventilation (using a CV ratio of 30:2).

#### *Intravenous access and drugs*

##### *Peripheral versus central venous drug delivery*

Establish intravenous access if this has not already been achieved. Although peak drug concentrations are higher and circulation times are shorter when drugs are injected into a central venous catheter compared with a peripheral cannula,<sup>268</sup> insertion of a central venous catheter requires interruption of CPR and is associated with several complications. Peripheral venous cannulation is quicker, easier to perform and safer. Drugs injected peripherally must be followed by a flush of at least 20 ml of fluid and elevation of the extremity for 10–20 s to facilitate drug delivery to the central circulation.

##### *Intraosseous route*

If intravenous access is difficult or impossible, consider the IO route. Although normally considered as an alternative route for vascular access in children, it is now established as an effective route in adults.<sup>269</sup> Intraosseous injection of drugs achieves adequate plasma concentrations in a time comparable with injection through a central venous catheter.<sup>270</sup> The recent availability of mechanical IO devices has increased the ease of performing this technique.<sup>271</sup>

##### *Tracheal route*

Unpredictable plasma concentrations are achieved when drugs are given via a tracheal tube, and the optimal tracheal dose of most drugs is unknown. During CPR, the equipotent dose of adrenaline given via the trachea is three to ten times higher than the intravenous dose.<sup>272,273</sup> Some animal studies suggest that the lower adrenaline concentrations achieved when the drug is given via the trachea may produce transient beta-adrenergic effects, which will cause hypotension and lower coronary artery perfusion pressure.<sup>274–277</sup> Given the completely unreliable plasma concentrations achieved and increased availability of suitable IO devices, the tracheal route for drug delivery is no longer recommended.

Drug delivery via a supraglottic airway device is even less reliable and should not be attempted.<sup>278</sup>

#### *Adrenaline*

Despite the widespread use of adrenaline during resuscitation, and several studies involving vasopressin, there is no placebo-controlled study that shows that the routine use of any vasopressor at any stage during human cardiac arrest increases neurologically intact survival to hospital discharge. Current evidence is insufficient to support or refute the routine use of any particular drug or sequence of drugs. Despite the lack of human data, the use of adrenaline is still recommended, based largely on animal data and increased short-term survival in humans.<sup>245,246</sup> The alpha-adrenergic actions of adrenaline cause vasoconstriction, which increases myocardial and cerebral perfusion pressure. The higher coronary blood flow increases the frequency and amplitude of the VF waveform and should improve the chance of restoring a circulation when defibrillation is attempted.<sup>260,279,280</sup> Although adrenaline improves short-term survival, animal data indicate that it impairs the microcirculation<sup>281,282</sup> and post-cardiac arrest myocardial dysfunction,<sup>283,284</sup> which both might impact on long-term outcome. The optimal dose of adrenaline is not known, and there are no data supporting the use of repeated doses. There are few data on the pharmacokinetics of adrenaline during CPR. The optimal duration of CPR and number of shocks that should be given before giving drugs is unknown. On the basis of expert consensus, for VF/VT give adrenaline after the third shock once chest compressions have resumed, and then repeat every 3–5 min during cardiac arrest (alternate cycles). Do not interrupt CPR to give drugs.

#### *Anti-arrhythmic drugs*

There is no evidence that giving any anti-arrhythmic drug routinely during human cardiac arrest increases survival to hospital discharge. In comparison with placebo<sup>285</sup> and lidocaine,<sup>286</sup> the use of amiodarone in shock-refractory VF improves the short-term outcome of survival to hospital admission. In these studies, the anti-arrhythmic therapy was given if VF/VT persisted after at least three shocks; however, these were delivered using the conventional three-stacked shocks strategy. There are no data on the use of amiodarone for shock-refractory VF/VT when single shocks are used. On the basis of expert consensus, if VF/VT persists after three shocks, give 300 mg amiodarone by bolus injection. A further dose of 150 mg may be given for recurrent or refractory VF/VT, followed by an infusion of 900 mg over 24 h. Lidocaine, 1 mg  $\text{kg}^{-1}$ , may be used as an alternative if amiodarone is not available, but do not give lidocaine if amiodarone has been given already.

#### *Magnesium*

The routine use of magnesium in cardiac arrest does not increase survival.<sup>287–291</sup> and is not recommended in cardiac arrest unless torsades de pointes is suspected (see peri-arrest arrhythmias).

#### *Bicarbonate*

Routine administration of sodium bicarbonate during cardiac arrest and CPR or after return of spontaneous circulation is not recommended. Give sodium bicarbonate (50 mmol) if cardiac arrest is associated with hyperkalaemia or tricyclic antidepressant overdose; repeat the dose according to the clinical condition and the result of serial blood gas analysis. During cardiac arrest, arterial blood gas values do not reflect the acid–base state of the tissues<sup>292</sup>; the tissue pH will be lower than that in arterial blood. If a central venous catheter is *in situ*, central venous blood gas analysis will provide a closer estimate of tissue acid/base state than that provided by arterial blood.

### *Persistent ventricular fibrillation/pulseless ventricular tachycardia*

In VF/VT persists, consider changing the position of the pads/paddles (see Section 3).<sup>223</sup> Review all potentially reversible causes (see below) and treat any that are identified. Persistent VF/VT may be an indication for percutaneous coronary intervention or thrombolysis—in these cases, a mechanical device CPR may help to maintain high-quality CPR for a prolonged period.<sup>293</sup>

The duration of any individual resuscitation attempt is a matter of clinical judgement, taking into consideration the circumstances and the perceived prospect of a successful outcome. If it was considered appropriate to start resuscitation, it is usually considered worthwhile continuing, as long as the patient remains in VF/VT.

### **Non-shockable rhythms (PEA and asystole)**

Pulseless electrical activity (PEA) is defined as cardiac arrest in the presence of electrical activity that would normally be associated with a palpable pulse. These patients often have some mechanical myocardial contractions, but these are too weak to produce a detectable pulse or blood pressure—this sometimes described as ‘pseudo-PEA’ (see below). PEA is often caused by reversible conditions, and can be treated if those conditions are identified and corrected. Survival following cardiac arrest with asystole or PEA is unlikely unless a reversible cause can be found and treated effectively.

If the initial monitored rhythm is PEA or asystole, start CPR 30:2 and give adrenaline 1 mg as soon as venous access is achieved. If asystole is displayed, check without stopping CPR, that the leads are attached correctly. Once an advanced airway has been sited, continue chest compressions without pausing during ventilation. After 2 min of CPR, recheck the rhythm. If asystole is present, resume CPR immediately. If an organised rhythm is present, attempt to palpate a pulse. If no pulse is present (or if there is any doubt about the presence of a pulse), continue CPR. Give adrenaline 1 mg (IV/IO) every alternate CPR cycle (i.e., about every 3–5 min) once vascular access is obtained. If a pulse is present, begin post-resuscitation care. If signs of life return during CPR, check the rhythm and attempt to palpate a pulse.

Whenever a diagnosis of asystole is made, check the ECG carefully for the presence of P waves, because this may respond to cardiac pacing. There is no benefit in attempting to pace true asystole. If there is doubt about whether the rhythm is asystole or fine VF, do not attempt defibrillation; instead, continue chest compressions and ventilation. Fine VF that is difficult to distinguish from asystole will not be shocked successfully into a perfusing rhythm. Continuing good-quality CPR may improve the amplitude and frequency of the VF and improve the chance of successful defibrillation to a perfusing rhythm. Delivering repeated shocks in an attempt to defibrillate what is thought to be fine VF will increase myocardial injury, both directly from the electricity and indirectly from the interruptions in coronary blood flow.

During the treatment of asystole or PEA, following a 2-min cycle of CPR, if the rhythm has changed to VF, follow the algorithm for shockable rhythms. Otherwise, continue CPR and give adrenaline every 3–5 min following the failure to detect a palpable pulse with the pulse check. If VF is identified on the monitor midway through a 2-min cycle of CPR, complete the cycle of CPR before formal rhythm and shock delivery if appropriate—this strategy will minimise interruptions in chest compressions.

### **Potentially reversible causes**

Potential causes or aggravating factors for which specific treatment exists must be considered during any cardiac arrest. For ease

of memory, these are divided into two groups of four based upon their initial letter: either H or T. More details on many of these conditions are covered in Section 8.<sup>294</sup>

### *Use of ultrasound imaging during advanced life support*

Several studies have examined the use of ultrasound during cardiac arrest to detect potentially reversible causes. Although no studies have shown that use of this imaging modality improves outcome, there is no doubt that echocardiography has the potential to detect reversible causes of cardiac arrest (e.g., cardiac tamponade, pulmonary embolism, ischaemia (regional wall motion abnormality), aortic dissection, hypovolaemia, pneumothorax).<sup>295–302</sup> When available for use by trained clinicians, ultrasound may be of use in assisting with diagnosis and treatment of potentially reversible causes of cardiac arrest. The integration of ultrasound into advanced life support requires considerable training if interruptions to chest compressions are to be minimised. A sub-xiphoid probe position has been recommended.<sup>295,301,303</sup> Placement of the probe just before chest compressions are paused for a planned rhythm assessment enables a well-trained operator to obtain views within 10 s.

Absence of cardiac motion on sonography during resuscitation of patients in cardiac arrest is highly predictive of death<sup>304–306</sup> although sensitivity and specificity has not been reported.

### **The four ‘Hs’**

Minimise the risk of hypoxia by ensuring that the patient’s lungs are ventilated adequately with 100% oxygen during CPR. Make sure there is adequate chest rise and bilateral breath sounds. Using the techniques described in Section 4e, check carefully that the tracheal tube is not misplaced in a bronchus or the oesophagus.

Pulseless electrical activity caused by hypovolaemia is due usually to severe haemorrhage. This may be precipitated by trauma (Section 8h),<sup>294</sup> gastrointestinal bleeding or rupture of an aortic aneurysm. Intravascular volume should be restored rapidly with warmed fluid, coupled with urgent surgery to stop the haemorrhage. Hyperkalaemia, hypokalaemia, hypocalcaemia, acidaemia and other metabolic disorders are detected by biochemical tests or suggested by the patient’s medical history, e.g., renal failure (Section 8a).<sup>294</sup> A 12-lead ECG may be diagnostic. Intravenous calcium chloride is indicated in the presence of hyperkalaemia, hypocalcaemia and calcium channel-blocker overdose. Suspect hypothermia in any drowning incident (Sections 8c and d)<sup>294</sup>; use a low-reading thermometer.

### **The four ‘Ts’**

A tension pneumothorax may be the primary cause of PEA and may follow attempts at central venous catheter insertion. The diagnosis is made clinically. Decompress rapidly by needle thoracocentesis, and then insert a chest drain. In the context of cardiac arrest from major trauma, bilateral thoracostomies may provide a more reliable way of decompressing a suspected tension pneumothorax.

Cardiac tamponade is difficult to diagnose because the typical signs of distended neck veins and hypotension are usually obscured by the arrest itself. Cardiac arrest after penetrating chest trauma is highly suggestive of tamponade and is an indication for needle pericardiocentesis or resuscitative thoracotomy (see Section 8h).<sup>294</sup> The increasing use of ultrasound is making the diagnosis of cardiac tamponade much more reliable.

In the absence of a specific history, the accidental or deliberate ingestion of therapeutic or toxic substances may be revealed only by laboratory investigations (Section 8b).<sup>294</sup> Where available, the



appropriate antidotes should be used, but most often treatment is supportive and standard ALS protocols should be followed.

The commonest cause of thromboembolic or mechanical circulatory obstruction is massive pulmonary embolus. If pulmonary embolism is a possible cause of the cardiac arrest, consider giving a fibrinolytic drug immediately (Section 4f).<sup>307</sup>

#### 4e Airway management and ventilation

##### Introduction

Patients requiring resuscitation often have an obstructed airway, usually secondary to loss of consciousness, but occasionally it may be the primary cause of cardiorespiratory arrest. Prompt assessment, with control of the airway and ventilation of the lungs, is essential. This will help to prevent secondary hypoxic damage to the brain and other vital organs. Without adequate oxygenation it may be impossible to restore a spontaneous cardiac output. These principles may not apply to the witnessed primary cardiac arrest in the vicinity of a defibrillator; in this case, the priority is immediate defibrillation.

##### Airway obstruction

###### *Causes of airway obstruction*

Obstruction of the airway may be partial or complete. It may occur at any level, from the nose and mouth down to the trachea. In the unconscious patient, the commonest site of airway obstruction is at the soft palate and epiglottis.<sup>308,309</sup> Obstruction may also be caused by vomit or blood (regurgitation of gastric contents or trauma), or by foreign bodies. Laryngeal obstruction may be caused by oedema from burns, inflammation or anaphylaxis. Upper airway stimulation may cause laryngeal spasm. Obstruction of the airway below the larynx is less common, but may arise from excessive bronchial secretions, mucosal oedema, bronchospasm, pulmonary oedema or aspiration of gastric contents.

###### *Recognition of airway obstruction*

Airway obstruction can be subtle and is often missed by health-care professionals, let alone by laypeople. The 'look, listen and feel' approach is a simple, systematic method of detecting airway obstruction.

- Look for chest and abdominal movements.
- Listen and feel for airflow at the mouth and nose.

In partial airway obstruction, air entry is diminished and usually noisy. Inspiratory stridor is caused by obstruction at the laryngeal level or above. Expiratory wheeze implies obstruction of the lower airways, which tend to collapse and obstruct during expiration. Other characteristic sounds include:

- Gurgling is caused by liquid or semisolid foreign material in the large airways.
- Snoring arises when the pharynx is partially occluded by the soft palate or epiglottis.
- Crowing is the sound of laryngeal spasm.

In a patient who is making respiratory efforts, complete airway obstruction causes paradoxical chest and abdominal movement, often described as 'see-saw' breathing. As the patient attempts to breathe in, the chest is drawn in and the abdomen expands; the opposite occurs during expiration. This is in contrast to the

normal breathing pattern of synchronous movement upwards and outwards of the abdomen (pushed down by the diaphragm) with the lifting of the chest wall. During airway obstruction, other accessory muscles of respiration are used, with the neck and the shoulder muscles contracting to assist movement of the thoracic cage. Full examination of the neck, chest and abdomen is required to differentiate the paradoxical movements that may mimic normal respiration. The examination must include listening for the absence of breath sounds in order to diagnose complete airway obstruction reliably; any noisy breathing indicates partial airway obstruction. During apnoea, when spontaneous breathing movements are absent, complete airway obstruction is recognised by failure to inflate the lungs during attempted positive pressure ventilation. Unless airway patency can be re-established to enable adequate lung ventilation within a period of a very few minutes, neurological and other vital organ injury may occur, leading to cardiac arrest.

##### Basic airway management

Once any degree of obstruction is recognised, immediate measures must be taken to create and maintain a clear airway. There are three manoeuvres that may improve the patency of an airway obstructed by the tongue or other upper airway structures: head tilt, chin lift, and jaw thrust.

###### *Head tilt and chin lift*

The rescuer's hand is placed on the patient's forehead and the head gently tilted back; the fingertips of the other hand are placed under the point of the patient's chin, which is lifted gently to stretch the anterior neck structures (Fig. 4.3).<sup>310–315</sup>



Fig. 4.3. Head tilt and chin lift.






Fig. 4.4. Jaw thrust.

#### Jaw thrust

Jaw thrust is an alternative manoeuvre for bringing the mandible forward and relieving obstruction by the soft palate and epiglottis. The rescuer's index and other fingers are placed behind the angle of the mandible, and pressure is applied upwards and forwards. Using the thumbs, the mouth is opened slightly by downward displacement of the chin (Fig. 4.4).

These simple positional methods are successful in most cases where airway obstruction results from relaxation of the soft tissues. If a clear airway cannot be achieved, look for other causes of airway obstruction. Use a finger sweep, forceps or suction to remove any solid foreign body seen in the mouth. Remove broken or displaced dentures, but leave well-fitting dentures as they help to maintain the contours of the mouth, facilitating a good seal for ventilation.

#### Airway management in patients with suspected cervical spine injury

If spinal injury is suspected (e.g., if the victim has fallen, been struck on the head or neck, or has been rescued after diving into shallow water), maintain the head, neck, chest and lumbar region in the neutral position during resuscitation. Excessive head tilt could aggravate the injury and damage the cervical spinal cord;<sup>316–320</sup> however, this complication has not been documented and the relative risk is unknown. When there is a risk of cervical spine injury, establish a clear upper airway by using jaw thrust or chin lift in combination with manual in-line stabilisation (MILS) of the head and neck by an assistant.<sup>321,322</sup> If life-threatening airway obstruction persists despite effective application of jaw thrust or chin lift, add head tilt in small increments until the airway is open; establishing a patent airway takes priority over concerns about a potential cervical spine injury.

#### Adjuncts to basic airway techniques

Despite a total lack of published data on the use of nasopharyngeal and oropharyngeal airways during CPR, they are often helpful, and sometimes essential, to maintain an open airway, particularly when resuscitation is prolonged. The position of the head and neck must be maintained to keep the airway aligned. Oropharyngeal and nasopharyngeal airways overcome backward displacement of the soft palate and tongue in an unconscious patient, but head tilt and jaw thrust may also be required.

#### Oropharyngeal airways

Oropharyngeal airways are available in sizes suitable for the newborn to large adults. An estimate of the size required is obtained by selecting an airway with a length corresponding to the vertical distance between the patient's incisors and the angle of the jaw. The most common sizes are 2, 3 and 4 for small, medium and large adults, respectively.

If the glossopharyngeal and laryngeal reflexes are present, insertion of an oropharyngeal may cause airway vomiting or laryngospasm; thus, insertion should be attempted only in comatose patients (Fig. 4.5). The oropharyngeal airway can become obstructed at three possible sites:<sup>323</sup> part of the tongue can occlude the end of the airway; the airway can lodge in the vallecula; and the airway can be obstructed by the epiglottis.

#### Nasopharyngeal airways

In patients who are not deeply unconscious, a nasopharyngeal airway is tolerated better than an oropharyngeal airway. The nasopharyngeal airway may be life saving in patients with clenched jaws, trismus or maxillofacial injuries, when insertion of an oral airway is impossible. Inadvertent insertion of a nasopharyngeal airway through a fracture of the skull base and into the cranial vault is possible, but extremely rare.<sup>324,325</sup> In the presence of a known or suspected basal skull fracture an oral airway is preferred but, if this is not possible and the airway is obstructed, gentle insertion of a nasopharyngeal airway may be life saving (i.e., the benefits may far outweigh the risks).



Fig. 4.5. Insertion of oropharyngeal airway.

The tubes are sized in millimetres according to their internal diameter, and the length increases with diameter. The traditional methods of sizing a nasopharyngeal airway (measurement against the patient's little finger or anterior nares) do not correlate with the airway anatomy and are unreliable.<sup>326</sup> Sizes of 6–7 mm are suitable for adults. Insertion can cause damage to the mucosal lining of the nasal airway, resulting in bleeding in up to 30% of cases.<sup>327</sup> If the tube is too long it may stimulate the laryngeal or glossopharyngeal reflexes to produce laryngospasm or vomiting.

### Oxygen

During CPR, give oxygen whenever it is available. There are no data to indicate the optimal arterial blood oxygen saturation ( $\text{SaO}_2$ ) during CPR. There are animal data<sup>328</sup> and some observational clinical data indicating an association between high  $\text{SaO}_2$  after ROSC and worse outcome.<sup>329</sup> A standard oxygen mask will deliver up to 50% oxygen concentration, providing the flow of oxygen is high enough. A mask with a reservoir bag (non-rebreathing mask), can deliver an inspired oxygen concentration of 85% at flows of  $10\text{--}15\text{ l min}^{-1}$ . Initially, give the highest possible oxygen concentration. As soon as the arterial blood oxygen saturation can be measured reliably, by pulse oximeter ( $\text{SpO}_2$ ) or arterial blood gas analysis, titrate the inspired oxygen concentration to achieve an arterial blood oxygen saturation in the range of 94–98%.

### Suction

Use a wide-bore rigid sucker (Yankauer) to remove liquid (blood, saliva and gastric contents) from the upper airway. Use the sucker cautiously if the patient has an intact gag reflex; pharyngeal stimulation can provoke vomiting.

### Ventilation

Provide artificial ventilation as soon as possible for any patient in whom spontaneous ventilation is inadequate or absent. Expired air ventilation (rescue breathing) is effective, but the rescuer's expired oxygen concentration is only 16–17%, so it must be replaced as soon as possible by ventilation with oxygen-enriched air. The pocket resuscitation mask is used widely. It is similar to an anaesthetic facemask, and enables mouth-to-mask ventilation. It has a unidirectional valve, which directs the patient's expired air away from the rescuer. The mask is transparent so that vomit or blood from the patient can be seen. Some masks have a connector for the addition of oxygen. When using masks without a connector, supplemental oxygen can be given by placing the tubing underneath one side and ensuring an adequate seal. Use a two-hand technique to maximise the seal with the patient's face (Fig. 4.6).

High airway pressures can be generated if the tidal volume or inspiratory flow is excessive, predisposing to gastric inflation and subsequent risk of regurgitation and pulmonary aspiration. The possibility of gastric inflation is increased by:

- malalignment of the head and neck, and an obstructed airway;
- an incompetent oesophageal sphincter (present in all patients with cardiac arrest);
- a high airway inflation pressure.

Conversely, if inspiratory flow is too low, inspiratory time will be prolonged and the time available to give chest compressions is reduced. Deliver each breath over approximately 1 s and transfer a volume that corresponds to normal chest movement; this represents a compromise between giving an adequate volume, minimising the risk of gastric inflation, and allowing adequate time for chest compressions. During CPR with an unprotected airway,



Fig. 4.6. Mouth-to-mask ventilation.

give two ventilations after each sequence of 30 chest compressions.

### Self-inflating bag

The self-inflating bag can be connected to a facemask, tracheal tube or supraglottic airway device (SAD). Without supplemental oxygen, the self-inflating bag ventilates the patient's lungs with ambient air (21% oxygen). The delivered oxygen concentration can be increased to about 85% by using a reservoir system and attaching oxygen at a flow  $10\text{ l min}^{-1}$ .

Although the bag-mask device enables ventilation with high concentrations of oxygen, its use by a single person requires considerable skill. When used with a face mask, it is often difficult to achieve a gas-tight seal between the mask and the patient's face, and to maintain a patent airway with one hand while squeezing the bag with the other.<sup>330</sup> Any significant leak will cause hypoventilation and, if the airway is not patent, gas may be forced into the stomach.<sup>331,332</sup> This will reduce ventilation further and greatly increase the risk of regurgitation and aspiration.<sup>333</sup> Cricoid pressure can reduce this risk<sup>334,335</sup> but requires the presence of a trained assistant. Poorly applied cricoid pressure may make it more difficult to ventilate the patient's lungs.<sup>334,336–339</sup>

The two-person technique for bag-mask ventilation is preferable (Fig. 4.7). One person holds the facemask in place using a jaw thrust with both hands, and an assistant squeezes the bag. In this way, a better seal can be achieved and the patient's lungs can be ventilated more effectively and safely.

Once a tracheal tube or a supraglottic airway device has been inserted, ventilate the lungs at a rate of  $10\text{ breaths min}^{-1}$  and continue chest compressions without pausing during ventilations. The laryngeal seal achieved with a supraglottic airway device is unlikely to be good enough to prevent at least some gas leaking when inspiration coincides with chest compressions. Moderate gas leakage is acceptable, particularly as most of this gas will pass up through the patient's mouth. If excessive gas leakage results in inadequate ventilation of the patient's lungs, chest compressions will have to be



Fig. 4.7. The two-person technique for bag-mask ventilation.

interrupted to enable ventilation, using a compression-ventilation ratio of 30:2.

#### Automatic ventilators

Very few studies address specific aspects of ventilation during advanced life support. There is some data indicating that the ventilation rates delivered by healthcare personnel during cardiac arrest are excessive,<sup>242,340,341</sup> although other studies have shown more normal ventilation rates.<sup>245,342,343</sup> Automatic ventilators or resuscitators provide a constant flow of gas to the patient during inspiration; the volume delivered is dependent on the inspiratory time (a longer time provides a greater tidal volume). Because pressure in the airway rises during inspiration, these devices are often pressure limited to protect the lungs against barotrauma. An automatic ventilator can be used with either a facemask or other airway device (e.g., tracheal tube, supraglottic airway device).

An automatic resuscitator should be set initially to deliver a tidal volume of 6–7 ml kg<sup>-1</sup> at 10 breaths min<sup>-1</sup>. Some ventilators have coordinated markings on the controls to facilitate easy and rapid adjustment for patients of different sizes, and others are capable of sophisticated variation in respiratory parameters. In the presence of a spontaneous circulation, the correct setting will be determined by analysis of the patient's arterial blood gases.

Automatic resuscitators provide many advantages over alternative methods of ventilation.

- In unintubated patients, the rescuer has both hands free for mask and airway alignment.
- Cricoid pressure can be applied with one hand while the other seals the mask on the face.
- In intubated patients they free the rescuer for other tasks.<sup>344</sup>
- Once set, they provide a constant tidal volume, respiratory rate and minute ventilation; thus, they may help to avoid excessive ventilation.
- Are associated with lower peak airway pressures than manual ventilation, which reduces intrathoracic pressure and facilitates improved venous return and subsequent cardiac output.

A manikin study of simulated cardiac arrest and a study involving fire-fighters ventilating the lungs of anaesthetised patients both showed a significant decrease in gastric inflation with manually-triggered flow-limited oxygen-powered resuscitators and mask compared with a bag-mask.<sup>345,346</sup> However, the effect of automatic resuscitators on gastric inflation in humans in cardiac arrest has not been studied, and there are no data demonstrating clear benefit over bag-valve-mask devices.

#### Passive oxygen delivery

In the presence of a patent airway, chest compressions alone may result in some ventilation of the lungs.<sup>347</sup> Oxygen can be delivered passively, either via an adapted tracheal tube (Boussignac tube),<sup>348,349</sup> or with the combination of an oropharyngeal airway and standard oxygen mask with non-rebreather reservoir.<sup>350</sup> Although one study has shown higher neurologically intact survival with passive oxygen delivery (oral airway and oxygen mask) compared with bag-mask ventilation after out-of-hospital VF cardiac arrest, this was a retrospective analysis and is subject to numerous confounders.<sup>350</sup> There is insufficient evidence to support or refute the use of passive oxygen delivery during CPR to improve outcome when compared with oxygen delivery by positive pressure ventilation. Until further data are available, passive oxygen delivery without ventilation is not recommended for routine use during CPR.

#### Alternative airway devices

The tracheal tube has generally been considered the optimal method of managing the airway during cardiac arrest. There is evidence that, without adequate training and experience, the incidence of complications, such as unrecognised oesophageal intubation (6–17% in several studies involving paramedics)<sup>351–354</sup> and dislodgement, is unacceptably high.<sup>355</sup> Prolonged attempts at tracheal intubation are harmful; the cessation of chest compressions during this time will compromise coronary and cerebral perfusion. Several alternative airway devices have been considered for airway management during CPR. There are published studies on the use during CPR of the Combitube, the classic laryngeal mask airway (cLMA), the laryngeal tube (LT) and the I-gel, but none of these studies have been powered adequately to enable survival to be studied as a primary endpoint; instead, most researchers have studied insertion and ventilation success rates. The supraglottic airway devices (SADs) are easier to insert than a tracheal tube and, unlike tracheal intubation, can generally be inserted without interrupting chest compressions.<sup>356</sup>

There are no data supporting the routine use of any specific approach to airway management during cardiac arrest. The best technique is dependent on the precise circumstances of the cardiac arrest and the competence of the rescuer.

#### Laryngeal mask airway (LMA)

The laryngeal mask airway (Fig. 4.8) is quicker and easier to insert than a tracheal tube.<sup>357–364</sup> The original LMA (cLMA), which is reusable, has been studied during CPR, but none of these studies has compared it directly with the tracheal tube. A wide variety of single-use LMAs are used for CPR, but they have different characteristics to the cLMA and there are no published data on their performance in this setting.<sup>365</sup> Reported rates of successful ventilation during CPR with the LMA are very high for in-hospital studies (86–100%)<sup>366–369</sup> but generally less impressive (71–90%)<sup>370–372</sup> for out-of-hospital cardiac arrest (OHCA). The reason for the relatively disappointing results from the LMA in OHCA is not clear.





Fig. 4.8. Insertion of a laryngeal mask airway.

When used by inexperienced personnel, ventilation of the lungs of anaesthetised patients is more efficient and easier with an LMA than with a bag-mask.<sup>330</sup> When an LMA can be inserted without delay it is preferable to avoid bag-mask ventilation altogether. In comparison with bag-mask ventilation, use of a self-inflating bag and LMA during cardiac arrest reduces the incidence of regurgitation.<sup>333</sup> One study showed similar arterial blood gas values in patients successfully resuscitated after out-of-hospital cardiac arrest when either an LMA or bag mask was used.<sup>373</sup>

In comparison with tracheal intubation, the perceived disadvantages of the LMA are the increased risk of aspiration and inability to provide adequate ventilation in patients with low lung and/or chest-wall compliance. There are no data demonstrating whether or not it is possible to provide adequate ventilation via an LMA without interruption of chest compressions. The ability to ventilate the lungs adequately while continuing to compress the chest may be one of the main benefits of a tracheal tube. There are remarkably few cases of pulmonary aspiration reported in the studies of the LMA during CPR.

#### Combitube

The Combitube is a double-lumen tube introduced blindly over the tongue, and provides a route for ventilation whether the tube has passed into the oesophagus. There are many studies of the Combitube in CPR and successful ventilation was achieved in 79–98% of patients.<sup>371,374–381</sup> Two RCTs of the Combitube versus tracheal intubation for out-of-hospital cardiac arrest showed no difference in survival.<sup>380,381</sup> Use of the Combitube is waning and in many parts of the world it is being replaced by other devices such as the LT.

#### Laryngeal tube

The LT was introduced in 2001 (Fig. 4.9); it is known as the King LT airway in the United States. In anaesthetised patients, the performance of the LT is favourable in comparison with the classic LMA and ProSeal LMA.<sup>382,383</sup> After just 2 h of training, nurses successfully inserted a laryngeal tube and achieved ventilation in 24 of 30 (80%) of OHCA.<sup>384</sup> A disposable version of the laryngeal tube (LT-D) is available and was inserted successfully by paramedics in 92 OHCA (85 on the first attempt and 7 on the second attempt).<sup>385</sup>



Fig. 4.9. Laryngeal tube. © 2010 ERC.

In a manikin CPR study, use of the LT-D reduced the no-flow time significantly in comparison with use of a tracheal tube.<sup>386</sup>

#### I-gel

The cuff of the I-gel is made of thermoplastic elastomer gel (styrene ethylene butadiene styrene) and does not require inflation; the stem of the I-gel incorporates a bite block and a narrow oesophageal drain tube (Fig. 4.10). It is very easy to insert, requiring only minimal training and a laryngeal seal pressure of 20–24 cm H<sub>2</sub>O can be achieved.<sup>387,388</sup> In two manikin studies, insertion of the I-gel was significantly faster than several other airway devices.<sup>356,389</sup> The ease of insertion of the I-gel and its favourable leak pressure make it theoretically very attractive as a resuscitation airway device for those inexperienced in tracheal intubation. Use of the I-gel during cardiac arrest has been reported but more data on its use in this setting are awaited.<sup>390,391</sup>

#### Other airway devices

##### ProSeal LMA

The ProSeal LMA (PLMA) has been studied extensively in anaesthetised patients, but there are no studies of its function and performance during CPR. It has several attributes that, in theory, make it more suitable than the cLMA for use during CPR: improved seal with the larynx enabling ventilation at higher airway



Fig. 4.10. I-gel. © 2010 ERC.



pressures,<sup>392</sup> the inclusion of a gastric drain tube enabling venting of liquid regurgitated gastric contents from the upper oesophagus and passage of a gastric tube to drain liquid gastric contents, and the inclusion of a bite block. The PLMA is slightly more difficult to insert than a cLMA and is relatively expensive. The Supreme LMA (SLMA) is a disposable version of the PLMA. Studies in anaesthetised patients indicate that it is relatively easy to insert and laryngeal seal pressures of 24–28 cm H<sub>2</sub>O can be achieved.<sup>393–395</sup> Data on the use of the SLMA during cardiac arrest are awaited.

#### *Intubating LMA*

The intubating LMA (ILMA) is relatively easy to insert<sup>396,397</sup> but subsequent blind insertion of a tracheal tube generally requires more training.<sup>398</sup> One study has documented use of the ILMA after failed intubation by direct laryngoscopy in 24 cardiac arrests by prehospital physicians in France.<sup>399</sup>

#### **Tracheal intubation**

There is insufficient evidence to support or refute the use of any specific technique to maintain an airway and provide ventilation in adults with cardiopulmonary arrest. Despite this, tracheal intubation is perceived as the optimal method of providing and maintaining a clear and secure airway. It should be used only when trained personnel are available to carry out the procedure with a high level of skill and confidence. A recent systematic review of randomised controlled trials (RCTs) of tracheal intubation versus alternative airway management in acutely ill and injured patients identified just three trials<sup>400</sup>: two were RCTs of the Combitube versus tracheal intubation for out-of-hospital cardiac arrest,<sup>380,381</sup> which showed no difference in survival. The third study was a RCT of prehospital tracheal intubation versus management of the airway with a bag-mask in children requiring airway management for cardiac arrest, primary respiratory disorders and severe injuries.<sup>401</sup> There was no overall benefit for tracheal intubation; on the contrary, of the children requiring airway management for a respiratory problem, those randomised to intubation had a lower survival rate than those in the bag-mask group. The Ontario Prehospital Advanced Life Support (OPALS) study documented no increase in survival to hospital discharge when the skills of tracheal intubation and injection of cardiac drugs were added to an optimised basic life support-automated external defibrillator (BLS-AED) system.<sup>244</sup>

The perceived advantages of tracheal intubation over bag-mask ventilation include: enabling ventilation without interrupting chest compressions<sup>402</sup>; enabling effective ventilation, particularly when lung and/or chest compliance is poor; minimising gastric inflation and therefore the risk of regurgitation; protection against pulmonary aspiration of gastric contents; and the potential to free the rescuer's hands for other tasks. Use of the bag-mask is more likely to cause gastric distension that, theoretically, is more likely to cause regurgitation with risk of aspiration. However, there are no reliable data to indicate that the incidence of aspiration is any more in cardiac arrest patients ventilated with bag-mask versus those that are ventilated via tracheal tube.

The perceived disadvantages of tracheal intubation over bag-valve-mask ventilation include:

- The risk of an unrecognised misplaced tracheal tube—in patients with out-of-hospital cardiac arrest the reliably documented incidence ranges from 0.5% to 17%: emergency physicians—0.5%<sup>403</sup>; paramedics—2.4%,<sup>404</sup> 6%,<sup>351,352</sup> 9%,<sup>353</sup> 17%.<sup>354</sup>
- A prolonged period without chest compressions while intubation is attempted—in a study of prehospital intubation by paramedics during 100 cardiac arrests the total duration of the interruptions in CPR associated with tracheal intubation attempts was 110 s

(IQR 54–198 s; range 13–446 s) and in 25% the interruptions were more than 3 min.<sup>405</sup> Tracheal intubation attempts accounted for almost 25% of all CPR interruptions.

- A comparatively high failure rate. Intubation success rates correlate with the intubation experience attained by individual paramedics.<sup>406</sup> Rates for failure to intubate are as high as 50% in prehospital systems with a low patient volume and providers who do not perform intubation frequently.<sup>407,408</sup>

Healthcare personnel who undertake prehospital intubation should do so only within a structured, monitored programme, which should include comprehensive competency-based training and regular opportunities to refresh skills. Rescuers must weigh the risks and benefits of intubation against the need to provide effective chest compressions. The intubation attempt may require some interruption of chest compressions but, once an advanced airway is in place, ventilation will not require interruption of chest compressions. Personnel skilled in advanced airway management should be able to undertake laryngoscopy without stopping chest compressions; a brief pause in chest compressions will be required only as the tube is passed through the vocal cords. Alternatively, to avoid any interruptions in chest compressions, the intubation attempt may be deferred until return of spontaneous circulation.<sup>350,409</sup> No intubation attempt should interrupt chest compressions for more than 10 s; if intubation is achievable within these constraints, recommence bag-mask ventilation. After intubation, tube placement must be confirmed and the tube secured adequately.

#### *Confirmation of correct placement of the tracheal tube*

Unrecognised oesophageal intubation is the most serious complication of attempted tracheal intubation. Routine use of primary and secondary techniques to confirm correct placement of the tracheal tube should reduce this risk.

#### *Clinical assessment*

Primary assessment includes observation of chest expansion bilaterally, auscultation over the lung fields bilaterally in the axillae (breath sounds should be equal and adequate) and over the epigastrium (breath sounds should not be heard). Clinical signs of correct tube placement (condensation in the tube, chest rise, breath sounds on auscultation of lungs, and inability to hear gas entering the stomach) are not completely reliable. The reported sensitivity (proportion of tracheal intubations correctly identified) and specificity (proportion of oesophageal intubations correctly identified) of clinical assessment varies: sensitivity 74–100%; specificity 66–100%.<sup>403,410–413</sup>

Secondary confirmation of tracheal tube placement by an exhaled carbon dioxide or oesophageal detection device should reduce the risk of unrecognised oesophageal intubation but the performance of the available devices varies considerably. Furthermore, none of the secondary confirmation techniques will differentiate between a tube placed in a main bronchus and one placed correctly in the trachea.

There are inadequate data to identify the optimal method of confirming tube placement during cardiac arrest, and all devices should be considered as adjuncts to other confirmatory techniques.<sup>414</sup> There are no data quantifying their ability to monitor tube position after initial placement.

#### *Oesophageal detector device*

The oesophageal detector device creates a suction force at the tracheal end of the tracheal tube, either by pulling back the plunger on a large syringe or releasing a compressed flexible bulb. Air is aspirated easily from the lower airways through a tracheal tube placed in the cartilage-supported rigid trachea. When the tube is in

the oesophagus, air cannot be aspirated because the oesophagus collapses when aspiration is attempted. The oesophageal detector device may be misleading in patients with morbid obesity, late pregnancy or severe asthma or when there are copious tracheal secretions; in these conditions the trachea may collapse when aspiration is attempted.<sup>352,410,415–417</sup> The performance of the syringe oesophageal detector device for identifying tracheal tube position has been reported in five cardiac arrest studies<sup>352,418–421</sup>; the sensitivity was 73–100% and the specificity 50–100%. The performance of the bulb oesophageal detector device for identifying tracheal tube position has been reported in three cardiac arrest studies<sup>410,415,421</sup>; the sensitivity was 71–75% and specificity 89–100%.

#### Carbon dioxide detectors

Carbon dioxide (CO<sub>2</sub>) detector devices measure the concentration of exhaled carbon dioxide from the lungs. The persistence of exhaled CO<sub>2</sub> after six ventilations indicates placement of the tracheal tube in the trachea or a main bronchus.<sup>403</sup> Confirmation of correct placement above the carina will require auscultation of the chest bilaterally in the mid-axillary lines. Broadly, there are three types of carbon dioxide detector device:

1. Disposable colorimetric end-tidal carbon dioxide (ETCO<sub>2</sub>) detectors use a litmus paper to detect CO<sub>2</sub>, and these devices generally give readings of purple (ETCO<sub>2</sub> < 0.5%), tan (ETCO<sub>2</sub> 0.5–2%) and yellow (ETCO<sub>2</sub> > 2%). In most studies, tracheal placement of the tube is considered verified if the tan colour persists after a few ventilations. In cardiac arrest patients, eight studies reveal 62–100% sensitivity in detecting tracheal placement of the tracheal tube and an 86–100% specificity in identifying non-tracheal position.<sup>258,414,420,422–426</sup> Although colorimetric CO<sub>2</sub> detectors identify placement in patients with good perfusion quite well, these devices are less accurate than clinical assessment in cardiac arrest patients because pulmonary blood flow may be so low that there is insufficient exhaled carbon dioxide. Furthermore, if the tracheal tube is in the oesophagus, six ventilations may lead to gastric distension, vomiting and aspiration.
2. Non-waveform electronic digital ETCO<sub>2</sub> devices generally measure ETCO<sub>2</sub> using an infrared spectrometer and display the results with a number; they do not provide a waveform graphical display of the respiratory cycle on a capnograph. Five studies of these devices for identification of tracheal tube position in cardiac arrest document 70–100% sensitivity and 100% specificity.<sup>403,412,414,418,422,427</sup>
3. End-tidal CO<sub>2</sub> detectors that include a waveform graphical display (capnographs) are the most reliable for verification of tracheal tube position during cardiac arrest. Two studies of waveform capnography to verify tracheal tube position in victims of cardiac arrest demonstrate 100% sensitivity and 100% specificity in identifying correct tracheal tube placement.<sup>403,428</sup> Three studies with a cumulative total of 194 tracheal and 22 oesophageal tube placements documented an overall 64% sensitivity and 100% specificity in identifying correct tracheal tube placement when using a capnograph in prehospital cardiac arrest victims.<sup>410,415,421</sup> However, in these studies intubation was undertaken only after arrival at hospital (time to intubation averaged more than 30 min) and many of the cardiac arrest victims studied had prolonged resuscitation times and very prolonged transport time.

Based on the available data, the accuracy of colorimetric CO<sub>2</sub> detectors, oesophageal detector devices and non-waveform capnometers does not exceed the accuracy of auscultation and direct visualization for confirming the tracheal position of a tube in victims of cardiac arrest. Waveform capnography is the most sensitive

and specific way to confirm and continuously monitor the position of a tracheal tube in victims of cardiac arrest and should supplement clinical assessment (auscultation and visualization of tube through cords). Waveform capnography will not discriminate between tracheal and bronchial placement of the tube—careful auscultation is essential. Existing portable monitors make capnographic initial confirmation and continuous monitoring of tracheal tube position feasible in almost all settings, including out-of-hospital, emergency department, and in-hospital locations where intubation is performed. In the absence of a waveform capnograph it may be preferable to use a supraglottic airway device when advanced airway management is indicated.

#### Thoracic impedance

There are smaller changes in thoracic impedance with oesophageal ventilations than with ventilation of the lungs.<sup>429–431</sup> Changes in thoracic impedance may be used to detect ventilation<sup>432</sup> and oesophageal intubation<sup>402,433</sup> during cardiac arrest. It is possible that this technology can be used to measure tidal volume during CPR. The role of thoracic impedance as a tool to detect tracheal tube position and adequate ventilation during CPR is undergoing further research but is not yet ready for routine clinical use.

#### Cricoid pressure

In non-arrest patients cricoid pressure may offer some measure of protection to the airway from aspiration but it may also impede ventilation or interfere with intubation. The role of cricoid during cardiac arrest has not been studied. Application of cricoid pressure during bag-mask ventilation reduces gastric inflation.<sup>334,335,434,435</sup>

Studies in anaesthetised patients show that cricoid pressure impairs ventilation in many patients, increases peak inspiratory pressures and causes complete obstruction in up to 50% of patients depending on the amount of cricoid pressure (in the range of recommended effective pressure) that is applied.<sup>334–339,436,437</sup>

The routine use of cricoid pressure in cardiac arrest is not recommended. If cricoid pressure is used during cardiac arrest, the pressure should be adjusted, relaxed or released if it impedes ventilation or intubation.

#### Securing the tracheal tube

Accidental dislodgement of a tracheal tube can occur at any time, but may be more likely during resuscitation and during transport. The most effective method for securing the tracheal tube has yet to be determined; use either conventional tapes or ties, or purpose-made tracheal tube holders.

#### Cricothyroidotomy

Occasionally it will be impossible to ventilate an apnoeic patient with a bag-mask, or to pass a tracheal tube or alternative airway device. This may occur in patients with extensive facial trauma or laryngeal obstruction caused by oedema or foreign material. In these circumstances, delivery of oxygen through a needle or surgical cricothyroidotomy may be life-saving. A tracheostomy is contraindicated in an emergency, as it is time consuming, hazardous and requires considerable surgical skill and equipment.

Surgical cricothyroidotomy provides a definitive airway that can be used to ventilate the patient's lungs until semi-elective intubation or tracheostomy is performed. Needle cricothyroidotomy is a much more temporary procedure providing only short-term oxygenation. It requires a wide-bore, non-kinking cannula, a high-pressure oxygen source, runs the risk of barotrauma and can be particularly ineffective in patients with chest trauma. It is also

prone to failure because of kinking of the cannula, and is unsuitable for patient transfer.

#### 4f Assisting the circulation

##### Drugs and fluids for cardiac arrest

This topic is divided into: drugs used during the management of a cardiac arrest; anti-arrhythmic drugs used in the peri-arrest period; other drugs used in the peri-arrest period; fluids; and routes for drug delivery. Every effort has been made to provide accurate information on the drugs in these guidelines, but literature from the relevant pharmaceutical companies will provide the most up-to-date data.

##### Drugs used during the treatment of cardiac arrest

Only a few drugs are indicated during the immediate management of a cardiac arrest, and there is limited scientific evidence supporting their use. Drugs should be considered only after initial shocks have been delivered (if indicated) and chest compressions and ventilation have been started. The evidence for the optimal timing and order of drug delivery, and the optimal dose, is limited.

There are three groups of drugs relevant to the management of cardiac arrest that were reviewed during the 2010 Consensus Conference: vasopressors, anti-arrhythmics and other drugs. Routes of drug delivery other than the optimal intravenous route were also reviewed and are discussed.

##### Vasopressors

Despite the continued widespread use of adrenaline and increased use of vasopressin during resuscitation in some countries, there is no placebo-controlled study that shows that the routine use of any vasopressor during human cardiac arrest increases survival to hospital discharge, although improved short-term survival has been documented.<sup>245,246</sup> The primary goal of cardiopulmonary resuscitation is to re-establish blood flow to vital organs until the restoration of spontaneous circulation. Despite the lack of data from cardiac arrest in humans, vasopressors continue to be recommended as a means of increasing cerebral and coronary perfusion during CPR.

##### Adrenaline (epinephrine) versus vasopressin

Adrenaline has been the primary sympathomimetic agent for the management of cardiac arrest for 40 years.<sup>438</sup> Its alpha-adrenergic, vasoconstrictive effects cause systemic vasoconstriction, which increases coronary and cerebral perfusion pressures. The beta-adrenergic actions of adrenaline (inotropic, chronotropic) may increase coronary and cerebral blood flow, but concomitant increases in myocardial oxygen consumption, ectopic ventricular arrhythmias (particularly when the myocardium is acidotic), transient hypoxaemia due to pulmonary arteriovenous shunting, impaired microcirculation,<sup>281</sup> and worse post-cardiac arrest myocardial dysfunction<sup>283,284</sup> may offset these benefits.

The potentially deleterious beta-effects of adrenaline have led to exploration of alternative vasopressors. Vasopressin is a naturally occurring antidiuretic hormone. In very high doses it is a powerful vasoconstrictor that acts by stimulation of smooth muscle V1 receptors. Three randomised controlled trials<sup>439–441</sup> and a meta-analysis<sup>442</sup> demonstrated no difference in outcomes (ROSC, survival to discharge, or neurological outcome) with vasopressin versus adrenaline as a first line vasopressor in cardiac arrest. Two more recent studies comparing adrenaline alone or in combination with vasopressin also demonstrated no difference in ROSC, survival

to discharge or neurological outcome.<sup>443,444</sup> There are no alternative vasopressors that provide survival benefit during cardiac arrest resuscitation when compared with adrenaline.

Participants at the 2010 Consensus Conference debated in depth the treatment recommendations that should follow from this evidence. Despite the absence of data demonstrating an increase in long-term survival, adrenaline has been the standard vasopressor in cardiac arrest. It was agreed that there is currently insufficient evidence to support or refute the use of any other vasopressor as an alternative to, or in combination with, adrenaline in any cardiac arrest rhythm to improve survival or neurological outcome. Current practice still supports adrenaline as the primary vasopressor for the treatment of cardiac arrest of all rhythms. Although the evidence of benefit from the use of adrenaline is limited, it was felt that the improved short-term survival documented in some studies<sup>245,246</sup> warranted its continued use, although in the absence of clinical evidence, the dose and timing have not been changed in the 2010 guidelines.

##### Adrenaline

###### Indications.

- Adrenaline is the first drug used in cardiac arrest of any cause: it is included in the ALS algorithm for use every 3–5 min of CPR (alternate cycles).
- Adrenaline is preferred in the treatment of anaphylaxis (Section 8g).<sup>294</sup>
- Adrenaline is a second-line treatment for cardiogenic shock.

**Dose.** During cardiac arrest, the initial IV/IO dose of adrenaline is 1 mg. There are no studies showing survival benefit for higher doses of adrenaline for patients in refractory cardiac arrest. In some cases, an adrenaline infusion is required in the post-resuscitation period.

Following return of spontaneous circulation, even small doses of adrenaline (50–100 µg) may induce tachycardia, myocardial ischaemia, VT and VF. Once a perfusing rhythm is established, if further adrenaline is deemed necessary, titrate the dose carefully to achieve an appropriate blood pressure. Intravenous doses of 50 µg are usually sufficient for most hypotensive patients. Use adrenaline cautiously in patients with cardiac arrest associated with cocaine or other sympathomimetic drugs.

**Use.** Adrenaline is available most commonly in two dilutions:

- 1 in 10,000 (10 ml of this solution contains 1 mg of adrenaline).
- 1 in 1000 (1 ml of this solution contains 1 mg of adrenaline).

Both these dilutions are used routinely in Europe.

##### Anti-arrhythmics

As with vasopressors, the evidence that anti-arrhythmic drugs are of benefit in cardiac arrest is limited. No anti-arrhythmic drug given during human cardiac arrest has been shown to increase survival to hospital discharge, although amiodarone has been shown to increase survival to hospital admission.<sup>285,286</sup> Despite the lack of human long-term outcome data, the balance of evidence is in favour of the use anti-arrhythmic drugs for the management of arrhythmias in cardiac arrest.

##### Amiodarone

Amiodarone is a membrane-stabilising anti-arrhythmic drug that increases the duration of the action potential and refractory period in atrial and ventricular myocardium. Atrioventricular

conduction is slowed, and a similar effect is seen with accessory pathways. Amiodarone has a mild negative inotropic action and causes peripheral vasodilation through non-competitive  $\alpha$ -blocking effects. The hypotension that occurs with intravenous amiodarone is related to the rate of delivery and is due more to the solvent (Polysorbate 80 and benzyl alcohol), which causes histamine release, rather than the drug itself.<sup>445</sup> The use of an aqueous amiodarone preparation that is relatively free from these side effects has recently been approved for use in the United States.<sup>446,447</sup>

Following three initial shocks, amiodarone in shock-refractory VF improves the short-term outcome of survival to hospital admission compared with placebo<sup>285</sup> or lidocaine.<sup>286</sup> Amiodarone also appears to improve the response to defibrillation when given to humans or animals with VF or haemodynamically unstable ventricular tachycardia.<sup>446–450</sup> There is no evidence to indicate the optimal time at which amiodarone should be given when using a single-shock strategy. In the clinical studies to date, the amiodarone was given if VF/VT persisted after at least three shocks. For this reason, and in the absence of any other data, amiodarone 300 mg is recommended if VF/VT persists after three shocks.

**Indications.** Amiodarone is indicated in

- refractory VF/VT;
- haemodynamically stable ventricular tachycardia (VT) and other resistant tachyarrhythmias (Section 4g).

**Dose.** Consider an initial intravenous dose of 300 mg amiodarone, diluted in 5% dextrose (or other suitable solvent) to a volume of 20 ml (or from a pre-filled syringe), if VF/VT persists after the third shock. Give a further dose of 150 mg if VF/VT persists. Amiodarone can cause thrombophlebitis when injected into a peripheral vein; use a central vein if a central venous catheter is *in situ* but, if not, use a large peripheral vein or the IO route followed by a generous flush. Details about the use of amiodarone for the treatment of other arrhythmias are given in Section 4g.

**Clinical aspects of use.** Amiodarone may paradoxically be arrhythmogenic, especially if given concurrently with drugs that prolong the QT interval. However, it has a lower incidence of pro-arrhythmic effects than other anti-arrhythmic drugs under similar circumstances. The major acute adverse effects from amiodarone are hypotension and bradycardia, which can be prevented by slowing the rate of drug infusion, or can be treated with fluids and/or inotropic drugs. The side effects associated with prolonged oral use (abnormalities of thyroid function, corneal microdeposits, peripheral neuropathy, and pulmonary/hepatic infiltrates) are not relevant in the acute setting.

#### Lidocaine

Until the publication of the 2000 ILCOR guidelines, lidocaine was the anti-arrhythmic drug of choice. Comparative studies with amiodarone<sup>286</sup> have displaced it from this position, and lidocaine is now recommended only when amiodarone is unavailable. Amiodarone should be available at all hospital arrests and at all out-of-hospital arrests attended by emergency medical services.

Lidocaine is a membrane-stabilising anti-arrhythmic drug that acts by increasing the myocyte refractory period. It decreases ventricular automaticity, and its local anaesthetic action suppresses ventricular ectopic activity. Lidocaine suppresses activity of depolarised, arrhythmogenic tissues while interfering minimally with the electrical activity of normal tissues. Therefore, it is effective in suppressing arrhythmias associated with depolarisation (e.g., ischaemia, digitalis toxicity) but is relatively ineffective against

arrhythmias occurring in normally polarised cells (e.g., atrial fibrillation/flutter). Lidocaine raises the threshold for VF.

Lidocaine toxicity causes paraesthesia, drowsiness, confusion and muscular twitching progressing to convulsions. It is considered generally that a safe dose of lidocaine must not exceed  $3 \text{ mg kg}^{-1}$  over the first hour. If there are signs of toxicity, stop the infusion immediately; treat seizures if they occur. Lidocaine depresses myocardial function, but to a much lesser extent than amiodarone. The myocardial depression is usually transient and can be treated with intravenous fluids or vasopressors.

**Indications.** Lidocaine is indicated in refractory VF/VT (when amiodarone is unavailable).

**Dose.** When amiodarone is unavailable, consider an initial dose of 100 mg ( $1\text{--}1.5 \text{ mg kg}^{-1}$ ) of lidocaine for VF/pulseless VT refractory to three shocks. Give an additional bolus of 50 mg if necessary. The total dose should not exceed  $3 \text{ mg kg}^{-1}$  during the first hour.

**Clinical aspects of use.** Lidocaine is metabolised by the liver, and its half-life is prolonged if the hepatic blood flow is reduced, e.g., in the presence of reduced cardiac output, liver disease or in the elderly. During cardiac arrest normal clearance mechanisms do not function, thus high plasma concentrations may be achieved after a single dose. After 24 h of continuous infusion, the plasma half-life increases significantly. Reduce the dose in these circumstances, and regularly review the indication for continued therapy. Lidocaine is less effective in the presence of hypokalaemia and hypomagnesaemia, which should be corrected immediately.

#### Magnesium

Magnesium is an important constituent of many enzyme systems, especially those involved with ATP generation in muscle. It plays a major role in neurochemical transmission, where it decreases acetylcholine release and reduces the sensitivity of the motor endplate. Magnesium also improves the contractile response of the stunned myocardium, and limits infarct size by a mechanism that has yet to be fully elucidated.<sup>451</sup> The normal plasma range of magnesium is  $0.8\text{--}1.0 \text{ mmol l}^{-1}$ .

Hypomagnesaemia is often associated with hypokalaemia, and may contribute to arrhythmias and cardiac arrest. Hypomagnesaemia increases myocardial digoxin uptake and decreases cellular  $\text{Na}^+/\text{K}^+$ -ATP-ase activity. Patients with hypomagnesaemia, hypokalaemia, or both may become cardiotoxic even with therapeutic digitalis levels. Magnesium deficiency is not uncommon in hospitalised patients and frequently coexists with other electrolyte disturbances, particularly hypokalaemia, hypophosphataemia, hyponatraemia and hypocalcaemia.

Although the benefits of giving magnesium in known hypomagnesaemic states are recognised, the benefit of giving magnesium routinely during cardiac arrest is unproven. Studies in adults in and out of hospital<sup>287–291,452</sup> have failed to demonstrate any increase in the rate of ROSC when magnesium is given routinely during CPR.

**Indications.** Magnesium sulphate is indicated in

- ventricular or supraventricular tachycardia associated with hypomagnesaemia;
- torsades de pointes;
- digoxin toxicity.

**Dose.** Give an initial intravenous dose of 2 g (4 ml (8 mmol)) of 50% magnesium sulphate) peripherally over 1–2 min; it may be repeated after 10–15 min. Preparations of magnesium sulphate solutions differ among European countries.



**Clinical aspects of use.** Hypokalaemic patients are often hypomagnesaemic. If ventricular tachyarrhythmias arise, intravenous magnesium is a safe, effective treatment. The role of magnesium in acute myocardial infarction is still in doubt. Magnesium is excreted by the kidneys, but side effects associated with hypermagnesaemia are rare, even in renal failure. Magnesium inhibits smooth muscle contraction, causing vasodilation and a dose-related hypotension, which is usually transient and responds to intravenous fluids and vasopressors.

#### Other drugs

There is no evidence that routinely giving other drugs (e.g., atropine, procainamide, bretylium, calcium and hormones) during human cardiac arrest increases survival to hospital discharge. Recommendations for the use of these drugs are based on limited clinical studies, our understanding of the drug's pharmacodynamic properties and the pathophysiology of cardiac arrest.

#### Atropine

Atropine antagonises the action of the parasympathetic neurotransmitter acetylcholine at muscarinic receptors. Therefore, it blocks the effect of the vagus nerve on both the sinoatrial (SA) node and the atrioventricular (AV) node, increasing sinus automaticity and facilitating AV node conduction.

Side effects of atropine are dose-related (blurred vision, dry mouth and urinary retention); they are not relevant during a cardiac arrest. Acute confusional states may occur after intravenous injection, particularly in elderly patients. After cardiac arrest, dilated pupils should not be attributed solely to atropine.

Asystole during cardiac arrest is usually due to primary myocardial pathology rather than excessive vagal tone and there is no evidence that routine use of atropine is beneficial in the treatment of asystole or PEA. Several recent studies have failed to demonstrate any benefit from atropine in out-of-hospital or in-hospital cardiac arrests<sup>244,453–458</sup>; and its routine use for asystole or PEA is no longer recommended.

Atropine is indicated in:

- sinus, atrial, or nodal bradycardia when the haemodynamic condition of the patient is unstable (see Section 4g).

#### Calcium

Calcium plays a vital role in the cellular mechanisms underlying myocardial contraction. There is no data supporting any beneficial action for calcium after most cases of cardiac arrest<sup>453,459–463</sup>; conversely, other studies have suggested a possible adverse effect when given routinely during cardiac arrest (all rhythms).<sup>464,465</sup> High plasma concentrations achieved after injection may be harmful to the ischaemic myocardium and may impair cerebral recovery. Give calcium during resuscitation only when indicated specifically, i.e., in pulseless electrical activity caused by

- hyperkalaemia;
- hypocalcaemia;
- overdose of calcium channel-blocking drugs.

The initial dose of 10 ml 10% calcium chloride (6.8 mmol Ca<sup>2+</sup>) may be repeated if necessary. Calcium can slow the heart rate and precipitate arrhythmias. In cardiac arrest, calcium may be given by rapid intravenous injection. In the presence of a spontaneous circulation give it slowly. Do not give calcium solutions and sodium bicarbonate simultaneously by the same route.

#### Buffers

Cardiac arrest results in combined respiratory and metabolic acidosis because pulmonary gas exchange ceases and cellular metabolism becomes anaerobic. The best treatment of acidaemia in cardiac arrest is chest compression; some additional benefit is gained by ventilation. During cardiac arrest, arterial gas values may be misleading and bear little relationship to the tissue acid–base state<sup>292</sup>; analysis of central venous blood may provide a better estimation of tissue pH (see Section 4d). Bicarbonate causes generation of carbon dioxide, which diffuses rapidly into cells. It has the following effects.

- It exacerbates intracellular acidosis.
- It produces a negative inotropic effect on ischaemic myocardium.
- It presents a large, osmotically active, sodium load to an already compromised circulation and brain.
- It produces a shift to the left in the oxygen dissociation curve, further inhibiting release of oxygen to the tissues.

Mild acidaemia causes vasodilation and can increase cerebral blood flow. Therefore, full correction of the arterial blood pH may theoretically reduce cerebral blood flow at a particularly critical time. As the bicarbonate ion is excreted as carbon dioxide via the lungs, ventilation needs to be increased.

Several animal and clinical studies have examined the use of buffers during cardiac arrest. Clinical studies using Tribonate<sup>®466</sup> or sodium bicarbonate as buffers have failed to demonstrate any advantage.<sup>466–472</sup> Only two studies have found clinical benefit, suggesting that EMS systems using sodium bicarbonate earlier and more frequently had significantly higher ROSC and hospital discharge rates and better long-term neurological outcome.<sup>473,474</sup> Animal studies have generally been inconclusive, but some have shown benefit in giving sodium bicarbonate to treat cardiovascular toxicity (hypotension, cardiac arrhythmias) caused by tricyclic antidepressants and other fast sodium channel blockers (Section 8b).<sup>294,475</sup> Giving sodium bicarbonate routinely during cardiac arrest and CPR or after return of spontaneous circulation is not recommended. Consider sodium bicarbonate for

- life-threatening hyperkalaemia;
- cardiac arrest associated with hyperkalaemia;
- tricyclic overdose.

Give 50 mmol (50 ml of an 8.4% solution) of sodium bicarbonate intravenously. Repeat the dose as necessary, but use acid/base analysis (either arterial, central venous or marrow aspirate from IO needle) to guide therapy. Severe tissue damage may be caused by subcutaneous extravasation of concentrated sodium bicarbonate. The solution is incompatible with calcium salts as it causes the precipitation of calcium carbonate.

#### Fibrinolysis during CPR

Thrombus formation is a common cause of cardiac arrest, most commonly due to acute myocardial ischaemia following coronary artery occlusion by thrombus, but occasionally due to a dislodged venous thrombus causing a pulmonary embolism. The use of fibrinolytic drugs to break down coronary artery and pulmonary artery thrombus has been the subject of several studies. Fibrinolytics have also been demonstrated in animal studies to have beneficial effects on cerebral blood flow during cardiopulmonary resuscitation,<sup>476,477</sup> and a clinical study has reported less anoxic encephalopathy after fibrinolytic therapy during CPR.<sup>478</sup>

Several studies have examined the use of fibrinolytic therapy given during non-traumatic cardiac arrest unresponsive to

standard therapy.<sup>307,479–484</sup> and some have shown non-significant improvements in survival to hospital discharge,<sup>307,481</sup> and greater ICU survival.<sup>478</sup> A small series of case reports also reported survival to discharge in three cases refractory to standard therapy with VF or PEA treated with fibrinolytics.<sup>485</sup> Conversely, two large clinical trials<sup>486,487</sup> failed to show any significant benefit for fibrinolytics in out-of-hospital cardiac arrest unresponsive to initial interventions.

Results from the use of fibrinolytics in patients suffering cardiac arrest from suspected pulmonary embolus have been variable. A meta-analysis, which included patients with pulmonary embolus as a cause of the arrest, concluded that fibrinolytics increased the rate of ROSC, survival to discharge and long-term neurological function.<sup>488</sup> Several other studies have demonstrated an improvement in ROSC and admission to hospital or the intensive care unit, but not in survival to neurologically intact hospital discharge.<sup>307,479–481,483,484,489–492</sup>

Although several relatively small clinical studies<sup>307,479,481,490</sup> and case series<sup>478,485,493–495</sup> have not demonstrated any increase in bleeding complications with thrombolysis during CPR in non-traumatic cardiac arrest, a recent large study<sup>487</sup> and meta-analysis<sup>488</sup> have shown an increased risk of intracranial bleeding associated with the routine use of fibrinolytics during non-traumatic cardiac arrest. Successful fibrinolysis during cardiopulmonary resuscitation is usually associated with good neurological outcome.<sup>488,490,491</sup>

Fibrinolytic therapy should not be used routinely in cardiac arrest. Consider fibrinolytic therapy when cardiac arrest is caused by proven or suspected acute pulmonary embolus. Following fibrinolysis during CPR for acute pulmonary embolism, survival and good neurological outcome have been reported in cases requiring in excess of 60 min of CPR. If a fibrinolytic drug is given in these circumstances, consider performing CPR for at least 60–90 min before termination of resuscitation attempts.<sup>496,497</sup> Mortality from surgical embolectomy is high if it follows cardiac arrest and should be avoided in patients requiring CPR. In patients who are not candidates for fibrinolytic therapy, percutaneous mechanical thromboembolectomy should be considered. Ongoing CPR is not a contraindication to fibrinolysis.

### Intravenous fluids

Hypovolaemia is a potentially reversible cause of cardiac arrest. Infuse fluids rapidly if hypovolaemia is suspected. In the initial stages of resuscitation there are no clear advantages to using colloid, so use 0.9% sodium chloride or Hartmann's solution. Avoid dextrose, which is redistributed away from the intravascular space rapidly and causes hyperglycaemia, which may worsen neurological outcome after cardiac arrest.<sup>498–505</sup>

Whether fluids should be infused routinely during cardiac arrest is controversial. There are no published human studies of routine fluid use compared to no fluids during normovolaemic cardiac arrest. Two animal studies<sup>506,507</sup> show that the increase in right atrial pressure produced by infusion of normothermic fluid during CPR decreases coronary perfusion pressure, and another animal study<sup>508</sup> shows that the coronary perfusion pressure rise with adrenaline during CPR is not improved with the addition of a fluid infusion.

Small clinical studies have not shown any benefit with hypertonic fluid<sup>509</sup> or chilled fluid.<sup>510,511</sup> One animal study shows that hypertonic saline improves cerebral blood flow during CPR.<sup>512</sup> Ensure normovolaemia, but in the absence of hypovolaemia, infusion of an excessive volume of fluid is likely to be harmful.<sup>513</sup> Use intravenous fluid to flush peripherally injected drugs into the central circulation.

### Alternative routes for drug delivery

#### *Intraosseous route*

If intravenous access cannot be established within the first 2 min of resuscitation, consider gaining IO access. Intraosseous access has traditionally been used for children because of the difficulties in gaining intravenous access, but this route has now become established as a safe and effective route for gaining vascular access in adults too.<sup>271,514–517</sup> Tibial and humeral sites are readily accessible and provide equal flow rates for fluids.<sup>514</sup> Intraosseous delivery of resuscitation drugs will achieve adequate plasma concentrations. Several studies indicate that IO access is safe and effective for fluid resuscitation and drug delivery.<sup>269,518–524</sup>

#### *Drugs given via the tracheal tube*

Resuscitation drugs can also be given via the tracheal tube, but the plasma concentrations achieved using this route are very variable although generally considerably lower than those achieved by the IV or IO routes, particularly with adrenaline. Additionally, relatively large volumes of intratracheal fluid impair gas exchange. With the ease of gaining IO access and the lack of efficacy of tracheal drug administration, tracheal administration of drugs is no longer recommended

### CPR techniques and devices

At best, standard manual CPR produces coronary and cerebral perfusion that is just 30% of normal.<sup>525</sup> Several CPR techniques and devices may improve haemodynamics or short-term survival when used by well-trained providers in selected cases. However, the success of any technique or device depends on the education and training of the rescuers and on resources (including personnel). In the hands of some groups, novel techniques and adjuncts may be better than standard CPR. However, a device or technique which provides good quality CPR when used by a highly trained team or in a test setting may show poor quality and frequent interruptions when used in an uncontrolled clinical setting.<sup>526</sup> While no circulatory adjunct is currently recommended for routine use instead of manual CPR, some circulatory adjuncts are being routinely used in both out-of-hospital and in-hospital resuscitation. It is prudent that rescuers are well-trained and that if a circulatory adjunct is used, a program of continuous surveillance be in place to ensure that use of the adjunct does not adversely affect survival. Although manual chest compressions are often performed very poorly,<sup>527–529</sup> no adjunct has consistently been shown to be superior to conventional manual CPR.

#### *Open-chest CPR*

Open-chest CPR produces better coronary perfusion coronary pressure than standard CPR<sup>530</sup> and may be indicated for patients with cardiac arrest caused by trauma, in the early postoperative phase after cardiothoracic surgery<sup>531,532</sup> (see Section 8i)<sup>294</sup> or when the chest or abdomen is already open (transdiaphragmatic approach), for example, in trauma surgery.

#### *Interposed abdominal compression (IAC-CPR)*

The IAC-CPR technique involves compression of the abdomen during the relaxation phase of chest compression.<sup>533,534</sup> This enhances venous return during CPR<sup>535,536</sup> and improves ROSC and short-term survival.<sup>537,538</sup> Two studies showed improved survival to hospital discharge with IAC-CPR compared with standard CPR

for in-hospital cardiac arrest,<sup>537,538</sup> but another showed no survival advantage.<sup>539</sup>

#### *Active compression-decompression CPR (ACD-CPR)*

ACD-CPR is achieved with a hand-held device equipped with a suction cup to lift the anterior chest actively during decompression. Decreasing intrathoracic pressure during the decompression phase increases venous return to the heart and increases cardiac output and subsequent coronary and cerebral perfusion pressures during the compression phase.<sup>540–543</sup> Results of ACD-CPR have been mixed. In some clinical studies ACD-CPR improved haemodynamics compared with standard CPR,<sup>541,543–545</sup> but in another study it did not.<sup>546</sup> In three randomised studies,<sup>545,547,548</sup> ACD-CPR improved long-term survival after out-of-hospital cardiac arrest; however, in five other randomised studies, ACD-CPR made no difference to outcome.<sup>549–553</sup> The efficacy of ACD-CPR may be highly dependent on the quality and duration of training.<sup>554</sup>

A meta-analysis of 10 trials of out-of-hospital cardiac arrest and two of in-hospital cardiac arrest showed no early or late survival benefit to ACD-CPR over conventional CPR.<sup>205</sup> Two post-mortem studies have shown more rib and sternal fractures after ACD-CPR compared with conventional CPR,<sup>555,556</sup> but another found no difference.<sup>557</sup>

#### *Impedance threshold device (ITD)*

The impedance threshold device (ITD) is a valve that limits air entry into the lungs during chest recoil between chest compressions; this decreases intrathoracic pressure and increases venous return to the heart. When used with a cuffed tracheal tube and active compression–decompression (ACD),<sup>558–560</sup> the ITD is thought to act synergistically to enhance venous return during active decompression. The ITD has also been used during conventional CPR with a tracheal tube or facemask.<sup>561</sup> If rescuers can maintain a tight face-mask seal, the ITD may create the same negative intrathoracic pressure as when used with a tracheal tube.<sup>561</sup>

Most,<sup>562–569</sup> but not all,<sup>570–573</sup> animal studies have shown improved haemodynamics or outcomes during CPR when using the device. Several randomised trials have shown differing results. Two trials suggest that the use of an ITD in combination with ACD-CPR improves 24 h survival and survival to ICU admission in adult OHCA patients,<sup>560,574</sup> but these contrast with others which failed to show any improvement in ROSC or 24 h survival.<sup>558,561</sup> A recent meta-analysis demonstrated improved ROSC and short-term survival but no significant improvement in either survival to discharge or neurologically intact survival to discharge associated with the use of an ITD in the management of adult OHCA patients.<sup>575</sup> In the absence of data showing that the ITD increases survival to hospital discharge, its routine use in cardiac arrest is not recommended.

#### *Mechanical piston CPR*

Mechanical piston devices depress the sternum by means of a compressed gas-powered plunger mounted on a backboard. In several studies in animals,<sup>576</sup> mechanical piston CPR improved end-tidal carbon dioxide, cardiac output, cerebral blood flow, MAP and short-term neurological outcome. Studies in humans also document improvement in end-tidal carbon dioxide and mean arterial pressure when using mechanical piston CPR compared with conventional CPR.<sup>577–579</sup> One study has documented that the use of a piston CPR device compared with manual CPR increases interruption in CPR due to setting up and removal of the device from patients during transportation in out-of-hospital adult cardiac arrest.<sup>580</sup>

#### *Lund University cardiac arrest system (LUCAS) CPR*

The Lund University cardiac arrest system (LUCAS) is a gas-driven sternal compression device that incorporates a suction cup for active decompression. Although animal studies showed that LUCAS-CPR improves haemodynamic and short-term survival compared with standard CPR,<sup>581,582</sup> There are no published randomised human studies comparing LUCAS-CPR with standard CPR. A study using LUCAS for witnessed OHCA was unable to show any benefit (ROSC, survival to hospital or survival to hospital discharge) over standard CPR.<sup>583</sup> Case series totalling 200 patients have reported variable success in use of the LUCAS device, when implemented after an unsuccessful period of manual CPR.<sup>347,581,584–586</sup> One case series used LUCAS to perform CPR while PCI was being performed.<sup>293</sup> Eleven of 43 patients survived to hospital discharge neurologically intact. There are several other reports documenting use of LUCAS during PCI.<sup>585,587,588</sup> One post-mortem study showed similar injuries with LUCAS compared with standard CPR.<sup>589</sup> The early versions of the LUCAS device which were driven by high flow oxygen (LUCAS™1) should not be used in confined spaces where defibrillation in high ambient oxygen concentrations may risk a fire.<sup>590</sup>

#### *Load-distributing band CPR (AutoPulse)*

The load-distributing band (LDB) is a circumferential chest compression device comprising a pneumatically actuated constricting band and backboard. Although the use of LDB CPR improves haemodynamics,<sup>591–593</sup> results of clinical trials have been conflicting. Evidence from one multicenter randomised control trial in over 1000 adults documented no improvement in 4-h survival and worse neurological outcome when LDB-CPR was used by EMS providers for patients with primary out-of-hospital cardiac arrest.<sup>594</sup> However, a post hoc analysis of this study revealed significant heterogeneity between study sites.<sup>598</sup> A further study demonstrated lower odds of 30-day survival (OR 0.4) but subgroup analysis showed an increased rate of ROSC in LDB-CPR treated patients.<sup>595</sup> Other non-randomised human studies have reported increased rates of sustained ROSC,<sup>596,597</sup> increased survival to discharge following OHCA<sup>597</sup> and improved hemodynamics following failed resuscitation from in-hospital cardiac arrest.<sup>591</sup> Evidence from both clinical<sup>594,598</sup> and simulation<sup>599</sup> studies suggest that site-specific factors may influence resuscitation quality and efficacy of this device.

#### *The current status of LUCAS and AutoPulse*

Two large prospective randomised multicentre studies are currently underway to evaluate the load-distributing band (AutoPulse) and the Lund University cardiac arrest system (LUCAS). The results of these studies are awaited with interest. In hospital, mechanical devices have been used effectively to support patients undergoing primary coronary intervention (PCI)<sup>293,585</sup> and CT scans<sup>600</sup> and also for prolonged resuscitation attempts (e.g., hypothermia,<sup>601,602</sup> poisoning, thrombolysis for pulmonary embolism, prolonged transport, etc.) where rescuer fatigue may impair the effectiveness of manual chest compression. In the pre-hospital environment where extrication of patients, resuscitation in confined spaces and movement of patients on a trolley often preclude effective manual chest compressions, mechanical devices may also have an important role. During transport to hospital, manual CPR is often performed poorly; mechanical CPR can maintain good quality CPR during an ambulance transfer.<sup>343,603</sup> Mechanical devices also have the advantage of allowing defibrillation without interruption in external chest compression. The role of mechanical devices in all situations requires further evaluation.

## 4g Peri-arrest arrhythmias

The correct identification and treatment of arrhythmias in the critically ill patient may prevent cardiac arrest from occurring or from reoccurring after successful initial resuscitation. The treatment algorithms described in this section have been designed to enable the non-specialist ALS provider to treat the patient effectively and safely in an emergency; for this reason, they have been kept as simple as possible. If patients are not acutely ill there may be several other treatment options, including the use of drugs (oral or parenteral) that will be less familiar to the non-expert. In this situation there will be time to seek advice from cardiologists or other senior doctors with the appropriate expertise.

More comprehensive information on the management of arrhythmias can be found at [www.escardio.org](http://www.escardio.org).

### Principles of treatment

The initial assessment and treatment of a patient with an arrhythmia should follow the ABCDE approach. Key elements in this process include assessing for adverse signs; administration of high flow oxygen; obtaining intravenous access, and establishing monitoring (ECG, blood pressure, SpO<sub>2</sub>). Whenever possible, record a 12-lead ECG; this will help determine the precise rhythm, either before treatment or retrospectively. Correct any electrolyte abnormalities (e.g., K<sup>+</sup>, Mg<sup>2+</sup>, Ca<sup>2+</sup>). Consider the cause and context of arrhythmias when planning treatment.

The assessment and treatment of all arrhythmias addresses two factors: the condition of the patient (stable versus unstable), and the nature of the arrhythmia. Anti-arrhythmic drugs are slower in onset and less reliable than electrical cardioversion in converting a tachycardia to sinus rhythm; thus, drugs tend to be reserved for stable patients without adverse signs, and electrical cardioversion is usually the preferred treatment for the unstable patient displaying adverse signs.

### Adverse signs

The presence or absence of adverse signs or symptoms will dictate the appropriate treatment for most arrhythmias. The following adverse factors indicate a patient who is unstable because of the arrhythmia.

1. Shock—this is seen as pallor, sweating, cold and clammy extremities (increased sympathetic activity), impaired consciousness (reduced cerebral blood flow), and hypotension (e.g., systolic blood pressure <90 mm Hg).
2. Syncope—loss of consciousness, which occurs as a consequence of reduced cerebral blood flow.
3. Heart failure—arrhythmias compromise myocardial performance by reducing coronary artery blood flow. In acute situations this is manifested by pulmonary oedema (failure of the left ventricle) and/or raised jugular venous pressure, and hepatic engorgement (failure of the right ventricle).
4. Myocardial ischaemia—this occurs when myocardial oxygen consumption exceeds delivery. Myocardial ischaemia may present with chest pain (angina) or may occur without pain as an isolated finding on the 12 lead ECG (silent ischaemia). The presence of myocardial ischaemia is especially important if there is underlying coronary artery disease or structural heart disease because it may cause further life-threatening complications including cardiac arrest.

### Treatment options

Having determined the rhythm and the presence or absence of adverse signs, the options for immediate treatment are categorised as:

1. Electrical (cardioversion, pacing).
2. Pharmacological (anti-arrhythmic (and other) drugs).

### Tachycardias

#### *If the patient is unstable*

If the patient is unstable and deteriorating, with any of the adverse signs and symptoms described above being caused by the tachycardia, attempt synchronised cardioversion immediately (Fig. 4.11). In patients with otherwise normal hearts, serious signs and symptoms are uncommon if the ventricular rate is <150 beats min<sup>-1</sup>. Patients with impaired cardiac function or significant comorbidity may be symptomatic and unstable at lower heart rates. If cardioversion fails to restore sinus rhythm and the patient remains unstable, give amiodarone 300 mg intravenously over 10–20 min and re-attempt electrical cardioversion. The loading dose of amiodarone can be followed by an infusion of 900 mg over 24 h.

Repeated attempts at electrical cardioversion are not appropriate for recurrent (within hours or days) paroxysms (self-terminating episodes) of atrial fibrillation. This is relatively common in critically ill patients who may have ongoing precipitating factors causing the arrhythmia (e.g., metabolic disturbance, sepsis). Cardioversion does not prevent subsequent arrhythmias. If there are recurrent episodes, treat them with drugs.

#### *Synchronised electrical cardioversion*

If electrical cardioversion is used to convert atrial or ventricular tachyarrhythmias, the shock must be synchronised with the R wave of the ECG rather than with the T wave.<sup>604</sup> By avoiding the relative refractory period in this way, the risk of inducing ventricular fibrillation is minimised. Conscious patients must be anaesthetised or sedated before synchronised cardioversion is attempted. For a broad-complex tachycardia and AF, start with 200-J monophasic or 120–150J biphasic and increase in increments if this fails (see Section 3).<sup>223</sup> Atrial flutter and paroxysmal supraventricular tachycardia (SVT) will often convert with lower energies: start with 100-J monophasic or 70–120-J biphasic.


#### *If the patient is stable*

If the patient with tachycardia is stable (no adverse signs or symptoms) and is not deteriorating, pharmacological treatment may be possible. Evaluate the rhythm using a 12-lead ECG and assess the QRS duration. If the QRS duration is greater than 0.12 s (3 small squares on standard ECG paper) it is classified as a broad complex tachycardia. If the QRS duration is less than 0.12 s it is a narrow complex tachycardia.

All anti-arrhythmic treatments – physical manoeuvres, drugs, or electrical treatment – can also be pro-arrhythmic, so that clinical deterioration may be caused by the treatment rather than lack of effect. The use of multiple anti-arrhythmic drugs or high doses of a single drug can cause myocardial depression and hypotension. This may cause a deterioration of the cardiac rhythm. Expert help should be sought before using repeated doses or combinations of anti-arrhythmic drugs.



## Tachycardia Algorithm (with pulse)



\*Attempted electrical cardioversion is always undertaken under sedation or general anaesthesia

Fig. 4.11. Tachycardia algorithm. © 2010 ERC.

### Broad-complex tachycardia

Broad-complex tachycardias are usually ventricular in origin.<sup>605</sup> Although broad-complex tachycardias may be caused by supraventricular rhythms with aberrant conduction, in the unstable patient in the peri-arrest context assume they are ventricular in origin. In the stable patient with broad-complex tachycardia, the next step is to determine if the rhythm is regular or irregular.

#### Regular broad complex tachycardia

A regular broad-complex tachycardia is likely to be ventricular tachycardia or SVT with bundle branch block. If there is uncertainty about the source of the arrhythmia, give intravenous adenosine (using the strategy described below) as it may convert the rhythm to sinus and help diagnose the underlying rhythm.<sup>606</sup>

Stable ventricular tachycardia can be treated with amiodarone 300 mg intravenously over 20–60 min followed by an infusion of 900 mg over 24 h. Specialist advice should be sought before considering alternative treatments such as procainamide, nifekalant or sotalol.

#### Irregular broad complex tachycardia

Irregular broad complex tachycardia is most likely to be AF with bundle branch block. Another possible cause is AF with ventricular pre-excitation (Wolff–Parkinson–White (WPW) syndrome). There is more variation in the appearance and width of the QRS complexes than in AF with bundle branch block. A third possible cause is polymorphic VT (e.g., torsades de pointes), although this rhythm is relatively unlikely to be present without adverse features.

Seek expert help with the assessment and treatment of irregular broad-complex tachyarrhythmia. If treating AF with bundle branch block, treat as for AF (see below). If pre-excited AF (or atrial flutter) is suspected, avoid adenosine, digoxin, verapamil and diltiazem. These drugs block the AV node and cause a relative increase in pre-excitation—this can provoke severe tachycardias. Electrical cardioversion is usually the safest treatment option.

Treat torsades de pointes VT immediately by stopping all drugs known to prolong the QT interval. Correct electrolyte abnormalities, especially hypokalaemia. Give magnesium sulphate, 2 g, intravenously over 10 min.<sup>607,608</sup> Obtain expert help, as other treatment (e.g., overdrive pacing) may be indicated to prevent relapse once the arrhythmia has been corrected. If adverse features develop (which is usual), arrange immediate synchronised cardioversion. If the patient becomes pulseless, attempt defibrillation immediately (cardiac arrest algorithm).

### Narrow-complex tachycardia

The first step in the assessment of a narrow complex tachycardia is to determine if it is regular or irregular.

The commonest regular narrow-complex tachycardias include:

- sinus tachycardia;
- AV nodal re-entry tachycardia (AVNRT, the commonest type of SVT);
- AV re-entry tachycardia (AVRT), which is associated with Wolff–Parkinson–White (WPW) syndrome;
- atrial flutter with regular AV conduction (usually 2:1).

Irregular narrow-complex tachycardia is most commonly AF or sometimes atrial flutter with variable AV conduction ('variable block').

### Regular narrow-complex tachycardia

**Sinus tachycardia.** Sinus tachycardia is a common physiological response to a stimulus such as exercise or anxiety. In a sick patient it may be seen in response to many stimuli, such as pain, fever, anaemia, blood loss and heart failure. Treatment is almost always directed at the underlying cause; trying to slow sinus tachycardia will make the situation worse.

**AVNRT and AVRT (paroxysmal SVT).** AVNRT is the commonest type of paroxysmal SVT, often seen in people without any other form of heart disease and is relatively uncommon in a peri-arrest setting.<sup>609</sup> It causes a regular narrow-complex tachycardia, often with no clearly visible atrial activity on the ECG. Heart rates are usually well above the typical range of sinus rates at rest (60–120 beats min<sup>-1</sup>). It is usually benign, unless there is additional co-incidental structural heart disease or coronary disease.

AV re-entry tachycardia (AVRT) is seen in patients with the WPW syndrome and is also usually benign unless there happens to be additional structural heart disease. The common type of AVRT is a regular narrow-complex tachycardia, also often having no visible atrial activity on the ECG.

**Atrial flutter with regular AV conduction (often 2:1 block).** Atrial flutter with regular AV conduction (often 2:1 block) produces a regular narrow-complex tachycardia in which it may be difficult to see atrial activity and identify flutter waves with confidence, so it may be indistinguishable initially from AVNRT and AVRT. When atrial flutter with 2:1 block or even 1:1 conduction is accompanied by bundle branch block, it produces a regular broad-complex tachycardia that will usually be very difficult to distinguish from VT. Treatment of this rhythm as if it were VT will usually be effective, or will lead to slowing of the ventricular response and identification of the rhythm. Most typical atrial flutter has an atrial rate of about 300 beats min<sup>-1</sup>, so atrial flutter with 2:1 block tends to produce a tachycardia of about 150 beats min<sup>-1</sup>. Much faster rates are unlikely to be due to atrial flutter with 2:1 block.

**Treatment of regular narrow complex tachycardia.** If the patient is unstable with adverse features caused by the arrhythmia, attempt synchronised electrical cardioversion. It is reasonable to give adenosine to an unstable patient with a regular narrow-complex tachycardia while preparations are made for synchronised cardioversion; however, do not delay electrical cardioversion if the adenosine fails to restore sinus rhythm. In the absence of adverse features, proceed as follows.

- Start with vagal manoeuvres<sup>609</sup>: carotid sinus massage or the Valsalva manoeuvre will terminate up to a quarter of episodes of paroxysmal SVT. Carotid sinus massage stimulates baroreceptors, which increase vagal tone and reduces sympathetic drive, which slows conduction via the AV node. Carotid sinus massage is given by applying pressure over the carotid artery at the level of the cricoid cartilage. Massage the area with firm circular movements for about 5 s. If this does not terminate the arrhythmia, repeat on the opposite side. Avoid carotid massage if a carotid bruit is present: rupture of an atheromatous plaque could cause cerebral embolism and stroke. A Valsalva manoeuvre (forced expiration against a closed glottis) in the supine position may be the most effective technique. A practical way of achieving this without protracted explanation is to ask the patient to blow into a 20 ml syringe with enough force to push back the plunger. Record an ECG (preferably multi-lead) during each manoeuvre. If the rhythm is atrial flutter, slowing of the ventricular response will often occur and demonstrate flutter waves.

- If the arrhythmia persists and is not atrial flutter, use adenosine. Give 6 mg as a rapid intravenous bolus. Record an ECG (preferably multi-lead) during each injection. If the ventricular rate slows transiently but the arrhythmia then persists, look for atrial activity such as atrial flutter or other atrial tachycardia and treat accordingly. If there is no response to adenosine 6 mg, give a 12 mg bolus; if there is no response, give one further 12 mg-bolus. This strategy will terminate 90–95% of supraventricular arrhythmias.<sup>610</sup>
- Successful termination of a tachyarrhythmia by vagal manoeuvres or adenosine indicates that it was almost certainly AVNRT or AVRT. Monitor the patients for further rhythm abnormalities. Treat recurrence either with further adenosine or with a longer-acting drug with AV nodal-blocking action (e.g., diltiazem or verapamil).
- If adenosine is contraindicated or fails to terminate a regular narrow-complex tachycardia without demonstrating that it is atrial flutter, give a calcium channel blocker (e.g., verapamil or diltiazem).

#### *Irregular narrow-complex tachycardia*

An irregular narrow-complex tachycardia is most likely to be AF with an uncontrolled ventricular response or, less commonly, atrial flutter with variable AV block. Record a 12-lead ECG to identify the rhythm. If the patient is unstable with adverse features caused by the arrhythmia, attempt synchronised electrical cardioversion as described above. The European Society of Cardiology provides detailed guidelines on the management of AF.<sup>611</sup>

If there are no adverse features, treatment options include:

- rate control by drug therapy;
- rhythm control using drugs to encourage chemical cardioversion;
- rhythm control by electrical cardioversion;
- treatment to prevent complications (e.g., anticoagulation).

Obtain expert help to determine the most appropriate treatment for the individual patient. The longer a patient remains in AF, the greater is the likelihood of atrial clot developing. In general, patients who have been in AF for more than 48 h should not be treated by cardioversion (electrical or chemical) until they have received full anticoagulation or absence of atrial clot has been shown by transoesophageal echocardiography. If the clinical scenario dictates that cardioversion is required and the duration of AF is greater than 48 h (or the duration is unknown) give an initial intravenous bolus injection of heparin followed by a continuous infusion to maintain the activated partial thromboplastin time at 1.5–2 times the reference control value. Anticoagulation should be continued for at least 4 weeks thereafter.<sup>611</sup>

If the aim is to control heart rate, the drugs of choice are beta-blockers<sup>612,613</sup> and diltiazem.<sup>614,615</sup> Digoxin and amiodarone may be used in patients with heart failure. Magnesium has also been used although the data supporting this is more limited.<sup>616,617</sup>

If the duration of AF is less than 48 h and rhythm control is considered appropriate, chemical cardioversion may be attempted. Seek expert help and consider ibutilide, flecainide or dofetilide. Amiodarone (300 mg intravenously over 20–60 min followed by 900 mg over 24 h) may also be used but is less effective. Electrical cardioversion remains an option in this setting and will restore sinus rhythm in more patients than chemical cardioversion.

Seek expert help if any patient with AF is known or found to have ventricular pre-excitation (WPW syndrome). Avoid using adenosine, diltiazem, verapamil or digoxin in patients with pre-excited AF or atrial flutter, as these drugs block the AV node and cause a relative increase in pre-excitation.

## **Bradycardia**

A bradycardia is defined as a heart rate of  $<60$  beats  $\text{min}^{-1}$ . Bradycardia can have cardiac causes (e.g., myocardial infarction; myocardial ischaemia; sick sinus syndrome), non-cardiac causes (e.g., vasovagal response, hypothermia; hypoglycaemia; hypothyroidism, raised intracranial pressure) or be caused by drug toxicity (e.g., digoxin; beta-blockers; calcium channel blockers).

Bradycardias are caused by reduced sinoatrial node firing or failure of the atrial-ventricular conduction system. Reduced sinoatrial node firing is seen in sinus bradycardia (caused by excess vagal tone), sinus arrest, and sick sinus syndrome. Atrioventricular (AV) blocks are divided into first, second, and third degrees and may be associated with multiple medications or electrolyte disturbances, as well as structural problems caused by acute myocardial infarction and myocarditis. A first-degree AV block is defined by a prolonged P–R interval ( $>0.20$  s), and is usually benign. Second-degree AV block is divided into Mobitz types I and II. In Mobitz type I, the block is at the AV node, is often transient and may be asymptomatic. In Mobitz type II, the block is most often below the AV node at the bundle of His or at the bundle branches, and is often symptomatic, with the potential to progress to complete AV block. Third-degree heart block is defined by AV dissociation, which may be permanent or transient, depending on the underlying cause.

#### *Initial assessment*

Assess the patient with bradycardia using the ABCDE approach. Consider the potential cause of the bradycardia and look for the adverse signs. Treat any reversible causes of bradycardia identified in the initial assessment. If adverse signs are present start to treat the bradycardia. Initial treatments are pharmacological, with pacing being reserved for patients unresponsive to pharmacological treatments or with risks factors for asystole (Fig. 4.12).

#### *Pharmacological treatment*

If adverse signs are present, give atropine, 500  $\mu\text{g}$ , intravenously and, if necessary, repeat every 3–5 min to a total of 3 mg. Doses of atropine of less than 500  $\mu\text{g}$ , paradoxically, may cause further slowing of the heart rate.<sup>618</sup> In healthy volunteers a dose of 3 mg produces the maximum achievable increase in resting heart rate.<sup>619</sup> Use atropine cautiously in the presence of acute coronary ischaemia or myocardial infarction; increased heart rate may worsen ischaemia or increase the zone of infarction.

If treatment with atropine is ineffective, consider second line drugs. These include isoprenaline ( $5 \mu\text{g min}^{-1}$  starting dose), adrenaline ( $2\text{--}10 \mu\text{g min}^{-1}$ ) and dopamine ( $2\text{--}10 \mu\text{g kg}^{-1} \text{min}^{-1}$ ). Theophylline ( $100\text{--}200$  mg slow intravenous injection) should be considered if the bradycardia is caused by inferior myocardial infarction, cardiac transplant or spinal cord injury. Consider giving intravenous glucagon if beta-blockers or calcium channel blockers are a potential cause of the bradycardia. Do not give atropine to patients with cardiac transplants—it can cause a high-degree AV block or even sinus arrest.<sup>620</sup>

#### *Pacing*

Initiate transcutaneous pacing immediately if there is no response to atropine, or if atropine is unlikely to be effective.

Transcutaneous pacing can be painful and may fail to produce effective mechanical capture. Verify mechanical capture and reassess the patient's condition. Use analgesia and sedation to control pain, and attempt to identify the cause of the bradyarrhythmia.

If atropine is ineffective and transcutaneous pacing is not immediately available, fist pacing can be attempted while waiting for

## Bradycardia Algorithm




Fig. 4.12. Bradycardia algorithm. © 2010 ERC.

pacing equipment<sup>621–623</sup>: Give serial rhythmic blows with the closed fist over the left lower edge of the sternum to pace the heart at a physiological rate of 50–70 beats min<sup>-1</sup>.

Seek expert help to assess the need for temporary transvenous pacing. Temporary transvenous pacing should be considered if there is a history of recent asystole; Mobitz type II AV block; complete (third-degree) heart block (especially with broad QRS) or initial heart rate <40 beats min<sup>-1</sup>) or evidence of ventricular standstill of more than 3 s.

### Anti-arrhythmic drugs

#### Adenosine

Adenosine is a naturally occurring purine nucleotide. It slows transmission across the AV node but has little effect on other myocardial cells or conduction pathways. It is highly effective for

terminating paroxysmal SVT with re-entrant circuits that include the AV node (AVNRT). In other narrow-complex tachycardias, adenosine will reveal the underlying atrial rhythms by slowing the ventricular response. It has an extremely short half-life of 10–15 s and, therefore, is given as a rapid bolus into a fast running intravenous infusion or followed by a saline flush. The smallest dose likely to be effective is 6 mg (which is outside some current licences for an initial dose) and, if unsuccessful this can be followed with up to two doses each of 12 mg every 1–2 min. Patients should be warned of transient unpleasant side effects, in particular nausea, flushing, and chest discomfort.<sup>624</sup> Adenosine is not available in some European countries, but adenosine triphosphate (ATP) is an alternative. In a few European countries neither preparation may be available; verapamil is probably the next best choice. Theophylline and related compounds block the effect of adenosine. Patients receiving dipyridamole or carbamazepine, or with denervated (transplanted) hearts, display a markedly exaggerated effect



that may be hazardous. In these patients, or if injected into a central vein, reduce the initial dose of adenosine to 3 mg. In the presence of WPW syndrome, blockage of conduction across the AV node by adenosine may promote conduction across an accessory pathway. In the presence of supraventricular arrhythmias this may cause a dangerously rapid ventricular response. In the presence of WPW syndrome, rarely, adenosine may precipitate atrial fibrillation associated with a dangerously rapid ventricular response.

### Amiodarone

Intravenous amiodarone has effects on sodium, potassium and calcium channels as well as alpha- and beta-adrenergic blocking properties. Indications for intravenous amiodarone include:

- control of haemodynamically stable monomorphic VT, polymorphic VT and wide-complex tachycardia of uncertain origin;
- paroxysmal SVT uncontrolled by adenosine, vagal manoeuvres or AV nodal blockade;
- to control rapid ventricular rate due to accessory pathway conduction in pre-excited atrial arrhythmias;
- unsuccessful electrical cardioversion.

Give amiodarone, 300 mg intravenously, over 10–60 min depending on the circumstances and haemodynamic stability of the patient. This loading dose is followed by an infusion of 900 mg over 24 h. Additional infusions of 150 mg can be repeated as necessary for recurrent or resistant arrhythmias to a maximum manufacturer-recommended total daily dose of 2 g (this maximum licensed dose varies between different countries). In patients with severely impaired heart function, intravenous amiodarone is preferable to other anti-arrhythmic drugs for atrial and ventricular arrhythmias. Major adverse effects from amiodarone are hypotension and bradycardia, which can be prevented by slowing the rate of drug infusion. The hypotension associated with amiodarone is caused by vasoactive solvents (Polysorbate 80 and benzyl alcohol). A new aqueous formulation of amiodarone does not contain these solvents and causes no more hypotension than lidocaine.<sup>446</sup> Whenever possible, intravenous amiodarone should be given via a central venous catheter; it causes thrombophlebitis when infused into a peripheral vein. In an emergency it can be injected into a large peripheral vein.

### Calcium channel blockers: verapamil and diltiazem

Verapamil and diltiazem are calcium channel blocking drugs that slow conduction and increase refractoriness in the AV node. Intravenous diltiazem is not available in some countries. These actions may terminate re-entrant arrhythmias and control ventricular response rate in patients with a variety of atrial tachycardias. Indications include:

- stable regular narrow-complex tachycardias uncontrolled or unconverted by adenosine or vagal manoeuvres;
- to control ventricular rate in patients with AF or atrial flutter and preserved ventricular function when the duration of the arrhythmia is less than 48 h.

The initial dose of verapamil is 2.5–5 mg intravenously given over 2 min. In the absence of a therapeutic response or drug-induced adverse event, give repeated doses of 5–10 mg every 15–30 min to a maximum of 20 mg. Verapamil should be given only to patients with narrow-complex paroxysmal SVT or arrhythmias known with certainty to be of supraventricular origin. The administration of calcium channel blockers to a patient with ventricular tachycardia may cause cardiovascular collapse.

Diltiazem at a dose of 250  $\mu\text{g kg}^{-1}$ , followed by a second dose of 350  $\mu\text{g kg}^{-1}$ , is as effective as verapamil. Verapamil and, to a lesser extent, diltiazem may decrease myocardial contractility and critically reduce cardiac output in patients with severe LV dysfunction. For the reasons stated under adenosine (above), calcium channel blockers are considered harmful when given to patients with AF or atrial flutter associated with pre-excitation (WPW) syndrome.

### Beta-adrenergic blockers

Beta-blocking drugs (atenolol, metoprolol, labetalol (alpha- and beta-blocking effects), propranolol, esmolol) reduce the effects of circulating catecholamines and decrease heart rate and blood pressure. They also have cardioprotective effects for patients with acute coronary syndromes. Beta-blockers are indicated for the following tachycardias:

- narrow-complex regular tachycardias uncontrolled by vagal manoeuvres and adenosine in the patient with preserved ventricular function;
- to control rate in AF and atrial flutter when ventricular function is preserved.

The intravenous dose of atenolol ( $\beta_1$ ) is 5 mg given over 5 min, repeated if necessary after 10 min. Metoprolol ( $\beta_1$ ) is given in doses of 2–5 mg at 5-min intervals to a total of 15 mg. Propranolol ( $\beta_1$  and  $\beta_2$  effects), 100  $\mu\text{g kg}^{-1}$ , is given slowly in three equal doses at 2–3-min intervals.

Intravenous esmolol is a short-acting (half-life of 2–9 min)  $\beta_1$ -selective beta-blocker. It is given as an intravenous loading dose of 500  $\mu\text{g kg}^{-1}$  over 1 min, followed by an infusion of 50–200  $\mu\text{g kg}^{-1} \text{ min}^{-1}$ .

Side effects of beta-blockade include bradycardia, AV conduction delay and hypotension. Contraindications to the use of beta-adrenergic blocking drugs include second- or third-degree heart block, hypotension, severe congestive heart failure and lung disease associated with bronchospasm.

### Magnesium

Magnesium is the first line treatment for polymorphic ventricular tachycardia. It may also reduce ventricular rate in atrial fibrillation.<sup>617,625–627</sup> Give magnesium sulphate 2 g (8 mmol) over 10 min. This can be repeated once if necessary.

## 4h Post-resuscitation care

### Introduction

Successful ROSC is the just the first step toward the goal of complete recovery from cardiac arrest. The complex pathophysiological processes that occur following whole body ischaemia during cardiac arrest and the subsequent reperfusion response following successful resuscitation have been termed the post-cardiac arrest syndrome.<sup>628</sup> Many of these patients will require multiple organ support and the treatment they receive this post-resuscitation period influences significantly the ultimate neurological outcome.<sup>184,629–633</sup> The post-resuscitation phase starts at the location where ROSC is achieved but, once stabilised, the patient is transferred to the most appropriate high-care area (e.g., intensive care unit, coronary care unit) for continued monitoring and treatment. Of those patients admitted to intensive care units after cardiac arrest, approximately 25–56% will survive to be discharged from hospital depending on the system and quality of care.<sup>498,629,632,634–638</sup> Of the patients that survive to hospital

discharge, the vast majority have a good neurological outcome although many with some cognitive impairment.<sup>639</sup>

### Post-cardiac arrest syndrome

The post-cardiac arrest syndrome comprises post-cardiac arrest brain injury, post-cardiac arrest myocardial dysfunction, the systemic ischaemia/reperfusion response, and the persistent precipitating pathology.<sup>628</sup> The severity of this syndrome will vary with the duration and cause of cardiac arrest. It may not occur at all if the cardiac arrest is brief. Post-cardiac arrest brain injury manifests as coma, seizures, myoclonus, varying degrees of neurocognitive dysfunction and brain death. Among patients surviving to ICU admission but subsequently dying in-hospital, brain injury is the cause of death in 68% after out-of-hospital cardiac arrest and in 23% after in-hospital cardiac arrest.<sup>245,640</sup> Post-cardiac arrest brain injury may be exacerbated by microcirculatory failure, impaired autoregulation, hypercarbia, hyperoxia, pyrexia, hyperglycaemia and seizures. Significant myocardial dysfunction is common after cardiac arrest but typically recovers by 2–3 days.<sup>641,642</sup> The whole body ischaemia/reperfusion of cardiac arrest activates immunological and coagulation pathways contributing to multiple organ failure and increasing the risk of infection.<sup>643,644</sup> Thus, the post-cardiac arrest syndrome has many features in common with sepsis, including intravascular volume depletion and vasodilation.<sup>645,646</sup>

### Airway and breathing

Patients who have had a brief period of cardiac arrest responding immediately to appropriate treatment may achieve an immediate return of normal cerebral function. These patients do not require tracheal intubation and ventilation but should be given oxygen via a facemask. Hypoxaemia and hypercarbia both increase the likelihood of a further cardiac arrest and may contribute to secondary brain injury. Several animal studies indicate that hyperoxaemia causes oxidative stress and harms post-ischaemic neurones.<sup>647–650</sup> One animal study has demonstrated that adjusting the fractional inspired concentration ( $\text{FiO}_2$ ) to produce an arterial oxygen saturation of 94–96% in the first hour after ROSC ('controlled reoxygenation') achieved better neurological outcomes than achieved with the delivery of 100% oxygen.<sup>328</sup> A recent clinical registry study that included more than 6000 patients supports the animal data and shows post-resuscitation hyperoxaemia is associated with worse outcome, compared with both normoxaemia and hypoxaemia.<sup>329</sup> In clinical practice, as soon as arterial blood oxygen saturation can be monitored reliably (by blood gas analysis and/or pulse oximetry), it may be more practicable to titrate the inspired oxygen concentration to maintain the arterial blood oxygen saturation in the range of 94–98%.

Consider tracheal intubation, sedation and controlled ventilation in any patient with obtunded cerebral function. Ensure the tracheal tube is positioned correctly well above the carina. Hypocarbia causes cerebral vasoconstriction and a decreased cerebral blood flow.<sup>651</sup> After cardiac arrest, hypocapnoea induced by hyperventilation causes cerebral ischaemia.<sup>652–655</sup> There are no data to support the targeting of a specific arterial  $\text{PCO}_2$  after resuscitation from cardiac arrest, but it is reasonable to adjust ventilation to achieve normocapnia and to monitor this using the end-tidal  $\text{PCO}_2$  and arterial blood gas values.

Insert a gastric tube to decompress the stomach; gastric distension caused by mouth-to-mouth or bag-mask-valve ventilation will splint the diaphragm and impair ventilation. Give adequate doses of sedative, which will reduce oxygen consumption. Bolus doses of a neuromuscular blocking drug may be required, particularly if using therapeutic hypothermia (see below), but try to avoid infusions of neuromuscular blocking drugs because these may mask seizures.

Obtain a chest radiograph to check the position of the tracheal tube and central venous lines, assess for pulmonary oedema, and detect complications from CPR such as a pneumothorax associated with rib fractures.

### Circulation

The majority of out-of-hospital cardiac arrest patients have coronary artery disease.<sup>656,657</sup> Acute changes in coronary plaque morphology occur in 40–86% of cardiac arrest survivors and in 15–64% of autopsy studies.<sup>658</sup> It is well recognised that post-cardiac arrest patients with ST elevation myocardial infarction (STEMI) should undergo early coronary angiography and percutaneous coronary intervention (PCI) but, because chest pain and/or ST elevation are poor predictors of acute coronary occlusion in these patients,<sup>659</sup> this intervention should be considered in all post-cardiac arrest patients who are suspected of having coronary artery disease.<sup>629,633,659–665</sup> Several studies indicate that the combination of therapeutic hypothermia and PCI is feasible and safe after cardiac arrest caused by acute myocardial infarction.<sup>629,633,638,665,666</sup>

Post-cardiac arrest myocardial dysfunction causes haemodynamic instability, which manifests as hypotension, low cardiac index and arrhythmias.<sup>641</sup> Early echocardiography will enable the degree of myocardial dysfunction to be quantified.<sup>642</sup> In the ICU an arterial line for continuous blood pressure monitoring is essential. Treatment with fluid, inotropes and vasopressors may be guided by blood pressure, heart rate, urine output, and rate of plasma lactate clearance and central venous oxygen saturations. Non-invasive cardiac output monitors may help to guide treatment but there is no evidence that their use affects outcome. If treatment with fluid resuscitation and vasoactive drugs is insufficient to support the circulation, consider insertion of an intra-aortic balloon pump.<sup>629,638</sup> Infusion of relatively large volumes of fluids are tolerated remarkably well by patients with post-cardiac arrest syndrome.<sup>513,629,630,641</sup> Although early goal directed therapy is well-established in the treatment of sepsis,<sup>667</sup> and has been proposed as a treatment strategy after cardiac arrest,<sup>630</sup> there are no randomised, controlled data to support its routine use.

There are very few randomised trials evaluating the role of blood pressure on the outcome after cardiac arrest. One randomised study demonstrated no difference in the neurological outcome among patients randomised to a mean arterial blood pressure (MAP) of  $>100$  mm Hg versus  $\leq 100$  mm Hg 5 min after ROSC; however, good functional recovery was associated with a higher blood pressure during the first 2 h after ROSC.<sup>668</sup> In a registry study of more than 6000 post-cardiac arrest patients, hypotension (systolic blood pressure  $<90$  mm Hg) on admission to ICU was associated with worse outcome.<sup>668a</sup> Good outcomes have been achieved in studies of patients admitted after out-of-hospital cardiac arrest where the MAP target was low as 65–75 mm Hg<sup>629</sup> to as high as 90–100 mm Hg.<sup>632,669</sup> In the absence of definitive data, target the mean arterial blood pressure to achieve an adequate urine output ( $1 \text{ ml kg}^{-1} \text{ h}^{-1}$ ) and normal or decreasing plasma lactate values, taking into consideration the patient's normal blood pressure, the cause of the arrest and the severity of any myocardial dysfunction.<sup>628</sup> Importantly, hypothermia may increase urine output and impair lactate clearance.

Immediately after a cardiac arrest there is typically a period of hyperkalaemia. Subsequent endogenous catecholamine release promotes intracellular transportation of potassium, causing hypokalaemia. Hypokalaemia may predispose to ventricular arrhythmias. Give potassium to maintain the serum potassium concentration between 4.0 and 4.5 mmol  $\text{l}^{-1}$ .

## Disability (optimising neurological recovery)

### Cerebral perfusion

Immediately after ROSC there is a period of cerebral hyperaemia.<sup>670</sup> After asphyxial cardiac arrest, brain oedema may occur transiently after ROSC but it is rarely associated with clinically relevant increases in intracranial pressure.<sup>671,672</sup> Autoregulation of cerebral blood flow is impaired for some time after cardiac arrest, which means that cerebral perfusion varies with cerebral perfusion pressure instead of being linked to neuronal activity.<sup>673,674</sup> As discussed previously, following ROSC, maintain mean arterial pressure near the patient's normal level.

### Sedation

Although it has been common practice to sedate and ventilate patients for at least 24 h after ROSC, there are no high-level data to support a defined period of ventilation, sedation and neuromuscular blockade after cardiac arrest. Patients need to be well-sedated during treatment with therapeutic hypothermia, and the duration of sedation and ventilation is therefore influenced by this treatment. There are no data to indicate whether or not the choice of sedation influences outcome, but a combination of opioids and hypnotics is usually used. Short-acting drugs (e.g., propofol, alfentanil, remifentanil) will enable earlier neurological assessment. Adequate sedation will reduce oxygen consumption. During hypothermia, optimal sedation can reduce or prevent shivering, which enable the target temperature to be achieved more rapidly. Use of published sedation scales for monitoring these patients (e.g., the Richmond or Ramsay Scales) may be helpful.<sup>675,676</sup>

### Control of seizures

Seizures or myoclonus or both occur in 5–15% of adult patients who achieve ROSC and 10–40% of those who remain comatose.<sup>498,677–680</sup> Seizures increase cerebral metabolism by up to 3-fold<sup>681</sup> and may cause cerebral injury: treat promptly and effectively with benzodiazepines, phenytoin, sodium valproate, propofol, or a barbiturate. Myoclonus can be particularly difficult to treat; phenytoin is often ineffective. Clonazepam is the most effective antimyoclonic drug, but sodium valproate, levetiracetam and propofol may also be effective.<sup>682</sup> Maintenance therapy should be started after the first event once potential precipitating causes (e.g., intracranial haemorrhage, electrolyte imbalance) are excluded. No studies directly address the use of prophylactic anticonvulsant drugs after cardiac arrest in adults.

### Glucose control

There is a strong association between high blood glucose after resuscitation from cardiac arrest and poor neurological outcome.<sup>498–501,504,634,683,684</sup> Although one randomised controlled trial in a cardiac surgical intensive care unit showed that tight control of blood glucose (4.4–6.1 mmol l<sup>-1</sup> or 80–110 mg dl<sup>-1</sup>) using insulin reduced hospital mortality in critically ill adults,<sup>685</sup> a second study by the same group in medical ICU patients showed no mortality benefit from tight glucose control.<sup>686</sup> In one randomised trial of patients resuscitated from OHCA with ventricular fibrillation, strict glucose control (72–108 mg dl<sup>-1</sup>, 4–6 mmol l<sup>-1</sup>) gave no survival benefit compared with moderate glucose control (108–144 mg dl<sup>-1</sup>, 6–8 mmol l<sup>-1</sup>) and there were more episodes of hypoglycaemia in the strict glucose control group.<sup>687</sup> A large randomised trial of intensive glucose control (4.5–6.0 mmol l<sup>-1</sup>) versus conventional glucose control (10 mmol l<sup>-1</sup> or less) in general ICU patients reported increased 90-day mortality in patients treated

with intensive glucose control.<sup>688</sup> Another recent study and two meta-analyses of studies of tight glucose control versus conventional glucose control in critically ill patients showed no significant difference in mortality but found tight glucose control was associated with a significantly increased risk of hypoglycaemia.<sup>689–691</sup> Severe hypoglycaemia is associated with increased mortality in critically ill patients,<sup>692</sup> and comatose patients are at particular risk from unrecognised hypoglycaemia. There is some evidence that, irrespective of the target range, variability in glucose values is associated with mortality.<sup>693</sup>

Based on the available data, following ROSC blood glucose should be maintained at  $\leq 10$  mmol l<sup>-1</sup> (180 mg dl<sup>-1</sup>).<sup>694</sup> Hypoglycaemia should be avoided. Strict glucose control should not be implemented in adult patients with ROSC after cardiac arrest because of the increased risk of hypoglycaemia.

### Temperature control

#### Treatment of hyperpyrexia

A period of hyperthermia (hyperpyrexia) is common in the first 48 h after cardiac arrest.<sup>695–697</sup> Several studies document an association between post-cardiac arrest pyrexia and poor outcomes.<sup>498,695,697–700</sup> There are no randomised controlled trials evaluating the effect of treatment of pyrexia (defined as  $\geq 37.6$  °C) compared to no temperature control in patients after cardiac arrest. Although the effect of elevated temperature on outcome is not proved, it seems prudent to treat any hyperthermia occurring after cardiac arrest with antipyretics or active cooling.

#### Therapeutic hypothermia

Animal and human data indicate that mild hypothermia is neuroprotective and improves outcome after a period of global cerebral hypoxia-ischaemia.<sup>701,702</sup> Cooling suppresses many of the pathways leading to delayed cell death, including apoptosis (programmed cell death). Hypothermia decreases the cerebral metabolic rate for oxygen (CMRO<sub>2</sub>) by about 6% for each 1 °C reduction in temperature<sup>703</sup> and this may reduce the release of excitatory amino acids and free radicals.<sup>701</sup> Hypothermia blocks the intracellular consequences of excitotoxin exposure (high calcium and glutamate concentrations) and reduces the inflammatory response associated with the post-cardiac arrest syndrome.

*Which post-cardiac arrest patients should be cooled?* All studies of post-cardiac arrest therapeutic hypothermia have included only patients in coma. There is good evidence supporting the use of induced hypothermia in comatose survivors of out-of-hospital cardiac arrest caused by VF. One randomised trial<sup>704</sup> and a pseudo-randomised trial<sup>669</sup> demonstrated improved neurological outcome at hospital discharge or at 6 months in comatose patients after out-of-hospital VF cardiac arrest. Cooling was initiated within minutes to hours after ROSC and a temperature range of 32–34 °C was maintained for 12–24 h. Two studies with historical control groups showed improvement in neurological outcome after therapeutic hypothermia for comatose survivors of VF cardiac arrest.<sup>705–707</sup> Extrapolation of these data to other cardiac arrests (e.g., other initial rhythms, in-hospital arrests, paediatric patients) seems reasonable but is supported by only lower level data.

One small, randomised trial showed reduced plasma lactate values and oxygen extraction ratios in a group of comatose survivors after cardiac arrest with asystole or PEA who were cooled with a cooling cap.<sup>708</sup> Six studies with historical control groups have shown benefit using therapeutic hypothermia in comatose survivors of OHCA after all rhythm arrests.<sup>629,632,709–712</sup> Two non-randomised studies with concurrent controls indicate possible benefit of hypothermia following cardiac arrest from other initial rhythms in- and out-of-hospital.<sup>713,714</sup>

*How to cool?* The practical application of therapeutic hypothermia is divided into three phases: induction, maintenance, and rewarming.<sup>715</sup> External and/or internal cooling techniques can be used to initiate cooling. An infusion of 30 ml kg<sup>-1</sup> of 4 °C saline or Hartmann's solution decreases core temperature by approximately 1.5 °C<sup>629,633,638,706,707,711,716–727</sup> and this technique can be used to initiate cooling prehospital.<sup>511,728–731</sup>

Other methods of inducing and/or maintaining hypothermia include:

- Simple ice packs and/or wet towels are inexpensive; however, these methods may be more time consuming for nursing staff, may result in greater temperature fluctuations, and do not enable controlled rewarming.<sup>633,638,669,705,709,710,725,726,732–734</sup> Ice cold fluids alone cannot be used to maintain hypothermia,<sup>719</sup> but even the addition of simple ice packs may control the temperature adequately.<sup>725</sup>
- Cooling blankets or pads.<sup>727,735–740</sup>
- Transnasal evaporative cooling.<sup>740a</sup>
- Water or air circulating blankets.<sup>629,630,632,706,707,712,713,727,741–744</sup>
- Water circulating gel-coated pads.<sup>629,711,720,721,727,738,743,745</sup>
- Intravascular heat exchanger, placed usually in the femoral or subclavian veins.<sup>629,630,713,714,718,724,727,732,733,742,746–748</sup>
- Cardiopulmonary bypass.<sup>749</sup>

In most cases, it is easy to cool patients initially after ROSC because the temperature normally decreases within this first hour.<sup>498,698</sup> Initial cooling is facilitated by neuromuscular blockade and sedation, which will prevent shivering.<sup>750</sup> Magnesium sulphate, a naturally occurring NMDA receptor antagonist, that reduces the shivering threshold slightly, can also be given to reduce the shivering threshold.<sup>715,751</sup>

In the maintenance phase, a cooling method with effective temperature monitoring that avoids temperature fluctuations is preferred. This is best achieved with external or internal cooling devices that include continuous temperature feedback to achieve a set target temperature. The temperature is typically monitored from a thermistor placed in the bladder and/or oesophagus.<sup>715</sup> As yet, there are no data indicating that any specific cooling technique increases survival when compared with any other cooling technique; however, internal devices enable more precise temperature control compared with external techniques.<sup>727</sup>

Plasma electrolyte concentrations, effective intravascular volume and metabolic rate can change rapidly during rewarming, as they do during cooling. Thus, rewarming must be achieved slowly: the optimal rate is not known, but the consensus is currently about 0.25–0.5 °C of warming per hour.<sup>713</sup>

*When to cool?* Animal data indicate that earlier cooling after ROSC produces better outcomes.<sup>752</sup> Ultimately, starting cooling during cardiac arrest may be most beneficial—animal data indicate that this may facilitate ROSC.<sup>753,754</sup> Several clinical studies have shown that hypothermia can be initiated prehospital,<sup>510,728,729,731,740,740a</sup> but, as yet, there are no human data proving that time target temperature produces better outcomes. One registry-based case series of 986 comatose post-cardiac arrest patients suggested that time to initiation of cooling was not associated with improved neurological outcome post-discharge.<sup>665</sup> A case series of 49 consecutive comatose post-cardiac arrest patients intravascularly cooled after out-of-hospital cardiac arrest also documented that time to target temperature was not an independent predictor of neurologic outcome.<sup>748</sup>

*Physiological effects and complications of hypothermia.* The well-recognised physiological effects of hypothermia need to be managed carefully<sup>715</sup>:

- Shivering will increase metabolic and heat production, thus reducing cooling rates—strategies to reduce shivering are discussed above.
- Mild hypothermia increases systemic vascular resistance, causes arrhythmias (usually bradycardia).<sup>714</sup>
- It causes a diuresis and electrolyte abnormalities such as hypophosphatemia, hypokalemia, hypomagnesemia and hypocalcemia.<sup>715,755</sup>
- Hypothermia decreases insulin sensitivity and insulin secretion, hyperglycemia,<sup>669</sup> which will need treatment with insulin (see glucose control).
- Mild hypothermia impairs coagulation and increases bleeding although this has not been confirmed in many clinical studies.<sup>629,704</sup> In one registry study an increased rate of minor bleeding occurred with the combination of coronary angiography and therapeutic hypothermia, but this combination of interventions was the also the best predictor of good outcome.<sup>665</sup>
- Hypothermia can impair the immune system and increase infection rates.<sup>715,734,736</sup>
- The serum amylase concentration is commonly increased during hypothermia but the significance of this unclear.
- The clearance of sedative drugs and neuromuscular blockers is reduced by up to 30% at a core temperature of 34 °C.<sup>756</sup>

*Contraindications to hypothermia.* Generally recognised contraindications to therapeutic hypothermia, but which are not applied universally, include: severe systemic infection, established multiple organ failure, and pre-existing medical coagulopathy (fibrinolytic therapy is not a contraindication to therapeutic hypothermia).

#### Other therapies

Neuroprotective drugs (coenzyme Q10,<sup>737</sup> thiopental,<sup>757</sup> glucocorticoids,<sup>758,759</sup> nimodipine,<sup>760,761</sup> lidoflazine,<sup>762</sup> or diazepam<sup>452</sup>) used alone, or as an adjunct to therapeutic hypothermia, have not been demonstrated to increase neurologically intact survival when included in the post-arrest treatment of cardiac arrest. There is also insufficient evidence to support the routine use of high-volume haemofiltration<sup>763</sup> to improve neurological outcome in patients with ROSC after cardiac arrest.

#### Prognostication

Two thirds of those dying after admission to ICU following out-of-hospital cardiac arrest die from neurological injury; this has been shown both with<sup>245</sup> and without<sup>640</sup> therapeutic hypothermia. A quarter of those dying after admission to ICU following in-hospital cardiac arrest die from neurological injury. A means of predicting neurological outcome that can be applied to individual patients immediately after ROSC is required. Many studies have focused on prediction of poor long term outcome (vegetative state or death), based on clinical or test findings that indicate irreversible brain injury, to enable clinicians to limit care or withdraw organ support. The implications of these prognostic tests are such that they should have 100% specificity or zero false positive rate (FPR), i.e., proportion of individuals who eventually have a 'good' long-term outcome despite the prediction of a poor outcome. This topic of prognostication after cardiac arrest is controversial because: (1) many studies are confounded by self-fulfilling prophecy (treatment is rarely continued for long enough in sufficient patients to enable a true estimate of the false positive rate for any given prognosticator); (2) many studies include so few patients that even if the FPR is 0%, the upper limit of the 95% confidence interval may be high; and (3) most prognostication studies have been undertaken before implementation of therapeutic hypothermia



and there is evidence that this therapy makes these tests less reliable.

### Clinical examination

There are no clinical neurological signs that reliably predict poor outcome (cerebral performance category [CPC] 3 or 4, or death) less than 24 h after cardiac arrest. In adult patients who are comatose after cardiac arrest, and who have not been treated with hypothermia and who do not have confounding factors (such as hypotension, sedatives or muscle relaxants), the absence of both pupillary light and corneal reflex at  $\geq 72$  h reliably predicts poor outcome (FPR 0%; 95% CI 0–9%).<sup>680</sup> Absence of vestibulo-ocular reflexes at  $\geq 24$  h (FPR 0%; 95% CI 0–14%)<sup>764,765</sup> and a GCS motor score of 2 or less at  $\geq 72$  h (FPR 5%; 95% CI 2–9%)<sup>680</sup> are less reliable. Other clinical signs, including myoclonus, are not recommended for predicting poor outcome. The presence of myoclonus status in adults is strongly associated with poor outcome,<sup>679,680,766–768</sup> but rare cases of good neurological recovery have been described and accurate diagnosis is problematic.<sup>769–773</sup>

### Biochemical markers

Serum neuronal specific enolase elevations are associated with poor outcome for comatose patients after cardiac arrest.<sup>680,748,774–792</sup> Although specific cut-off values with a false positive rate of 0% have been reported, clinical application is limited due to variability in the 0% FPR cut-off values reported among various studies.

Serum S100 elevations are associated with poor outcome for comatose patients after cardiac arrest.<sup>680,774–776,782,784,785,787,788,791,793–798</sup>

Many other serum markers measured after sustained return of spontaneous circulation have been associated with poor outcome after cardiac arrest, including BNP,<sup>799</sup> vWF,<sup>800</sup> ICAM-1,<sup>800</sup> procalcitonin,<sup>794</sup> IL-1ra, RANTES, sTNFRII, IL-6, IL-8 and IL-10.<sup>645</sup> However, other studies found no relationship between outcome and serum IL-8,<sup>793</sup> and procalcitonin and sTREM-1.<sup>801</sup>

Worse outcomes for comatose survivors of cardiac arrest are also associated with increased levels of cerebrospinal fluid (CSF)-CK<sup>802,803</sup> and cerebrospinal fluid-CKBB.<sup>774,775,777,789,803–807</sup> However, one study found no relationship between cerebrospinal fluid-CKBB and prognosis.<sup>808</sup>

Outcomes are also associated with increased cerebrospinal fluid levels of other markers including NSE,<sup>775,784,789</sup> S100,<sup>784</sup> LDH, GOT,<sup>777,803</sup> neurofilament,<sup>809</sup> acid phosphatase and lactate.<sup>803</sup> Cerebrospinal fluid levels of beta-D-N-acetylglucosaminidase, and pyruvate were not associated with the prognosis of cardiac arrest.<sup>803</sup>

In summary, evidence does not support the use of serum or CSF biomarkers alone as predictors of poor outcomes in comatose patients after cardiac arrest with or without treatment with therapeutic hypothermia (TH). Limitations included small numbers of patients and/or inconsistency in cut-off values for predicting poor outcome.

### Electrophysiological studies

No electrophysiological study reliably predicts outcome of a comatose patient within the first 24 h after cardiac arrest. If somatosensory evoked potentials (SSEP) are measured after 24 h in comatose cardiac arrest survivors not treated with therapeutic hypothermia, bilateral absence of the N20 cortical response to median nerve stimulation predicts poor outcome (death or CPC 3 or 4) with a FPR of 0.7% (95% CI 0.1–3.7).<sup>774</sup> In the absence of confounding circumstances such as sedatives, hypotension, hypothermia or

hypoxemia, it is reasonable to use unprocessed EEG interpretation (specifically identifying generalized suppression to less than 20  $\mu$ V, burst suppression pattern with generalized epileptic activity, or diffuse periodic complexes on a flat background) observed between 24 and 72 h after ROSC to assist the prediction of a poor outcome (FPR 3%, 95% CI 0.9–11%) in comatose survivors of cardiac arrest not treated with hypothermia.<sup>774</sup> There is inadequate evidence to support the routine use of other electrophysiological studies (e.g., abnormal brainstem auditory evoked potentials) for prognostication of poor outcome in comatose cardiac arrest survivors.<sup>606</sup>

### Imaging studies

Many imaging modalities (magnetic resonance imaging [MRI], computed tomography [CT], single photon emission computed tomography [SPECT], cerebral angiography, transcranial Doppler, nuclear medicine, near infra-red spectroscopy [NIRS]) have been studied to determine their utility for prediction of outcome in adult cardiac arrest survivors.<sup>606</sup> There are no level one or level two studies that support the use of any imaging modality to predict outcome of comatose cardiac arrest survivors. Overall, those imaging studies that have been undertaken were limited by small sample sizes, variable time of imaging (many very late in the course), lack of comparison with a standardised method of prognostication, and early withdrawal of care. Despite tremendous potential, neuroimaging has yet to be proven as an independently accurate modality for prediction of outcome in individual comatose cardiac arrest survivors and, at this time, its routine use for this purpose is not recommended.

### Impact of therapeutic hypothermia on prognostication

There is inadequate evidence to recommend a specific approach to prognosticating poor outcome in post-cardiac arrest patients treated with therapeutic hypothermia. There are no clinical neurological signs, electrophysiological studies, biomarkers, or imaging modalities that can reliably predict neurological outcome in the first 24 h after cardiac arrest. Based on limited available evidence, potentially reliable prognosticators of poor outcome in patients treated with therapeutic hypothermia after cardiac arrest include bilateral absence of N20 peak on SSEP  $\geq 24$  h after cardiac arrest (FPR 0%, 95% CI 0–69%) and the absence of both corneal and pupillary reflexes 3 or more days after cardiac arrest (FPR 0%, 95% CI 0–48%).<sup>766,810</sup> Limited available evidence also suggests that a Glasgow Motor Score of 2 or less at 3 days post-ROSC (FPR 14% [95% CI 3–44%])<sup>766</sup> and the presence of status epilepticus (FPR of 7% [95% CI 1–25%] to 11.5% [95% CI 3–31%])<sup>811,812</sup> are potentially unreliable prognosticators of poor outcome in post-cardiac arrest patients treated with therapeutic hypothermia. One study of 111 post-cardiac arrest patients treated with therapeutic hypothermia attempted to validate prognostic criteria proposed by the American Academy of Neurology.<sup>774,813</sup> This study demonstrated that clinical exam findings at 36–72 h were unreliable predictors of poor neurological outcome while bilaterally absent N20 peak on somatosensory evoked potentials (false positive rate 0%, 95% CI 0–13%) and unreactive electroencephalogram background (false positive rate 0%, 95% CI 0–13%) were the most reliable. A decision rule derived using this dataset demonstrated that the presence of two independent predictors of poor neurological outcome (incomplete recovery brainstem reflexes, early myoclonus, unreactive electroencephalogram and bilaterally absent cortical SSEPs) predicted poor neurological outcome with a false positive rate of 0% (95% CI 0–14%). Serum biomarkers such as NSE are potentially valuable as adjunctive studies in prognostication of poor outcome in patients treated with hypothermia, but their reliability is limited because few patients have been studied and the assay is not well

standardisation.<sup>814,815</sup> Given the limited available evidence, decisions to limit care should not be made based on the results of a single prognostication tool.

## Organ donation

Solid organs have been successfully transplanted after cardiac death.<sup>816</sup> This group of patients offers an untapped opportunity to increase the organ donor pool. Organ retrieval from non-heart beating donors is classified as controlled or uncontrolled.<sup>817</sup> Controlled donation occurs after planned withdrawal of treatment following non-survivable injuries/illnesses. Uncontrolled donation describes donation after a patient is brought in dead or with on-going CPR that fails to restore a spontaneous circulation.

Graft function after transplantation is influenced by the duration of warm ischaemia time from cessation of cardiac output until organ preservation is undertaken. Where delays in the initiation of organ preservation are anticipated mechanical chest compression devices may be useful for maintaining effective circulation and organ perfusion whilst the necessary regulatory steps to allow organ donation to occur are undertaken.<sup>818–820</sup>

## Cardiac arrest centres

There is wide variability in survival among hospitals caring for patients after resuscitation from cardiac arrest.<sup>498,631,635,636,821–823</sup> There is some low-level evidence that ICUs admitting more than 50 post-cardiac arrest patients per year produce better survival rates than those admitting less than 20 cases per year.<sup>636</sup> Another observational study showed that unadjusted survival to discharge was greater in hospitals that received  $\geq 40$  cardiac arrest patients/year compared with those that received  $< 40$  per year, but this difference disappeared after adjustment for patient factors.<sup>824</sup>

Several studies with historic control groups have shown improved survival after implementation of a comprehensive package of post-resuscitation care that includes therapeutic hypothermia and percutaneous coronary intervention.<sup>629,632,633</sup> There is also evidence of improved survival after out-of-hospital cardiac arrest in large hospitals with cardiac catheter facilities compared with smaller hospitals with no cardiac catheter facilities.<sup>631</sup> Several studies of out-of-hospital adult cardiac arrest failed to demonstrate any effect of transport interval from the scene to the receiving hospital on survival to hospital discharge if return of spontaneous circulation was achieved at the scene and transport intervals were short (3–11 min).<sup>825–827</sup> This implies that it may be safe to bypass local hospitals and transport the post-cardiac arrest patient to a regional cardiac arrest centre.

There is indirect evidence that regional cardiac resuscitation systems of care improve outcome after ST elevation myocardial infarction (STEMI).<sup>828–850</sup>

The implication from all these data is that specialist cardiac arrest centres and systems of care may be effective but, as yet, there is no direct evidence to support this hypothesis.<sup>851–853</sup>

## References

- Nolan J, Soar J, Eikeland H. The chain of survival. *Resuscitation* 2006;71:270–1.
- Gwinnutt CL, Columb M, Harris R. Outcome after cardiac arrest in adults in UK hospitals: effect of the 1997 guidelines. *Resuscitation* 2000;47:125–35.
- Peberdy MA, Kaye W, Ornato JP, et al. Cardiopulmonary resuscitation of adults in the hospital: a report of 14720 cardiac arrests from the National Registry of Cardiopulmonary Resuscitation. *Resuscitation* 2003;58:297–308.
- Meaney PA, Nadkarni VM, Kern KB, Indik JH, Halperin HR, Berg RA. Rhythms and outcomes of adult in-hospital cardiac arrest. *Crit Care Med* 2010;38:101–8.
- Smith GB. In-hospital cardiac arrest: is it time for an in-hospital 'chain of prevention'? *Resuscitation* 2010.
- National Confidential Enquiry into Patient Outcome and Death. An acute problem? London: NCEPOD; 2005.
- Hodgetts TJ, Kenward G, Vlachonikolis I, et al. Incidence, location and reasons for avoidable in-hospital cardiac arrest in a district general hospital. *Resuscitation* 2002;54:115–23.
- Kause J, Smith G, Prytherch D, Parr M, Flabouris A, Hillman K. A comparison of antecedents to cardiac arrests, deaths and emergency intensive care admissions in Australia and New Zealand, and the United Kingdom—the ACADEMIA study. *Resuscitation* 2004;62:275–82.
- Castagna J, Weil MH, Shubin H. Factors determining survival in patients with cardiac arrest. *Chest* 1974;65:527–9.
- Herlitz J, Bang A, Aune S, Ekstrom L, Lundstrom G, Holmberg S. Characteristics and outcome among patients suffering in-hospital cardiac arrest in monitored and non-monitored areas. *Resuscitation* 2001;48:125–35.
- Buist M, Bernard S, Nguyen TV, Moore G, Anderson J. Association between clinically abnormal observations and subsequent in-hospital mortality: a prospective study. *Resuscitation* 2004;62:137–41.
- Franklin C, Mathew J. Developing strategies to prevent in-hospital cardiac arrest: analyzing responses of physicians and nurses in the hours before the event. *Crit Care Med* 1994;22:244–7.
- Hodgetts TJ, Kenward G, Vlachonikolis IG, Payne S, Castle N. The identification of risk factors for cardiac arrest and formulation of activation criteria to alert a medical emergency team. *Resuscitation* 2002;54:125–31.
- McQuillan P, Pilkington S, Allan A, et al. Confidential inquiry into quality of care before admission to intensive care. *BMJ* 1998;316:1853–8.
- Jacques T, Harrison GA, McLaws ML, Kilborn G. Signs of critical conditions and emergency responses (SOCCER): a model for predicting adverse events in the inpatient setting. *Resuscitation* 2006;69:175–83.
- McGavin F, Cretikos MA, Jones D, et al. Documentation of clinical review and vital signs after major surgery. *Med J Aust* 2008;189:380–3.
- Cashman JN. In-hospital cardiac arrest: what happens to the false arrests? *Resuscitation* 2002;53:271–6.
- Hein A, Thoren AB, Herlitz J. Characteristics and outcome of false cardiac arrests in hospital. *Resuscitation* 2006;69:191–7.
- Kenward G, Robinson A, Bradburn S, Steeds R. False cardiac arrests: the right time to turn away? *Postgrad Med J* 2007;83:344–7.
- Fuhrmann L, Lippert A, Perner A, Ostergaard D. Incidence, staff awareness and mortality of patients at risk on general wards. *Resuscitation* 2008;77:325–30.
- Chatterjee MT, Moon JC, Murphy R, McCrea D. The "OBS" chart: an evidence based approach to re-design of the patient observation chart in a district general hospital setting. *Postgrad Med J* 2005;81:663–6.
- Smith GB, Prytherch DR, Schmidt PE, Featherstone PI. Review and performance evaluation of aggregate weighted 'track and trigger' systems. *Resuscitation* 2008;77:170–9.
- Smith GB, Prytherch DR, Schmidt PE, Featherstone PI, Higgins B. A review, and performance evaluation, of single-parameter "track and trigger" systems. *Resuscitation* 2008;79:11–21.
- Hillman K, Chen J, Cretikos M, et al. Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. *Lancet* 2005;365:2091–7.
- Needleman J, Buerhaus P, Mattke S, Stewart M, Zelevinsky K. Nurse-staffing levels and the quality of care in hospitals. *N Engl J Med* 2002;346:1715–22.
- DeVita MA, Smith GB, Adam SK, et al. Identifying the hospitalised patient in crisis—a consensus conference on the afferent limb of rapid response systems. *Resuscitation* 2010;81:375–82.
- Hogan J. Why don't nurses monitor the respiratory rates of patients? *Br J Nurs* 2006;15:489–92.
- Buist M. The rapid response team paradox: why doesn't anyone call for help? *Crit Care Med* 2008;36:634–6.
- Andrews T, Waterman H. Packaging: a grounded theory of how to report physiological deterioration effectively. *J Adv Nurs* 2005;52:473–81.
- Derham C. Achieving comprehensive critical care. *Nurs Crit Care* 2007;12:124–31.
- Smith GB, Poplett N. Knowledge of aspects of acute care in trainee doctors. *Postgrad Med J* 2002;78:335–8.
- Meek T. New house officers' knowledge of resuscitation, fluid balance and analgesia. *Anaesthesia* 2000;55:1128–9.
- Gould TH, Upton PM, Collins P. A survey of the intended management of acute postoperative pain by newly qualified doctors in the south west region of England in August 1992. *Anaesthesia* 1994;49:807–10.
- Jackson E, Warner J. How much do doctors know about consent and capacity? *J R Soc Med* 2002;95:601–3.
- Kruger PS, Longden PJ. A study of a hospital staff's knowledge of pulse oximetry. *Anaesth Intensive Care* 1997;25:38–41.
- Howell M. Pulse oximetry: an audit of nursing and medical staff understanding. *Br J Nurs* 2002;11:191–7.
- Wheeler DW, Remondos DD, Whittlestone KD, et al. Doctors' confusion over ratios and percentages in drug solutions: the case for standard labelling. *J R Soc Med* 2004;97:380–3.
- Goldacre MJ, Lambert T, Evans J, Turner G. Preregistration house officers' views on whether their experience at medical school prepared them well for their jobs: national questionnaire survey. *BMJ* 2003;326:1011–2.
- Perkins GD, Barrett H, Bullock I, et al. The Acute Care Undergraduate TEaching (ACUTE) Initiative: consensus development of core competencies in acute care for undergraduates in the United Kingdom. *Intensive Care Med* 2005;31:1627–33.
- Smith CM, Perkins GD, Bullock I, Bion JF. Undergraduate training in the care of the acutely ill patient: a literature review. *Intensive Care Med* 2007;33:901–7.

41. Thwaites BC, Shankar S, Niblett D, Saunders J. Can consultants resuscitate? *J R Coll Physicians Lond* 1992;26:265–7.
42. Saravanan P, Soar J. A survey of resuscitation training needs of senior anaesthetists. *Resuscitation* 2005;64:93–6.
43. Featherstone P, Smith GB, Linnell M, Easton S, Osgood VM. Impact of a one-day inter-professional course (ALERTtrade mark) on attitudes and confidence in managing critically ill adult patients. *Resuscitation* 2005;65:329–36.
44. Campello G, Granja C, Carvalho F, Dias C, Azevedo LF, Costa-Pereira A. Immediate and long-term impact of medical emergency teams on cardiac arrest prevalence and mortality: a plea for periodic basic life-support training programs. *Crit Care Med* 2009;37:3054–61.
45. Bellomo R, Goldsmith D, Uchino S, et al. A prospective before-and-after trial of a medical emergency team. *Med J Aust* 2003;179:283–7.
46. Bellomo R, Goldsmith D, Uchino S, et al. Prospective controlled trial of effect of medical emergency team on postoperative morbidity and mortality rates. *Crit Care Med* 2004;32:916–21.
47. DeVita MA, Braithwaite RS, Mahidhara R, Stuart S, Foraida M, Simmons RL. Use of medical emergency team responses to reduce hospital cardiopulmonary arrests. *Qual Saf Health Care* 2004;13:251–4.
48. Foraida MI, DeVita MA, Braithwaite RS, Stuart SA, Brooks MM, Simmons RL. Improving the utilization of medical crisis teams (Condition C) at an urban tertiary care hospital. *J Crit Care* 2003;18:87–94.
49. Green AL, Williams A. An evaluation of an early warning clinical marker referral tool. *Intensive Crit Care Nurs* 2006;22:274–82.
50. Spearpoint KG, Gruber PC, Brett SJ. Impact of the Immediate Life Support course on the incidence and outcome of in-hospital cardiac arrest calls: an observational study over 6 years. *Resuscitation* 2009;80:638–43.
51. Soar J, Perkins GD, Harris S, et al. The immediate life support course. *Resuscitation* 2003;57:21–6.
52. Harrison GA, Jacques TC, Kilborn G, McLaws ML. The prevalence of recordings of the signs of critical conditions and emergency responses in hospital wards—the SOCCER study. *Resuscitation* 2005;65:149–57.
53. Hall S, Williams E, Richards S, Subbe C, Gemmell L. Waiting to exhale: critical care outreach and recording of ventilatory frequency. *Br J Anaesth* 2003;90:570–1.
54. McBride J, Knight D, Piper J, Smith G. Long-term effect of introducing an early warning score on respiratory rate charting on general wards. *Resuscitation* 2005;65:41–4.
55. Goldhill DR, Worthington L, Mulcahy A, Tarling M, Sumner A. The patient-at-risk team: identifying and managing seriously ill ward patients. *Anaesthesia* 1999;54:853–60.
56. Subbe CP, Davies RG, Williams E, Rutherford P, Gemmell L. Effect of introducing the Modified Early Warning score on clinical outcomes, cardio-pulmonary arrests and intensive care utilisation in acute medical admissions. *Anaesthesia* 2003;58:797–802.
57. Armitage M, Eddleston J, Stokes T. Recognising and responding to acute illness in adults in hospital: summary of NICE guidance. *BMJ* 2007;335:258–9.
58. Chen J, Hillman K, Bellomo R, Flabouris A, Finfer S, Cretikos M. The impact of introducing medical emergency team system on the documentations of vital signs. *Resuscitation* 2009;80:35–43.
59. Odell M, Rechner IJ, Kapila A, et al. The effect of a critical care outreach service and an early warning scoring system on respiratory rate recording on the general wards. *Resuscitation* 2007;74:470–5.
60. Critical care outreach 2003: progress in developing services. The National Outreach Report. London, UK: Department of Health and National Health Service Modernisation Agency; 2003.
61. Gao H, McDonnell A, Harrison DA, et al. Systematic review and evaluation of physiological track and trigger warning systems for identifying at-risk patients on the ward. *Intensive Care Med* 2007;33:667–79.
62. Cuthbertson BH. Optimising early warning scoring systems. *Resuscitation* 2008;77:153–4.
63. Cretikos M, Chen J, Hillman K, Bellomo R, Finfer S, Flabouris A. The objective medical emergency team activation criteria: a case-control study. *Resuscitation* 2007;73:62–72.
64. Fieselmann J, Hendryx M, Helms C, Wakefield D. Respiratory rate predicts cardiopulmonary arrest for internal medicine patients. *J Gen Intern Med* 1993;8:354–60.
65. Henry OF, Blacher J, Verdavaine J, Duviquet M, Safar ME. Alpha 1-acid glycoprotein is an independent predictor of in-hospital death in the elderly. *Age Ageing* 2003;32:37–42.
66. Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. *Thorax* 2007;62:253–9.
67. Sleiman I, Morandi A, Sabatini T, et al. Hyperglycemia as a predictor of in-hospital mortality in elderly patients without diabetes mellitus admitted to a sub-intensive care unit. *J Am Geriatr Soc* 2008;56:1106–10.
68. Alarcon T, Barcena A, Gonzalez-Montalvo JL, Penalosa C, Salgado A. Factors predictive of outcome on admission to an acute geriatric ward. *Age Ageing* 1999;28:429–32.
69. Goel A, Pinckney RG, Littenberg B. APACHE II predicts long-term survival in COPD patients admitted to a general medical ward. *J Gen Intern Med* 2003;18:824–30.
70. Rowat AM, Dennis MS, Wardlaw JM. Central periodic breathing observed on hospital admission is associated with an adverse prognosis in conscious acute stroke patients. *Cerebrovasc Dis* 2006;21:340–7.
71. Neary WD, Prytherch D, Foy C, Heather BP, Earnshaw JJ. Comparison of different methods of risk stratification in urgent and emergency surgery. *Br J Surg* 2007;94:1300–5.
72. Asadollahi K, Hastings IM, Beeching NJ, Gill GV. Laboratory risk factors for hospital mortality in acutely admitted patients. *QJM* 2007;100:501–7.
73. Jones AE, Aborn LS, Kline JA. Severity of emergency department hypotension predicts adverse hospital outcome. *Shock* 2004;22:410–4.
74. Duckitt RW, Buxton-Thomas R, Walker J, et al. Worthing physiological scoring system: derivation and validation of a physiological early-warning system for medical admissions. An observational, population-based single-centre study. *Br J Anaesth* 2007;98:769–74.
75. Kellett J, Deane B. The Simple Clinical Score predicts mortality for 30 days after admission to an acute medical unit. *QJM* 2006;99:771–81.
76. Prytherch DR, Sirl JS, Schmidt P, Featherstone PI, Weaver PC, Smith GB. The use of routine laboratory data to predict in-hospital death in medical admissions. *Resuscitation* 2005;66:203–7.
77. Smith GB, Prytherch DR, Schmidt PE, et al. Should age be included as a component of track and trigger systems used to identify sick adult patients? *Resuscitation* 2008;78:109–15.
78. Olsson T, Terent A, Lind L. Rapid Emergency Medicine score: a new prognostic tool for in-hospital mortality in nonsurgical emergency department patients. *J Intern Med* 2004;255:579–87.
79. Prytherch DR, Sirl JS, Weaver PC, Schmidt P, Higgins B, Sutton GL. Towards a national clinical minimum data set for general surgery. *Br J Surg* 2003;90:1300–5.
80. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. *QJM* 2001;94:521–6.
81. Goodacre S, Turner J, Nicholl J. Prediction of mortality among emergency medical admissions. *Emerg Med J* 2006;23:372–5.
82. Paterson R, MacLeod DC, Thetford D, et al. Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. *Clin Med* 2006;6:281–4.
83. Cuthbertson BH, Boroujerdi M, McKie L, Aucott L, Prescott G. Can physiological variables and early warning scoring systems allow early recognition of the deteriorating surgical patient? *Crit Care Med* 2007;35:402–9.
84. Goldhill DR, McNarry AF. Physiological abnormalities in early warning scores are related to mortality in adult inpatients. *Br J Anaesth* 2004;92:882–4.
85. Harrison GA, Jacques T, McLaws ML, Kilborn G. Combinations of early signs of critical illness predict in-hospital death—the SOCCER study (signs of critical conditions and emergency responses). *Resuscitation* 2006;71:327–34.
86. Bell MB, Konrad D, Granath F, Ekblom A, Martling CR. Prevalence and sensitivity of MET-criteria in a Scandinavian University Hospital. *Resuscitation* 2006;70:66–73.
87. Gardner-Thorpe J, Love N, Wrightson J, Walsh S, Keeling N. The value of Modified Early Warning Score (MEWS) in surgical in-patients: a prospective observational study. *Ann R Coll Surg Engl* 2006;88:571–5.
88. Quarterman CP, Thomas AN, McKenna M, McNamee R. Use of a patient information system to audit the introduction of modified early warning scoring. *J Eval Clin Pract* 2005;11:133–8.
89. Goldhill DR, McNarry AF, Hadjianastassiou VG, Tekkis PP. The longer patients are in hospital before Intensive Care admission the higher their mortality. *Intensive Care Med* 2004;30:1908–13.
90. Goldhill DR, McNarry AF, Mandersloot G, McGinley A. A physiologically-based early warning score for ward patients: the association between score and outcome. *Anaesthesia* 2005;60:547–53.
91. Boniatti MM, Azzolini N, da Fonseca DL, et al. Prognostic value of the calling criteria in patients receiving a medical emergency team review. *Resuscitation* 2010;81:667–70.
92. Prytherch DR, Smith GB, Schmidt PE, Featherstone PI. ViEWS-Towards a national early warning score for detecting adult inpatient deterioration. *Resuscitation* 2010;81:932–7.
93. Mitchell IA, McKay H, Van Leuvan C, et al. A prospective controlled trial of the effect of a multi-faceted intervention on early recognition and intervention in deteriorating hospital patients. *Resuscitation* 2010.
94. Smith GB, Prytherch DR, Schmidt P, et al. Hospital-wide physiological surveillance—a new approach to the early identification and management of the sick patient. *Resuscitation* 2006;71:19–28.
95. Sandroni C, Ferro G, Santangelo S, et al. In-hospital cardiac arrest: survival depends mainly on the effectiveness of the emergency response. *Resuscitation* 2004;62:291–7.
96. Soar J, McKay U. A revised role for the hospital cardiac arrest team? *Resuscitation* 1998;38:145–9.
97. Featherstone P, Chalmers T, Smith GB. RSVP: a system for communication of deterioration in hospital patients. *Br J Nurs* 2008;17:860–4.
98. Marshall S, Harrison J, Flanagan B. The teaching of a structured tool improves the clarity and content of interprofessional clinical communication. *Qual Saf Health Care* 2009;18:137–40.
99. Lee A, Bishop G, Hillman KM, Daffurn K. The Medical Emergency Team. *Anaesth Intensive Care* 1995;23:183–6.
100. Devita MA, Bellomo R, Hillman K, et al. Findings of the first consensus conference on medical emergency teams. *Crit Care Med* 2006;34:2463–78.
101. Ball C, Kirkby M, Williams S. Effect of the critical care outreach team on patient survival to discharge from hospital and readmission to critical care: non-randomised population based study. *BMJ* 2003;327:1014.

102. Zenker P, Schlesinger A, Hauck M, et al. Implementation and impact of a rapid response team in a children's hospital. *Jt Comm J Qual Patient Saf* 2007;33:418–25.
103. Dean BS, Decker MJ, Hupp D, Urbach AH, Lewis E, Benes-Stickle J. Condition HELLP: a pediatric rapid response team triggered by patients and parents. *J Healthc Qual* 2008;30:28–31.
104. Ray EM, Smith R, Massie S, et al. Family alert: implementing direct family activation of a pediatric rapid response team. *Jt Comm J Qual Patient Saf* 2009;35:575–80.
105. Kenward G, Castle N, Hodgetts T, Shaikh L. Evaluation of a medical emergency team one year after implementation. *Resuscitation* 2004;61:257–63.
106. Chan PS, Khalid A, Longmore LS, Berg RA, Kosiborod M, Spertus JA. Hospital-wide code rates and mortality before and after implementation of a rapid response team. *JAMA* 2008;300:2506–13.
107. Dacey MJ, Mirza ER, Wilcox V, et al. The effect of a rapid response team on major clinical outcome measures in a community hospital. *Crit Care Med* 2007;35:2076–82.
108. Story DA, Shelton AC, Poustie SJ, Colin-Thome NJ, McNicol PL. The effect of critical care outreach on postoperative serious adverse events. *Anaesthesia* 2004;59:762–6.
109. Story DA, Shelton AC, Poustie SJ, Colin-Thome NJ, McIntyre RE, McNicol PL. Effect of an anaesthesia department led critical care outreach and acute pain service on postoperative serious adverse events. *Anaesthesia* 2006;61:24–8.
110. Flabouris A, Chen J, Hillman K, Bellomo R, Finfer S. Timing and interventions of emergency teams during the MERIT study. *Resuscitation* 2010;81:25–30.
111. Jones D, Bellomo R, Bates S, et al. Long term effect of a medical emergency team on cardiac arrests in a teaching hospital. *Crit Care* 2005;9:R808–15.
112. Galhotra S, DeVita MA, Simmons RL, Schmid A. Impact of patient monitoring on the diurnal pattern of medical emergency team activation. *Crit Care Med* 2006;34:1700–6.
113. Baxter AD, Cardinal P, Hooper J, Patel R. Medical emergency teams at The Ottawa Hospital: the first two years. *Can J Anaesth* 2008;55:223–31.
114. Benson L, Mitchell C, Link M, Carlson G, Fisher J. Using an advanced practice nursing model for a rapid response team. *Jt Comm J Qual Patient Saf* 2008;34:743–7.
115. Bertaut Y, Campbell A, Goodlett D. Implementing a rapid-response team using a nurse-to-nurse consult approach. *J Vasc Nurs* 2008;26:37–42.
116. Buist MD, Moore GE, Bernard SA, Waxman BP, Anderson JN, Nguyen TV. Effects of a medical emergency team on reduction of incidence of and mortality from unexpected cardiac arrests in hospital: preliminary study. *BMJ* 2002;324:387–90.
117. Buist M, Harrison J, Abaloz E, Van Dyke S. Six year audit of cardiac arrests and medical emergency team calls in an Australian outer metropolitan teaching hospital. *BMJ* 2007;335:1210–2.
118. Chamberlain B, Donley K, Maddison J. Patient outcomes using a rapid response team. *Clin Nurse Spec* 2009;23:11–2.
119. Hatler C, Mast D, Bedker D, et al. Implementing a rapid response team to decrease emergencies outside the ICU: one hospital's experience. *Medsurg Nurs* 2009;18, 84–90, 126.
120. Jones D, Bellomo R, Bates S, et al. Patient monitoring and the timing of cardiac arrests and medical emergency team calls in a teaching hospital. *Intensive Care Med* 2006;32:1352–6.
121. Moldenhauer K, Sabel A, Chu ES, Mehler PS. Clinical triggers: an alternative to a rapid response team. *Jt Comm J Qual Patient Saf* 2009;35:164–74.
122. Offner PJ, Heit J, Roberts R. Implementation of a rapid response team decreases cardiac arrest outside of the intensive care unit. *J Trauma* 2007;62:1223–7 [discussion 7–8].
123. Gould D. Promoting patient safety: The Rapid Medical Response Team. *Perm J* 2007;11:26–34.
124. Jolley J, Bendyk H, Holaday B, Lombardozzi KA, Harmon C. Rapid response teams: do they make a difference? *Dimens Crit Care Nurs* 2007;26:253–60, quiz 61–2.
125. Konrad D, Jaderling G, Bell M, Granath F, Ekblom A, Martling CR. Reducing in-hospital cardiac arrests and hospital mortality by introducing a medical emergency team. *Intensive Care Med* 2010;36:100–6.
126. Chen J, Bellomo R, Flabouris A, Hillman K, Finfer S. The relationship between early emergency team calls and serious adverse events. *Crit Care Med* 2009;37:148–53.
127. Bristow PJ, Hillman KM, Chey T, et al. Rates of in-hospital arrests, deaths and intensive care admissions: the effect of a medical emergency team. *Med J Aust* 2000;173:236–40.
128. King E, Horvath R, Shulkin DJ. Establishing a rapid response team (RRT) in an academic hospital: one year's experience. *J Hosp Med* 2006;1:296–305.
129. McFarlan SJ, Hensley S. Implementation and outcomes of a rapid response team. *J Nurs Care Qual* 2007;22:307–13, quiz 14–5.
130. Rothschild JM, Woolf S, Finn KM, et al. A controlled trial of a rapid response system in an academic medical center. *Jt Comm J Qual Patient Saf* 2008;34, 417–25, 365.
131. Chan PS, Jain R, Nallmothu BK, Berg RA, Sasson C. Rapid Response Teams: a systematic review and meta-analysis. *Arch Intern Med* 2010;170:18–26.
132. Leeson-Payne CG, Aitkenhead AR. A prospective study to assess the demand for a high dependency unit. *Anaesthesia* 1995;50:383–7.
133. Guidelines for the utilisation of intensive care units. European Society of Intensive Care Medicine. *Intensive Care Med* 1994;20:163–4.
134. Haupt MT, Bekes CE, Brilli RJ, et al. Guidelines on critical care services and personnel: recommendations based on a system of categorization of three levels of care. *Crit Care Med* 2003;31:2677–83.
135. Peberdy MA, Ornato JP, Larkin GL, et al. Survival from in-hospital cardiac arrest during nights and weekends. *JAMA* 2008;299:785–92.
136. Hillson SD, Rich EC, Dowd B, Luxenberg MG. Call nights and patients care: effects on inpatients at one teaching hospital. *J Gen Intern Med* 1992;7:405–10.
137. Bell CM, Redelmeier DA. Mortality among patients admitted to hospitals on weekends as compared with weekdays. *N Engl J Med* 2001;345:663–8.
138. Beck DH, McQuillan P, Smith GB. Waiting for the break of dawn? The effects of discharge time, discharge TISS scores and discharge facility on hospital mortality after intensive care. *Intensive Care Med* 2002;28:1287–93.
139. Goldfrad C, Rowan K. Consequences of discharges from intensive care at night. *Lancet* 2000;355:1138–42.
140. Tourangeau AE, Cranley LA, Jeffs L. Impact of nursing on hospital patient mortality: a focused review and related policy implications. *Qual Saf Health Care* 2006;15:4–8.
141. Aiken LH, Clarke SP, Sloane DM, Sochalski J, Silber JH. Hospital nurse staffing and patient mortality, nurse burnout, and job dissatisfaction. *JAMA* 2002;288:1987–93.
142. Parr MJ, Hadfield JH, Flabouris A, Bishop G, Hillman K. The Medical Emergency Team: 12 month analysis of reasons for activation, immediate outcome and not-for-resuscitation orders. *Resuscitation* 2001;50:39–44.
143. Baskett PJ, Lim A. The varying ethical attitudes towards resuscitation in Europe. *Resuscitation* 2004;62:267–73.
144. Baskett PJ, Steen PA, Bossaert L. European Resuscitation Council guidelines for resuscitation 2005, Section 8. The ethics of resuscitation and end-of-life decisions. *Resuscitation* 2005;67(Suppl. 1):S171–80.
145. Lippert FK, Raffay V, Georgiou M, Steen PA, Bossaert L. European Resuscitation Council Guidelines for Resuscitation 2010, Section 10. The ethics of resuscitation and end-of-life decisions. *Resuscitation* 2010;81:1445–51.
146. Smith GB. Increased do not attempt resuscitation decision making in hospitals with a medical emergency teams system-cause and effect? *Resuscitation* 2008;79:346–7.
147. Chen J, Flabouris A, Bellomo R, Hillman K, Finfer S. The Medical Emergency Team System and not-for-resuscitation orders: results from the MERIT study. *Resuscitation* 2008;79:391–7.
148. Jones DA, McIntyre T, Baldwin I, Mercer I, Kattula A, Bellomo R. The medical emergency team and end-of-life care: a pilot study. *Crit Care Resusc* 2007;9:151–6.
149. Excellence NifHaC. NICE clinical guideline 50 Acutely ill patients in hospital: recognition of and response to acute illness in adults in hospital. London: National Institute for Health and Clinical Excellence; 2007.
150. Muller D, Agrawal R, Arntz HR. How sudden is sudden cardiac death? *Circulation* 2006;114:1146–50.
151. Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. *J Am Coll Cardiol* 2000;36:2226–33.
152. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. *Circulation* 2003;108:3092–6.
153. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. *J Am Coll Cardiol* 2000;36:2212–8.
154. Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. *Circulation* 2008;117:2184–91.
155. Hobbs JB, Peterson DR, Moss AJ, et al. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. *JAMA* 2006;296:1249–54.
156. Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Circulation* 2004;110:1879–84.
157. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. *J Am Coll Cardiol* 2003;41:987–93.
158. Peters S. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: personal experience from different primary and tertiary centres. *J Cardiovasc Med (Hagerstown)* 2007;8:521–6.
159. Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation* 2002;105:1342–7.
160. Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. *Circulation* 2009;119:1703–10.
161. Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. *Heart* 2003;89:66–70.
162. Amital H, Glikson M, Burstein M, et al. Clinical characteristics of unexpected death among young enlisted military personnel: results of a three-decade retrospective surveillance. *Chest* 2004;126:528–33.
163. Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. *J Am Coll Cardiol* 2000;35:1493–501.
164. Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. *Cardiovasc Res* 2001;50:399–408.



165. Drory Y, Turetz Y, Hiss Y, et al. Sudden unexpected death in persons less than 40 years of age. *Am J Cardiol* 1991;68:1388–92.
166. Kramer MR, Drory Y, Lev B. Sudden death in young soldiers. High incidence of syncope prior to death. *Chest* 1988;93:345–7.
167. Quigley F, Greene M, O'Connor D, Kelly F. A survey of the causes of sudden cardiac death in the under 35-year-age group. *Ir Med J* 2005;98:232–5.
168. Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15–35-year olds in Sweden during 1992–99. *J Intern Med* 2002;252:529–36.
169. Wisten A, Messner T. Young Swedish patients with sudden cardiac death have a lifestyle very similar to a control population. *Scand Cardiovasc J* 2005;39:137–42.
170. Wisten A, Messner T. Symptoms preceding sudden cardiac death in the young are common but often misinterpreted. *Scand Cardiovasc J* 2005;39:143–9.
171. Behr ER, Dalageorgou C, Christiansen M, et al. Sudden arrhythmic death syndrome: familial evaluation identifies inheritable heart disease in the majority of families. *Eur Heart J* 2008;29:1670–80.
172. Brothers JA, Stephens P, Gaynor JW, Lorber R, Vricella LA, Paridon SM. Anomalous aortic origin of a coronary artery with an interarterial course: should family screening be routine? *J Am Coll Cardiol* 2008;51:2062–4.
173. Gimeno JR, Lacunza J, Garcia-Alberola A, et al. Penetrance and risk profile in inherited cardiac diseases studied in a dedicated screening clinic. *Am J Cardiol* 2009;104:406–10.
174. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AA. Sudden unexplained death: heritability and diagnostic yield of cardiologic and genetic examination in surviving relatives. *Circulation* 2005;112:207–13.
175. Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). *Eur Heart J* 2009;30:2631–71.
176. Colman N, Bakker A, Linzer M, Reitsma JB, Wieling W, Wilde AA. Value of history-taking in syncope patients: in whom to suspect long QT syndrome? *Europace* 2009;11:937–43.
177. Oh JH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope? *Arch Intern Med* 1999;159:375–80.
178. Calkins H, Shyr Y, Frumin H, Schork A, Morady F. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. *Am J Med* 1995;98:365–73.
179. Tester DJ, Kopplin LJ, Creighton W, Burke AP, Ackerman MJ. Pathogenesis of unexplained drowning: new insights from a molecular autopsy. *Mayo Clin Proc* 2005;80:596–600.
180. Johnson JN, Hofman N, Haglund CM, Cascino GD, Wilde AA, Ackerman MJ. Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy. *Neurology* 2009;72:224–31.
181. McCormick JM, McAlister H, Crawford J, et al. Misdiagnosis of long QT syndrome as epilepsy at first presentation. *Ann Emerg Med* 2009;54:26–32.
182. Chandra N, Papadakis M, Sharma S. Preparticipation screening of young competitive athletes for cardiovascular disorders. *Phys Sportsmed* 2010;38:54–63.
183. Olasveengen TM, Lund-Kordahl I, Steen PA, Sunde K. Out-of-hospital advanced life support with or without a physician: effects on quality of CPR and outcome. *Resuscitation* 2009;80:1248–52.
184. Kirves H, Skrifvars MB, Vahakuopus M, Ekstrom K, Martikainen M, Castren M. Adherence to resuscitation guidelines during prehospital care of cardiac arrest patients. *Eur J Emerg Med* 2007;14:75–81.
185. Schneider T, Mauer D, Diehl P, Eberle B, Dick W. Quality of on-site performance in prehospital advanced cardiac life support (ACLS). *Resuscitation* 1994;27:207–13.
186. Arntz HR, Wenzel V, Dissmann R, Marschall A, Breckwoldt J, Muller D. Out-of-hospital thrombolysis during cardiopulmonary resuscitation in patients with high likelihood of ST-elevation myocardial infarction. *Resuscitation* 2008;76:180–4.
187. Bell A, Lockey D, Coats T, Moore F, Davies G. Physician Response Unit—a feasibility study of an initiative to enhance the delivery of pre-hospital emergency medical care. *Resuscitation* 2006;69:389–93.
188. Lossius HM, Soreide E, Hotvedt R, et al. Prehospital advanced life support provided by specially trained physicians: is there a benefit in terms of life years gained? *Acta Anaesthesiol Scand* 2002;46:771–8.
189. Dickinson ET, Schneider RM, Verdile VP. The impact of prehospital physicians on out-of-hospital nonasystolic cardiac arrest. *Prehosp Emerg Care* 1997;1:132–5.
190. Soo LH, Gray D, Young T, Huff N, Skene A, Hampton JR. Resuscitation from out-of-hospital cardiac arrest: is survival dependent on who is available at the scene? *Heart* 1999;81:47–52.
191. Frandsen F, Nielsen JR, Gram L, et al. Evaluation of intensified prehospital treatment in out-of-hospital cardiac arrest: survival and cerebral prognosis. The Odense ambulance study. *Cardiology* 1991;79:256–64.
192. Sipria A, Talvik R, Korgvee A, Sarapuu S, Oopik A. Out-of-hospital resuscitation in Tartu: effect of reorganization of Estonian EMS system. *Am J Emerg Med* 2000;18:469–73.
193. Estner HL, Gunzel C, Ndrepepa G, et al. Outcome after out-of-hospital cardiac arrest in a physician-staffed emergency medical system according to the Utstein style. *Am Heart J* 2007;153:792–9.
194. Eisenburger P, Czappek G, Sterz F, et al. Cardiac arrest patients in an alpine area during a six year period. *Resuscitation* 2001;51:39–46.
195. Gottschalk A, Burmeister MA, Freitag M, Cavus E, Standl T. Influence of early defibrillation on the survival rate and quality of life after CPR in prehospital emergency medical service in a German metropolitan area. *Resuscitation* 2002;53:15–20.
196. Hampton JR, Dowling M, Nicholas C. Comparison of results from a cardiac ambulance manned by medical or non-medical personnel. *Lancet* 1977;1:526–9.
197. Schneider T, Mauer D, Diehl P, et al. Early defibrillation by emergency physicians or emergency medical technicians? A controlled, prospective multicentre study. *Resuscitation* 1994;27:197–206.
198. Soo LH, Gray D, Young T, Skene A, Hampton JR. Influence of ambulance crew's length of experience on the outcome of out-of-hospital cardiac arrest. *Eur Heart J* 1999;20:535–40.
199. Yen ZS, Chen YT, Ko PC, et al. Cost-effectiveness of different advanced life support providers for victims of out-of-hospital cardiac arrests. *J Formos Med Assoc* 2006;105:1001–7.
200. Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. *JAMA* 2008;300:1423–31.
201. Fischer M, Krep H, Wierich D, et al. Comparison of the emergency medical services systems of Birmingham and Bonn: process efficacy and cost effectiveness. *Anesthesiol Intensivmed Notfallmed Schmerzther* 2003;38:630–42.
202. Bottiger BW, Grabner C, Bauer H, et al. Long term outcome after out-of-hospital cardiac arrest with physician staffed emergency medical services: the Utstein style applied to a mid-sized urban/suburban area. *Heart* 1999;82:674–9.
203. Bjornsson HM, Marelsson S, Magnusson V, Sigurdsson G, Thorgeirsson G. Prehospital cardiac life support in the Reykjavik area 1999–2002. *Laeknabladid* 2006;92:591–7.
204. Mitchell RG, Brady W, Guly UM, Pirrallo RG, Robertson CE. Comparison of two emergency response systems and their effect on survival from out of hospital cardiac arrest. *Resuscitation* 1997;35:225–9.
205. Lafuente-Lafuente C, Melero-Bascones M. Active chest compression–decompression for cardiopulmonary resuscitation. *Cochrane Database Syst Rev* 2004;CD002751.
206. Lewis RP, Stang JM, Fulkerson PK, Sampson KL, Scoles A, Warren JV. Effectiveness of advanced paramedics in a mobile coronary care system. *JAMA* 1979;241:1902–4.
207. Silfvast T, Ekstrand A. The effect of experience of on-site physicians on survival from prehospital cardiac arrest. *Resuscitation* 1996;31:101–5.
208. Morrison LJ, Visentin LM, Kiss A, et al. Validation of a rule for termination of resuscitation in out-of-hospital cardiac arrest. *N Engl J Med* 2006;355:478–87.
209. Richman PB, Vadeboncoeur TF, Chikani V, Clark L, Bobrow BJ. Independent evaluation of an out-of-hospital termination of resuscitation (TOR) clinical decision rule. *Acad Emerg Med* 2008;15:517–21.
210. Morrison LJ, Verbeek PR, Zhan C, Kiss A, Allan KS. Validation of a universal prehospital termination of resuscitation clinical prediction rule for advanced and basic life support providers. *Resuscitation* 2009;80:324–8.
211. Sasson C, Hegg AJ, Macy M, Park A, Kellermann A, McNally B. Prehospital termination of resuscitation in cases of refractory out-of-hospital cardiac arrest. *JAMA* 2008;300:1432–8.
212. Skrifvars MB, Vayrynen T, Kuisma M, et al. Comparison of Helsinki and European Resuscitation Council “do not attempt to resuscitate” guidelines, and a termination of resuscitation clinical prediction rule for out-of-hospital cardiac arrest patients found in asystole or pulseless electrical activity. *Resuscitation* 2010.
213. Ong ME, Jaffey J, Stiell I, Nesbitt L. Comparison of termination-of-resuscitation guidelines for basic life support: defibrillator providers in out-of-hospital cardiac arrest. *Ann Emerg Med* 2006;47:337–43.
214. Morrison LJ, Verbeek PR, Vermeulen MJ, et al. Derivation and evaluation of a termination of resuscitation clinical prediction rule for advanced life support providers. *Resuscitation* 2007;74:266–75.
215. Bailey ED, Wydro GC, Cone DC. Termination of resuscitation in the prehospital setting for adult patients suffering nontraumatic cardiac arrest. National Association of EMS Physicians Standards and Clinical Practice Committee. *Prehosp Emerg Care* 2000;4:190–5.
216. Verbeek PR, Vermeulen MJ, Ali FH, Messenger DW, Summers J, Morrison LJ. Derivation of a termination-of-resuscitation guideline for emergency medical technicians using automated external defibrillators. *Acad Emerg Med* 2002;9:671–8.
217. Ong ME, Tan EH, Ng FS, et al. Comparison of termination-of-resuscitation guidelines for out-of-hospital cardiac arrest in Singapore EMS. *Resuscitation* 2007;75:244–51.
218. Pircher IR, Stadlbauer KH, Severing AC, et al. A prediction model for out-of-hospital cardiopulmonary resuscitation. *Anesth Analg* 2009;109:1196–201.
219. van Walraven C, Forster AJ, Parish DC, et al. Validation of a clinical decision aid to discontinue in-hospital cardiac arrest resuscitations. *JAMA* 2001;285:1602–6.
220. van Walraven C, Forster AJ, Stiell IG. Derivation of a clinical decision rule for the discontinuation of in-hospital cardiac arrest resuscitations. *Arch Intern Med* 1999;159:129–34.
221. McCullough PA, Thompson RJ, Tobin KJ, Kahn JK, O'Neill WW. Validation of a decision support tool for the evaluation of cardiac arrest victims. *Clin Cardiol* 1998;21:195–200.
222. Christenson J, Andrusiek D, Everson-Stewart S, et al. Chest compression fraction determines survival in patients with out-of-hospital ventricular fibrillation. *Circulation* 2009;120:1241–7.
223. Deakin CD, Nolan JP, Sunde K, Koster RW. European Resuscitation Council Guidelines for Resuscitation 2010. Section 3. Electrical therapies: automated external defibrillators, defibrillation, cardioversion and pacing. *Resuscitation* 2010;81:1293–304.

224. Gabbott D, Smith G, Mitchell S, et al. Cardiopulmonary resuscitation standards for clinical practice and training in the UK. *Resuscitation* 2005;64:13–9.
225. Dyson E, Smith GB. Common faults in resuscitation equipment—guidelines for checking equipment and drugs used in adult cardiopulmonary resuscitation. *Resuscitation* 2002;55:137–49.
226. Brennan RT, Braslow A. Skill mastery in public CPR classes. *Am J Emerg Med* 1998;16:653–7.
227. Chamberlain D, Smith A, Woollard M, et al. Trials of teaching methods in basic life support (3): comparison of simulated CPR performance after first training and at 6 months, with a note on the value of re-training. *Resuscitation* 2002;53:179–87.
228. Eberle B, Dick WF, Schneider T, Wisser G, Doetsch S, Tzanova I. Checking the carotid pulse check: diagnostic accuracy of first responders in patients with and without a pulse. *Resuscitation* 1996;33:107–16.
229. Lapostolle F, Le Toumelin P, Agostinucci JM, Catineau J, Adnet F. Basic cardiac life support providers checking the carotid pulse: performance, degree of conviction, and influencing factors. *Acad Emerg Med* 2004;11:878–80.
230. Liberman M, Lavoie A, Mulder D, Sampalis J. Cardiopulmonary resuscitation: errors made by pre-hospital emergency medical personnel. *Resuscitation* 1999;42:47–55.
231. Moule P. Checking the carotid pulse: diagnostic accuracy in students of the healthcare professions. *Resuscitation* 2000;44:195–201.
232. Nyman J, Sihvonen M. Cardiopulmonary resuscitation skills in nurses and nursing students. *Resuscitation* 2000;47:179–84.
233. Perkins GD, Stephenson B, Hulme J, Monsieus KG. Birmingham assessment of breathing study (BABS). *Resuscitation* 2005;64:109–13.
234. Ruppert M, Reith MW, Widmann JH, et al. Checking for breathing: evaluation of the diagnostic capability of emergency medical services personnel, physicians, medical students, and medical laypersons. *Ann Emerg Med* 1999;34:720–9.
235. Tibballs J, Russell P. Reliability of pulse palpation by healthcare personnel to diagnose paediatric cardiac arrest. *Resuscitation* 2009;80:61–4.
236. Bang A, Herlitz J, Martinell S. Interaction between emergency medical dispatcher and caller in suspected out-of-hospital cardiac arrest calls with focus on agonal breathing. A review of 100 tape recordings of true cardiac arrest cases. *Resuscitation* 2003;56:25–34.
237. Bohm K, Rosenqvist M, Hollenberg J, Biber B, Engerstrom L, Svensson L. Dispatcher-assisted telephone-guided cardiopulmonary resuscitation: an underused lifesaving system. *Eur J Emerg Med* 2007;14:256–9.
238. Bobrow BJ, Zuercher M, Ewy GA, et al. Gasping during cardiac arrest in humans is frequent and associated with improved survival. *Circulation* 2008;118:2550–4.
239. Vaillancourt C, Verma A, Trickett J, et al. Evaluating the effectiveness of dispatch-assisted cardiopulmonary resuscitation instructions. *Acad Emerg Med* 2007;14:877–83.
240. White L, Rogers J, Bloomingdale M, et al. Dispatcher-assisted cardiopulmonary resuscitation: risks for patients not in cardiac arrest. *Circulation* 2010;121:91–7.
241. Perkins GD, Roberts C, Gao F. Delays in defibrillation: influence of different monitoring techniques. *Br J Anaesth* 2002;89:405–8.
242. Abella BS, Alvarado JP, Myklebust H, et al. Quality of cardiopulmonary resuscitation during in-hospital cardiac arrest. *JAMA* 2005;293:305–10.
243. Abella BS, Sandbo N, Vassilatos P, et al. Chest compression rates during cardiopulmonary resuscitation are suboptimal: a prospective study during in-hospital cardiac arrest. *Circulation* 2005;111:428–34.
244. Stiell IG, Wells GA, Field B, et al. Advanced cardiac life support in out-of-hospital cardiac arrest. *N Engl J Med* 2004;351:647–56.
245. Olasveengen TM, Sunde K, Brunborg C, Thowsen J, Steen PA, Wik L. Intravenous drug administration during out-of-hospital cardiac arrest: a randomized trial. *JAMA* 2009;302:2222–9.
246. Herlitz J, Ekstrom L, Wennerblom B, Axelsson A, Bang A, Holmberg S. Adrenaline in out-of-hospital ventricular fibrillation. Does it make any difference? *Resuscitation* 1995;29:195–201.
247. Holmberg M, Holmberg S, Herlitz J. Low chance of survival among patients requiring adrenaline (epinephrine) or intubation after out-of-hospital cardiac arrest in Sweden. *Resuscitation* 2002;54:37–45.
248. Bradley SM, Gabriel EE, Aufderheide TP, et al. Survival Increases with CPR by Emergency Medical Services before defibrillation of out-of-hospital ventricular fibrillation or ventricular tachycardia: observations from the Resuscitation Outcomes Consortium. *Resuscitation* 2010;81:155–62.
249. Hollenberg J, Herlitz J, Lindqvist J, et al. Improved survival after out-of-hospital cardiac arrest is associated with an increase in proportion of emergency crew—witnessed cases and bystander cardiopulmonary resuscitation. *Circulation* 2008;118:389–96.
250. Iwami T, Nichol G, Hiraide A, et al. Continuous improvements in “chain of survival” increased survival after out-of-hospital cardiac arrests: a large-scale population-based study. *Circulation* 2009;119:728–34.
251. Edelson DP, Abella BS, Kramer-Johansen J, et al. Effects of compression depth and pre-shock pauses predict defibrillation failure during cardiac arrest. *Resuscitation* 2006;71:137–45.
252. Eftestol T, Sunde K, Steen PA. Effects of interrupting precordial compressions on the calculated probability of defibrillation success during out-of-hospital cardiac arrest. *Circulation* 2002;105:2270–3.
253. Sunde K, Eftestol T, Askenberg C, Steen PA. Quality assessment of defibrillation and advanced life support using data from the medical control module of the defibrillator. *Resuscitation* 1999;41:237–47.
254. Rea TD, Shah S, Kudenchuk PJ, Copass MK, Cobb LA. Automated external defibrillators: to what extent does the algorithm delay CPR? *Ann Emerg Med* 2005;46:132–41.
255. van Alem AP, Sanou BT, Koster RW. Interruption of cardiopulmonary resuscitation with the use of the automated external defibrillator in out-of-hospital cardiac arrest. *Ann Emerg Med* 2003;42:449–57.
256. Pytte M, Kramer-Johansen J, Eilevstjonn J, et al. Haemodynamic effects of adrenaline (epinephrine) depend on chest compression quality during cardiopulmonary resuscitation in pigs. *Resuscitation* 2006;71:369–78.
257. Pregel AW, Lindner KH, Ensinger H, Grunert A. Plasma catecholamine concentrations after successful resuscitation in patients. *Crit Care Med* 1992;20:609–14.
258. Bhende MS, Thompson AE. Evaluation of an end-tidal CO<sub>2</sub> detector during pediatric cardiopulmonary resuscitation. *Pediatrics* 1995;95:395–9.
259. Sehra R, Underwood K, Checchia P. End tidal CO<sub>2</sub> is a quantitative measure of cardiac arrest. *Pacing Clin Electrophysiol* 2003;26:515–7.
260. Eftestol T, Wik L, Sunde K, Steen PA. Effects of cardiopulmonary resuscitation on predictors of ventricular fibrillation defibrillation success during out-of-hospital cardiac arrest. *Circulation* 2004;110:10–5.
261. Eftestol T, Sunde K, Aase SO, Husoy JH, Steen PA. Predicting outcome of defibrillation by spectral characterization and nonparametric classification of ventricular fibrillation in patients with out-of-hospital cardiac arrest. *Circulation* 2000;102:1523–9.
262. Amir O, Schliamser JE, Nemer S, Arie M. Ineffectiveness of precordial thump for cardioversion of malignant ventricular tachyarrhythmias. *Pacing Clin Electrophysiol* 2007;30:153–6.
263. Haman L, Parizek P, Vojacek J. Precordial thump efficacy in termination of induced ventricular arrhythmias. *Resuscitation* 2009;80:14–6.
264. Pellis T, Kette F, Lovisa D, et al. Utility of pre-cordial thump for treatment of out of hospital cardiac arrest: a prospective study. *Resuscitation* 2009;80:17–23.
265. Kohl P, King AM, Boulin C. Antiarrhythmic effects of acute mechanical stimulation. In: Kohl P, Sachs F, Franz MR, editors. *Cardiac mechano-electric feedback and arrhythmias: from pipette to patient*. Philadelphia: Elsevier Saunders; 2005. p. 304–14.
266. Caldwell G, Millar G, Quinn E, Vincent R, Chamberlain DA. Simple mechanical methods for cardioversion: defence of the precordial thump and cough version. *Br Med J (Clin Res Ed)* 1985;291:627–30.
267. Krijne R. Rate acceleration of ventricular tachycardia after a precordial chest thump. *Am J Cardiol* 1984;53:964–5.
268. Emerman CL, Pinchak AC, Hancock D, Hagen JF. Effect of injection site on circulation times during cardiac arrest. *Crit Care Med* 1988;16:1138–41.
269. Glaeser PW, Hellmich TR, Szwedzuga D, Losek JD, Smith DS. Five-year experience in prehospital intraosseous infusions in children and adults. *Ann Emerg Med* 1993;22:1119–24.
270. Wenzel V, Lindner KH, Augenstein S, et al. Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. *Crit Care Med* 1999;27:1565–9.
271. Shavit I, Hoffmann Y, Galbraith R, Waisman Y. Comparison of two mechanical intraosseous infusion devices: a pilot, randomized crossover trial. *Resuscitation* 2009;80:1029–33.
272. Schuttler J, Bartsch A, Ebeling BJ, et al. Endobronchial administration of adrenaline in preclinical cardiopulmonary resuscitation. *Anasth Intensivther Notfallmed* 1987;22:63–8.
273. Hornchen U, Schuttler J, Stoeckel H, Eichelkraut W, Hahn N. Endobronchial instillation of epinephrine during cardiopulmonary resuscitation. *Crit Care Med* 1987;15:1037–9.
274. Vaknin Z, Manisterski Y, Ben-Abraham R, et al. Is endotracheal adrenaline deleterious because of the beta adrenergic effect? *Anesth Analg* 2001;92:1408–12.
275. Manisterski Y, Vaknin Z, Ben-Abraham R, et al. Endotracheal epinephrine: a call for larger doses. *Anesth Analg* 2002;95:1037–41, table of contents.
276. Efrati O, Ben-Abraham R, Barak A, et al. Endobronchial adrenaline: should it be reconsidered? Dose response and haemodynamic effect in dogs. *Resuscitation* 2003;59:117–22.
277. Elizur A, Ben-Abraham R, Manisterski Y, et al. Tracheal epinephrine or norepinephrine preceded by beta blockade in a dog model. Can beta blockade bestow any benefits? *Resuscitation* 2003;59:271–6.
278. Pregel AW, Rembecki M, Wenzel V, Steinbach G. A comparison of the endotracheal tube and the laryngeal mask airway as a route for endobronchial lidocaine administration. *Anesth Analg* 2001;92:1505–9.
279. Berg RA, Hilwig RW, Kern KB, Ewy GA. Precursorshock cardiopulmonary resuscitation improves ventricular fibrillation median frequency and myocardial readiness for successful defibrillation from prolonged ventricular fibrillation: a randomized, controlled swine study. *Ann Emerg Med* 2002;40:563–70.
280. Achleitner U, Wenzel V, Strohmenger HU, et al. The beneficial effect of basic life support on ventricular fibrillation mean frequency and coronary perfusion pressure. *Resuscitation* 2001;51:151–8.
281. Fries M, Tang W, Chang YT, Wang J, Castillo C, Weil MH. Microvascular blood flow during cardiopulmonary resuscitation is predictive of outcome. *Resuscitation* 2006;71:248–53.
282. Ristagno G, Tang W, Huang L, et al. Epinephrine reduces cerebral perfusion during cardiopulmonary resuscitation. *Crit Care Med* 2009;37:1408–15.
283. Tang W, Weil MH, Sun S, Gazmuri RJ, Bisera J. Progressive myocardial dysfunction after cardiac resuscitation. *Crit Care Med* 1993;21:1046–50.

284. Angelos MG, Butke RL, Panchal AR, et al. Cardiovascular response to epinephrine varies with increasing duration of cardiac arrest. *Resuscitation* 2008;77:101–10.
285. Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. *N Engl J Med* 1999;341:871–8.
286. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. *N Engl J Med* 2002;346:884–90.
287. Thel MC, Armstrong AL, McNulty SE, Califf RM, O'Connor CM. Randomised trial of magnesium in in-hospital cardiac arrest. *Duke Internal Medicine Housestaff. Lancet* 1997;350:1272–6.
288. Allegra J, Lavery R, Cody R, et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. *Resuscitation* 2001;49:245–9.
289. Fatovich D, Prentice D, Dobb G. Magnesium in in-hospital cardiac arrest. *Lancet* 1998;351:446.
290. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. *Emerg Med J* 2002;19:57–62.
291. Miller B, Craddock L, Hoffenberg S, et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. *Resuscitation* 1995;30:3–14.
292. Weil MH, Rackow EC, Trevino R, Grundle W, Falk JL, Griffel MI. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. *N Engl J Med* 1986;315:153–6.
293. Wagner H, Terkelsen CJ, Friberg H, et al. Cardiac arrest in the catheterisation laboratory: a 5-year experience of using mechanical chest compressions to facilitate PCI during prolonged resuscitation efforts. *Resuscitation* 2010;81:383–7.
294. Soar J, Perkins GD, Abbas G, et al. European Resuscitation Council Guidelines for Resuscitation 2010. Section 8. Cardiac arrest in special circumstances: electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. *Resuscitation* 2010;81:1400–33.
295. Price S, Uddin S, Quinn T. Echocardiography in cardiac arrest. *Curr Opin Crit Care* 2010;16:211–5.
296. Memtsoudis SG, Rosenberger P, Löffler M, et al. The usefulness of transesophageal echocardiography during intraoperative cardiac arrest in non-cardiac surgery. *Anesth Analg* 2006;102:1653–7.
297. Comess KA, DeRook FA, Russell ML, Tognazzi-Evans TA, Beach KW. The incidence of pulmonary embolism in unexplained sudden cardiac arrest with pulseless electrical activity. *Am J Med* 2000;109:351–6.
298. Niendorff DF, Rassias AJ, Palac R, Beach ML, Costa S, Greenberg M. Rapid cardiac ultrasound of inpatients suffering PEA arrest performed by nonexpert sonographers. *Resuscitation* 2005;67:81–7.
299. Tayal VS, Kline JA. Emergency echocardiography to detect pericardial effusion in patients in PEA and near-PEA states. *Resuscitation* 2003;59:315–8.
300. van der Wouw PA, Koster RW, Delemarre BJ, de Vos R, Lampe-Schoenmaeckers AJ, Lie KI. Diagnostic accuracy of transesophageal echocardiography during cardiopulmonary resuscitation. *J Am Coll Cardiol* 1997;30:780–3.
301. Hernandez C, Shuler K, Hannan H, Sonyika C, Likourezos A, Marshall J. C.A.U.S.E.: Cardiac arrest ultra-sound exam—a better approach to managing patients in primary non-arrhythmogenic cardiac arrest. *Resuscitation* 2008;76:198–206.
302. Steiger HV, Rimbach K, Muller E, Breikreutz R. Focused emergency echocardiography: lifesaving tool for a 14-year-old girl suffering out-of-hospital pulseless electrical activity arrest because of cardiac tamponade. *Eur J Emerg Med* 2009;16:103–5.
303. Breikreutz R, Walcher F, Seeger FH. Focused echocardiographic evaluation in resuscitation management: concept of an advanced life support-conformed algorithm. *Crit Care Med* 2007;35:S150–61.
304. Blaivas M, Fox JC. Outcome in cardiac arrest patients found to have cardiac standstill on the bedside emergency department echocardiogram. *Acad Emerg Med* 2001;8:616–21.
305. Salen P, O'Connor R, Sierzenski P, et al. Can cardiac sonography and capnography be used independently and in combination to predict resuscitation outcomes? *Acad Emerg Med* 2001;8:610–5.
306. Salen P, Melniker L, Chooljian C, et al. Does the presence or absence of sonographically identified cardiac activity predict resuscitation outcomes of cardiac arrest patients? *Am J Emerg Med* 2005;23:459–62.
307. Bottiger BW, Bode C, Kern S, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. *Lancet* 2001;357:1583–5.
308. Boidin MP. Airway patency in the unconscious patient. *Br J Anaesth* 1985;57:306–10.
309. Nandi PR, Charlesworth CH, Taylor SJ, Nunn JF, Dore CJ. Effect of general anaesthesia on the pharynx. *Br J Anaesth* 1991;66:157–62.
310. Guildner CW. Resuscitation: opening the airway. A comparative study of techniques for opening an airway obstructed by the tongue. *JACEP* 1976;5:588–90.
311. Safar P, Escarraga LA, Chang F. Upper airway obstruction in the unconscious patient. *J Appl Physiol* 1959;14:760–4.
312. Greene DG, Elam JO, Dobkin AB, Studley CL. Cinefluorographic study of hyperextension of the neck and upper airway patency. *JAMA* 1961;176:570–3.
313. Morikawa S, Safar P, Decarlo J. Influence of the head/neck position upon upper airway patency. *Anesthesiology* 1961;22:265–70.
314. Ruben HM, Elam JO, Ruben AM, Greene DG. Investigation of upper airway problems in resuscitation. 1: studies of pharyngeal x-rays and performance by laymen. *Anesthesiology* 1961;22:271–9.
315. Elam JO, Greene DG, Schneider MA, et al. Head-tilt method of oral resuscitation. *JAMA* 1960;172:812–5.
316. Aprahamian C, Thompson BM, Finger WA, Darin JC. Experimental cervical spine injury model: evaluation of airway management and splinting techniques. *Ann Emerg Med* 1984;13:584–7.
317. Donaldson 3rd WF, Heil BV, Donaldson VP, Silvaggio VJ. The effect of airway maneuvers on the unstable C1–C2 segment. A cadaver study. *Spine* 1997;22:1215–8.
318. Donaldson 3rd WF, Towers JD, Doctor A, Brand A, Donaldson VP. A methodology to evaluate motion of the unstable spine during intubation techniques. *Spine* 1993;18:2020–3.
319. Hauswald M, Sklar DP, Tandberg D, Garcia JF. Cervical spine movement during airway management: cinefluoroscopic appraisal in human cadavers. *Am J Emerg Med* 1991;9:535–8.
320. Brimacombe J, Keller C, Kunzel KH, Gaber O, Boehler M, Puhlinger F. Cervical spine motion during airway management: a cinefluoroscopic study of the posteriorly destabilized third cervical vertebrae in human cadavers. *Anesth Analg* 2000;91:1274–8.
321. Majernick TG, Bieniek R, Houston JB, Hughes HG. Cervical spine movement during orotracheal intubation. *Ann Emerg Med* 1986;15:417–20.
322. Lennarson PJ, Smith DW, Sawin PD, Todd MM, Sato Y, Traynelis VC. Cervical spinal motion during intubation: efficacy of stabilization maneuvers in the setting of complete segmental instability. *J Neurosurg Spine* 2001;94:265–70.
323. Marsh AM, Nunn JF, Taylor SJ, Charlesworth CH. Airway obstruction associated with the use of the Guedel airway. *Br J Anaesth* 1991;67:517–23.
324. Schade K, Borzotta A, Michaels A. Intracranial malposition of nasopharyngeal airway. *J Trauma* 2000;49:967–8.
325. Muzzi DA, Losasso TJ, Cucchiara RF. Complication from a nasopharyngeal airway in a patient with a basilar skull fracture. *Anesthesiology* 1991;74:366–8.
326. Roberts K, Porter K. How do you size a nasopharyngeal airway. *Resuscitation* 2003;56:19–23.
327. Stoneham MD. The nasopharyngeal airway. Assessment of position by fibre-optic laryngoscopy. *Anaesthesia* 1993;48:575–80.
328. Balan IS, Fiskum G, Hazelton J, Cotto-Cumba C, Rosenthal RE. Oximetry-guided reoxygenation improves neurological outcome after experimental cardiac arrest. *Stroke* 2006;37:3008–13.
329. Kilgannon JH, Jones AE, Shapiro NI, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. *JAMA* 2010;303:2165–71.
330. Alexander R, Hodgson P, Lomax D, Bullen C. A comparison of the laryngeal mask airway and Guedel airway, bag and face mask for manual ventilation following formal training. *Anaesthesia* 1993;48:231–4.
331. Doerges V, Sauer C, Ocker H, Wenzel V, Schmucker P. Smaller tidal volumes during cardiopulmonary resuscitation: comparison of adult and paediatric self-inflatable bags with three different ventilatory devices. *Resuscitation* 1999;43:31–7.
332. Ocker H, Wenzel V, Schmucker P, Dorges V. Effectiveness of various airway management techniques in a bench model simulating a cardiac arrest patient. *J Emerg Med* 2001;20:7–12.
333. Stone BJ, Chantler PJ, Baskett PJ. The incidence of regurgitation during cardiopulmonary resuscitation: a comparison between the bag valve mask and laryngeal mask airway. *Resuscitation* 1998;38:3–6.
334. Petit SP, Russell WJ. The prevention of gastric inflation—a neglected benefit of cricoid pressure. *Anaesth Intensive Care* 1988;16:139–43.
335. Lawes EG, Campbell I, Mercer D. Inflation pressure, gastric insufflation and rapid sequence induction. *Br J Anaesth* 1987;59:315–8.
336. Hartsilver EL, Vanner RG. Airway obstruction with cricoid pressure. *Anaesthesia* 2000;55:208–11.
337. Allman KG. The effect of cricoid pressure application on airway patency. *J Clin Anesth* 1995;7:197–9.
338. Hocking G, Roberts FL, Thew ME. Airway obstruction with cricoid pressure and lateral tilt. *Anaesthesia* 2001;56:825–8.
339. Mac GPJH, Ball DR. The effect of cricoid pressure on the cricoid cartilage and vocal cords: an endoscopic study in anaesthetised patients. *Anaesthesia* 2000;55:263–8.
340. Auferdeheide TP, Sigurdsson G, Pirrallo RG, et al. Hyperventilation-induced hypotension during cardiopulmonary resuscitation. *Circulation* 2004;109:1960–5.
341. O'Neill JF, Deakin CD. Do we hyperventilate cardiac arrest patients? *Resuscitation* 2007;73:82–5.
342. Olasveengen TM, Vik E, Kuzovlev A, Sunde K. Effect of implementation of new resuscitation guidelines on quality of cardiopulmonary resuscitation and survival. *Resuscitation* 2009;80:407–11.
343. Olasveengen TM, Wik L, Steen PA. Quality of cardiopulmonary resuscitation before and during transport in out-of-hospital cardiac arrest. *Resuscitation* 2008;76:185–90.
344. Weiss SJ, Ernst AA, Jones R, et al. Automatic transport ventilator versus bag valve in the EMS setting: a prospective, randomized trial. *South Med J* 2005;98:970–6.
345. Stallinger A, Wenzel V, Wagner-Berger H, et al. Effects of decreasing inspiratory flow rate during simulated basic life support ventilation of a cardiac arrest patient on lung and stomach tidal volumes. *Resuscitation* 2002;54:167–73.

346. Noordergraaf GJ, van Dun PJ, Kramer BP, et al. Can first responders achieve and maintain normocapnia when sequentially ventilating with a bag-valve device and two oxygen-driven resuscitators? A controlled clinical trial in 104 patients. *Eur J Anaesthesiol* 2004;21:367–72.
347. Deakin CD, O'Neill JF, Tabor T. Does compression-only cardiopulmonary resuscitation generate adequate passive ventilation during cardiac arrest? *Resuscitation* 2007;75:53–9.
348. Saissy JM, Boussignac G, Cheptel E, et al. Efficacy of continuous insufflation of oxygen combined with active cardiac compression–decompression during out-of-hospital cardiorespiratory arrest. *Anesthesiology* 2000;92:1523–30.
349. Bertrand C, Hemery F, Carli P, et al. Constant flow insufflation of oxygen as the sole mode of ventilation during out-of-hospital cardiac arrest. *Intensive Care Med* 2006;32:843–51.
350. Bobrow BJ, Ewy GA, Clark L, et al. Passive oxygen insufflation is superior to bag-valve-mask ventilation for witnessed ventricular fibrillation out-of-hospital cardiac arrest. *Ann Emerg Med* 2009;54:656–62 e1.
351. Jones JH, Murphy MP, Dickson RL, Somerville GG, Brizendine EJ. Emergency physician-verified out-of-hospital intubation: miss rates by paramedics. *Acad Emerg Med* 2004;11:707–9.
352. Pelucio M, Halligan L, Dhindsa H. Out-of-hospital experience with the syringe esophageal detector device. *Acad Emerg Med* 1997;4:563–8.
353. Jemmett ME, Kendal KM, Fourre MW, Burton JH. Unrecognized misplacement of endotracheal tubes in a mixed urban to rural emergency medical services setting. *Acad Emerg Med* 2003;10:961–5.
354. Katz SH, Falk JL. Misplaced endotracheal tubes by paramedics in an urban emergency medical services system. *Ann Emerg Med* 2001;37:32–7.
355. Nolan JP, Soar J. Airway techniques and ventilation strategies. *Curr Opin Crit Care* 2008;14:279–86.
356. Gatward JJ, Thomas MJ, Nolan JP, Cook TM. Effect of chest compressions on the time taken to insert airway devices in a manikin. *Br J Anaesth* 2008;100:351–6.
357. Davies PR, Tighe SQ, Greenslade GL, Evans GH. Laryngeal mask airway and tracheal tube insertion by unskilled personnel. *Lancet* 1990;336:977–9.
358. Flaishon R, Sotman A, Ben-Abraham R, Rudick V, Varssano D, Weinbroum AA. Antichemical protective gear prolongs time to successful airway management: a randomized, crossover study in humans. *Anesthesiology* 2004;100:260–6.
359. Ho BY, Skinner HJ, Mahajan RP. Gastro-oesophageal reflux during day case gynaecological laparoscopy under positive pressure ventilation: laryngeal mask vs. tracheal intubation. *Anaesthesia* 1998;53:921–4.
360. Reinhart DJ, Simmons G. Comparison of placement of the laryngeal mask airway with endotracheal tube by paramedics and respiratory therapists. *Ann Emerg Med* 1994;24:260–3.
361. Rewari W, Kaul HL. Regurgitation and aspiration during gynaecological laparoscopy: comparison between laryngeal mask airway and tracheal intubation. *J Anaesthesiol Clin Pharmacol* 1999;15:67–70.
362. Pennant JH, Walker MB. Comparison of the endotracheal tube and laryngeal mask in airway management by paramedical personnel. *Anesth Analg* 1992;74:531–4.
363. Maltby JR, Beriault MT, Watson NC, Liepert DJ, Fick GH. LMA-Classic and LMA-ProSeal are effective alternatives to endotracheal intubation for gynecologic laparoscopy. *Can J Anaesth* 2003;50:71–7.
364. Deakin CD, Peters R, Tomlinson P, Cassidy M. Securing the prehospital airway: a comparison of laryngeal mask insertion and endotracheal intubation by UK paramedics. *Emerg Med J* 2005;22:64–7.
365. Cook TM, Hommers C. New airways for resuscitation? *Resuscitation* 2006;69:371–87.
366. Verghese C, Prior-Willeard PF, Baskett PJ. Immediate management of the airway during cardiopulmonary resuscitation in a hospital without a resident anaesthesiologist. *Eur J Emerg Med* 1994;1:123–5.
367. Kokkinis K. The use of the laryngeal mask airway in CPR. *Resuscitation* 1994;27:9–12.
368. Leach A, Alexander CA, Stone B. The laryngeal mask in cardiopulmonary resuscitation in a district general hospital: a preliminary communication. *Resuscitation* 1993;25:245–8.
369. The use of the laryngeal mask airway by nurses during cardiopulmonary resuscitation: results of a multicentre trial. *Anaesthesia* 1994;49:3–7.
370. Rumball CJ, MacDonald D. The PTL, Combitube, laryngeal mask, and oral airway: a randomized prehospital comparative study of ventilatory device effectiveness and cost-effectiveness in 470 cases of cardiorespiratory arrest. *Prehosp Emerg Care* 1997;1:1–10.
371. Tanigawa K, Shigematsu A. Choice of airway devices for 12,020 cases of nontraumatic cardiac arrest in Japan. *Prehosp Emerg Care* 1998;2:96–100.
372. Grantham H, Phillips G, Gilligan JE. The laryngeal mask in prehospital emergency care 1994;6:193–7.
373. Comparison of arterial blood gases of laryngeal mask airway and bag-valve-mask ventilation in out-of-hospital cardiac arrests. *Circ J* 2009;73:490–6.
374. Staudinger T, Brugger S, Watschinger B, et al. Emergency intubation with the Combitube: comparison with the endotracheal airway. *Ann Emerg Med* 1993;22:1573–5.
375. Lefrançois DP, Dufour DG. Use of the esophageal tracheal combitube by basic emergency medical technicians. *Resuscitation* 2002;52:77–83.
376. Ochs M, Vilke GM, Chan TC, Moats T, Buchanan J. Successful prehospital airway management by EMT-Ds using the combitube. *Prehosp Emerg Care* 2000;4:333–7.
377. Vezina D, Lessard MR, Bussieres J, Topping C, Trepanier CA. Complications associated with the use of the Esophageal-Tracheal Combitube. *Can J Anaesth* 1998;45:76–80.
378. Richards CF. Piriform sinus perforation during Esophageal-Tracheal Combitube placement. *J Emerg Med* 1998;16:37–9.
379. Rumball C, MacDonald D, Barber P, Wong H, Smecher C. Endotracheal intubation and esophageal tracheal Combitube insertion by regular ambulance attendants: a comparative trial. *Prehosp Emerg Care* 2004;8:15–22.
380. Rabitsch W, Schellongowski P, Staudinger T, et al. Comparison of a conventional tracheal airway with the Combitube in an urban emergency medical services system run by physicians. *Resuscitation* 2003;57:27–32.
381. Goldenberg IF, Campion BC, Siebold CM, McBride JW, Long LA. Esophageal gastric tube airway vs endotracheal tube in prehospital cardiopulmonary arrest. *Chest* 1986;90:90–6.
382. Cook TM, McCormick B, Asai T. Randomized comparison of laryngeal tube with classic laryngeal mask airway for anaesthesia with controlled ventilation. *Br J Anaesth* 2003;91:373–8.
383. Cook TM, McKinstry C, Hardy R, Twigg S. Randomized crossover comparison of the ProSeal laryngeal mask airway with the Laryngeal Tube during anaesthesia with controlled ventilation. *Br J Anaesth* 2003;91:678–83.
384. Kette F, Reffo I, Giordani G, et al. The use of laryngeal tube by nurses in out-of-hospital emergencies: preliminary experience. *Resuscitation* 2005;66:21–5.
385. Wiese CH, Semmel T, Muller JU, Bahr J, Ocker H, Graf BM. The use of the laryngeal tube disposable (LT-D) by paramedics during out-of-hospital resuscitation—an observational study concerning ERC guidelines 2005. *Resuscitation* 2009;80:194–8.
386. Wiese CH, Bartels U, Schultens A, et al. Using a Laryngeal Tube Suction-Device (LTS-D) reduces the “No Flow Time” in a single rescuer Manikin study. *J Emerg Med* 2009.
387. Wharton NM, Gibbison B, Gabbott DA, Haslam GM, Muchatuta N, Cook TM. I-gel insertion by novices in manikins and patients. *Anaesthesia* 2008;63:991–5.
388. Gatward JJ, Cook TM, Seller C, et al. Evaluation of the size 4 i-gel airway in one hundred non-paralysed patients. *Anaesthesia* 2008;63:1124–30.
389. Jackson KM, Cook TM. Evaluation of four airway training manikins as patient simulators for the insertion of eight types of supraglottic airway devices. *Anaesthesia* 2007;62:388–93.
390. Soar J. The I-gel supraglottic airway and resuscitation—some initial thoughts. *Resuscitation* 2007;74:197.
391. Thomas M, Benger J. Pre-hospital resuscitation using the iGEL. *Resuscitation* 2009;80:1437.
392. Cook TM, Nolan JP, Verghese C, et al. Randomized crossover comparison of the proSeal with the classic laryngeal mask airway in unparalysed anaesthetized patients. *Br J Anaesth* 2002;88:527–33.
393. Timmermann A, Cremer S, Eich C, et al. Prospective clinical and fiberoptic evaluation of the Supreme laryngeal mask airway. *Anesthesiology* 2009;110:262–5.
394. Cook TM, Gatward JJ, Handel J, et al. Evaluation of the LMA Supreme in 100 non-paralysed patients. *Anaesthesia* 2009;64:555–62.
395. Hosten T, Gurkan Y, Ozdamar D, Tekin M, Tokar K, Solak M. A new supraglottic airway device: LMA-supreme, comparison with LMA-ProSeal. *Acta Anaesthesiol Scand* 2009;53:852–7.
396. Burgoyne L, Cyna A. Laryngeal mask vs intubating laryngeal mask: insertion and ventilation by inexperienced resuscitators. *Anaesth Intensive Care* 2001;29:604–8.
397. Choyce A, Avidan MS, Shariff A, Del Aguila M, Radcliffe JJ, Chan T. A comparison of the intubating and standard laryngeal mask airways for airway management by inexperienced personnel. *Anaesthesia* 2001;56:357–60.
398. Baskett PJ, Parr MJ, Nolan JP. The intubating laryngeal mask. Results of a multicentre trial with experience of 500 cases. *Anaesthesia* 1998;53:1174–9.
399. Tentillier E, Heydenreich C, Cros AM, Schmitt V, Dindart JM, Thicoipe M. Use of the intubating laryngeal mask airway in emergency pre-hospital difficult intubation. *Resuscitation* 2008;77:30–4.
400. Lecky F, Bryden D, Little R, Tong N, Moulton C. Emergency intubation for acutely ill and injured patients. *Cochrane Database Syst Rev* 2008;CD001429.
401. Gausche M, Lewis RJ, Stratton SJ, et al. Effect of out-of-hospital pediatric endotracheal intubation on survival and neurological outcome: a controlled clinical trial. *JAMA* 2000;283:783–90.
402. Kramer-Johansen J, Wik L, Steen PA. Advanced cardiac life support before and after tracheal intubation—direct measurements of quality. *Resuscitation* 2006;68:61–9.
403. Grmec S. Comparison of three different methods to confirm tracheal tube placement in emergency intubation. *Intensive Care Med* 2002;28:701–4.
404. Lyon RM, Ferris JD, Young DM, McKeown DW, Oglesby AJ, Robertson C. Field intubation of cardiac arrest patients: a dying art? *Emerg Med J* 2010;27:321–3.
405. Wang HE, Simeone SJ, Weaver MD, Callaway CW. Interruptions in cardiopulmonary resuscitation from paramedic endotracheal intubation. *Ann Emerg Med* 2009;54:645e1–52e1.
406. Garza AG, Gratton MC, Coontz D, Noble E, Ma OJ. Effect of paramedic experience on orotracheal intubation success rates. *J Emerg Med* 2003;25:251–6.
407. Sayre MR, Sakles JC, Mistler AF, Evans JL, Kramer AT, Pancioli AM. Field trial of endotracheal intubation by basic EMTs. *Ann Emerg Med* 1998;31:228–33.
408. Bradley JS, Billows GL, Olinger ML, Boha SP, Cordell WH, Nelson DR. Prehospital oral endotracheal intubation by rural basic emergency medical technicians. *Ann Emerg Med* 1998;32:26–32.
409. Bobrow BJ, Clark LL, Ewy GA, et al. Minimally interrupted cardiac resuscitation by emergency medical services for out-of-hospital cardiac arrest. *JAMA* 2008;299:1158–65.



410. Takeda T, Tanigawa K, Tanaka H, Hayashi Y, Goto E, Tanaka K. The assessment of three methods to identify tracheal tube placement in the emergency setting. *Resuscitation* 2003;56.
411. Knapp S, Kofler J, Stoiser B, et al. The assessment of four different methods to verify tracheal tube placement in the critical care setting. *Anesth Analg* 1999;88:766–70.
412. Grmec S, Mally S. Prehospital determination of tracheal tube placement in severe head injury. *Emerg Med J* 2004;21:518–20.
413. Yao YX, Jiang Z, Lu XH, He JH, Ma XX, Zhu JH. A clinical study of impedance graph in verifying tracheal intubation. *Zhonghua Yi Xue Za Zhi* 2007;87:898–901.
414. Li J. Capnography alone is imperfect for endotracheal tube placement confirmation during emergency intubation. *J Emerg Med* 2001;20:223–9.
415. Tanigawa K, Takeda T, Goto E, Tanaka K. Accuracy and reliability of the self-inflating bulb to verify tracheal intubation in out-of-hospital cardiac arrest patients. *Anesthesiology* 2000;93:1432–6.
416. Baraka A, Khoury PJ, Siddik SS, Salem MR, Joseph NJ. Efficacy of the self-inflating bulb in differentiating esophageal from tracheal intubation in the parturient undergoing cesarean section. *Anesth Analg* 1997;84:533–7.
417. Davis DP, Stephen KA, Vilke GM. Inaccuracy in endotracheal tube verification using a Toomey syringe. *J Emerg Med* 1999;17:35–8.
418. Bozeman WP, Hexter D, Liang HK, Kelen GD. Esophageal detector device versus detection of end-tidal carbon dioxide level in emergency intubation. *Ann Emerg Med* 1996;27:595–9.
419. Jenkins WA, Verdile VP, Paris PM. The syringe aspiration technique to verify endotracheal tube position. *Am J Emerg Med* 1994;12:413–6.
420. Schaller RJ, Huff JS, Zahn A. Comparison of a colorimetric end-tidal CO<sub>2</sub> detector and an esophageal aspiration device for verifying endotracheal tube placement in the prehospital setting: a six-month experience. *Prehosp Disaster Med* 1997;12:57–63.
421. Tanigawa K, Takeda T, Goto E, Tanaka K. The efficacy of esophageal detector devices in verifying tracheal tube placement: a randomized cross-over study of out-of-hospital cardiac arrest patients. *Anesth Analg* 2001;92:375–8.
422. Anton WR, Gordon RW, Jordan TM, Posner KL, Cheney FW. A disposable end-tidal CO<sub>2</sub> detector to verify endotracheal intubation. *Ann Emerg Med* 1991;20:271–5.
423. MacLeod BA, Heller MB, Gerard J, Yealy DM, Menegazzi JJ. Verification of endotracheal tube placement with colorimetric end-tidal CO<sub>2</sub> detection. *Ann Emerg Med* 1991;20:267–70.
424. Ornato JP, Shipley JB, Racht EM, et al. Multicenter study of a portable, hand-size, colorimetric end-tidal carbon dioxide detection device. *Ann Emerg Med* 1992;21:518–23.
425. Sanders KC, Clum 3rd WB, Nguyen SS, Balasubramanian S. End-tidal carbon dioxide detection in emergency intubation in four groups of patients. *J Emerg Med* 1994;12:771–7.
426. Varon AJ, Morrino J, Civetta JM. Clinical utility of a colorimetric end-tidal CO<sub>2</sub> detector in cardiopulmonary resuscitation and emergency intubation. *J Clin Monit* 1991;7:289–93.
427. Vukmir RB, Heller MB, Stein KL. Confirmation of endotracheal tube placement: a miniaturized infrared qualitative CO<sub>2</sub> detector. *Ann Emerg Med* 1991;20:726–9.
428. Silvestri S, Ralls GA, Krauss B, et al. The effectiveness of out-of-hospital use of continuous end-tidal carbon dioxide monitoring on the rate of unrecognized misplaced intubation within a regional emergency medical services system. *Ann Emerg Med* 2005;45:497–503.
429. Mehta KH, Turley A, Peyrassé P, Jones J, Hall JE. An assessment of the ability of impedance respirometry distinguish oesophageal from tracheal intubation. *Anaesthesia* 2002;57:1090–3.
430. Absolom M, Roberts R, Bahlmann UB, Hall JE, Armstrong T, Turley A. The use of impedance respirometry to confirm tracheal intubation in children. *Anaesthesia* 2006;61:1145–8.
431. Kramer-Johansen J, Eilevstjonn J, Olasveengen TM, Tomlinson AE, Dorph E, Steen PA. Transthoracic impedance changes as a tool to detect malpositioned tracheal tubes. *Resuscitation* 2008;76:11–6.
432. Risdal M, Aase SO, Stavland M, Eftestol T. Impedance-based ventilation detection during cardiopulmonary resuscitation. *IEEE Trans Biomed Eng* 2007;54:2237–45.
433. Pytte M, Olasveengen TM, Steen PA, Sunde K. Misplaced and dislodged endotracheal tubes may be detected by the defibrillator during cardiopulmonary resuscitation. *Acta Anaesthesiol Scand* 2007;51:770–2.
434. Salem MR, Wong AY, Mani M, Sellick BA. Efficacy of cricoid pressure in preventing gastric inflation during bag-mask ventilation in pediatric patients. *Anesthesiology* 1974;40:96–8.
435. Moynihan RJ, Brock-Utne JG, Archer JH, Feld LH, Kreitzman TR. The effect of cricoid pressure on preventing gastric insufflation in infants and children. *Anesthesiology* 1993;78:652–6.
436. Ho AM, Wong W, Ling E, Chung DC, Tay BA. Airway difficulties caused by improperly applied cricoid pressure. *J Emerg Med* 2001;20:29–31.
437. Shorten GD, Alfille PH, Gliklich RE. Airway obstruction following application of cricoid pressure. *J Clin Anesth* 1991;3:403–5.
438. Proceedings of the guidelines 2000 conference for cardiopulmonary resuscitation and emergency cardiovascular care: an international consensus on science. *Ann Emerg Med* 2001;37:S1–200.
439. Lindner KH, Dirks B, Strohmenger HU, Pregel AW, Lindner IM, Lurie KG. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. *Lancet* 1997;349:535–7.
440. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. *N Engl J Med* 2004;350:105–13.
441. Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for in-hospital cardiac arrest: a randomised controlled trial. *Lancet* 2001;358:105–9.
442. Aung K, Htay T. Vasopressin for cardiac arrest: a systematic review and meta-analysis. *Arch Intern Med* 2005;165:17–24.
443. Callaway CW, Hostler D, Doshi AA, et al. Usefulness of vasopressin administered with epinephrine during out-of-hospital cardiac arrest. *Am J Cardiol* 2006;98:1316–21.
444. Gueugniaud PY, David JS, Chanzy E, et al. Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation. *N Engl J Med* 2008;359:21–30.
445. Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. *Agents Actions* 1985;16:470–7.
446. Somberg JC, Bailin SJ, Haffajee CI, et al. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. *Am J Cardiol* 2002;90:853–9.
447. Somberg JC, Timar S, Bailin SJ, et al. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. *Am J Cardiol* 2004;93:576–81.
448. Skrifvars MB, Kuisma M, Boyd J, et al. The use of undiluted amiodarone in the management of out-of-hospital cardiac arrest. *Acta Anaesthesiol Scand* 2004;48:582–7.
449. Petrovic T, Adnet F, Lapandry C. Successful resuscitation of ventricular fibrillation after low-dose amiodarone. *Ann Emerg Med* 1998;32:518–9.
450. Levine JH, Massumi A, Scheinman MM, et al. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. *Intravenous Amiodarone Multicenter Trial Group. J Am Coll Cardiol* 1996;27:67–75.
451. Matsusaka T, Hasebe N, Jin YT, Kawabe J, Kikuchi K. Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits. *Cardiovasc Res* 2002;54:568–75.
452. Longstreth Jr WT, Fahrenbruch CE, Olsufka M, Walsh TR, Copass MK, Cobb LA. Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. *Neurology* 2002;59:506–14.
453. Stiell IG, Wells GA, Hebert PC, Laupacis A, Weitzman BN. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. *Acad Emerg Med* 1995;2:264–73.
454. Engdahl J, Bang A, Lindqvist J, Herlitz J. Can we define patients with no and those with some chance of survival when found in asystole out of hospital? *Am J Cardiol* 2000;86:610–4.
455. Engdahl J, Bang A, Lindqvist J, Herlitz J. Factors affecting short- and long-term prognosis among 1069 patients with out-of-hospital cardiac arrest and pulseless electrical activity. *Resuscitation* 2001;51:17–25.
456. Dumot JA, Burval DJ, Sprung J, et al. Outcome of adult cardiopulmonary resuscitations at a tertiary referral center including results of “limited” resuscitations. *Arch Intern Med* 2001;161:1751–8.
457. Tortolani AJ, Risucci DA, Powell SR, Dixon R. In-hospital cardiopulmonary resuscitation during asystole. Therapeutic factors associated with 24-hour survival. *Chest* 1989;96:622–6.
458. Coon GA, Clinton JE, Ruiz E. Use of atropine for brady-asystolic prehospital cardiac arrest. *Ann Emerg Med* 1981;10:462–7.
459. Harrison EE, Amey BD. The use of calcium in cardiac resuscitation. *Am J Emerg Med* 1983;1:267–73.
460. Stueven HA, Thompson B, Aprahamian C, Tonsfeldt DJ, Kastenson EH. The effectiveness of calcium chloride in refractory electromechanical dissociation. *Ann Emerg Med* 1985;14:626–9.
461. Stueven HA, Thompson B, Aprahamian C, Tonsfeldt DJ, Kastenson EH. Lack of effectiveness of calcium chloride in refractory asystole. *Ann Emerg Med* 1985;14:630–2.
462. Stueven HA, Thompson BM, Aprahamian C, Tonsfeldt DJ. Calcium chloride: reassessment of use in asystole. *Ann Emerg Med* 1984;13:820–2.
463. Gando S, Tede I, Tujinaga H, Kubota M. Variation in serum ionized calcium on cardiopulmonary resuscitation. *J Anesth* 1988;2:154–60.
464. Stueven H, Thompson BM, Aprahamian C, Darin JC. Use of calcium in prehospital cardiac arrest. *Ann Emerg Med* 1983;12:136–9.
465. van Walraven C, Stiell IG, Wells GA, Hebert PC, Vandemheen K. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? The OTAC Study Group. *Ann Emerg Med* 1998;32:544–53.
466. Dybvik T, Strand T, Steen PA. Buffer therapy during out-of-hospital cardiopulmonary resuscitation. *Resuscitation* 1995;29:89–95.
467. Auferheide TP, Martin DR, Olson DW, et al. Prehospital bicarbonate use in cardiac arrest: a 3-year experience. *Am J Emerg Med* 1992;10:4–7.
468. Delooy H, Lewi PJ. Are inter-center differences in EMS-management and sodium-bicarbonate administration important for the outcome of CPR? The Cerebral Resuscitation Study Group. *Resuscitation* 1989;17(Suppl.):S199–206.
469. Roberts D, Landolfo K, Light R, Dobson K. Early predictors of mortality for hospitalized patients suffering cardiopulmonary arrest. *Chest* 1990;97:413–9.
470. Suljaga-Pechtel K, Goldberg E, Strickon P, Berger M, Skovron ML. Cardiopulmonary resuscitation in a hospitalized population: prospective study of factors associated with outcome. *Resuscitation* 1984;12:77–95.
471. Weil MH, Trevino RP, Rackow EC. Sodium bicarbonate during CPR. Does it help or hinder? *Chest* 1985;88:487.
472. Vukmir RB, Katz L. Sodium bicarbonate improves outcome in prolonged prehospital cardiac arrest. *Am J Emerg Med* 2006;24:156–61.

473. Bar-Joseph G, Abramson NS, Kelsey SF, Mashlach T, Craig MT, Safar P. Improved resuscitation outcome in emergency medical systems with increased usage of sodium bicarbonate during cardiopulmonary resuscitation. *Acta Anaesthesiol Scand* 2005;49:6–15.
474. Weaver WD, Eisenberg MS, Martin JS, et al. Myocardial Infarction Triage and Intervention Project, phase I: patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. *J Am Coll Cardiol* 1990;15:925–31.
475. Sandeman DJ, Alahakoon TI, Bentley SC. Tricyclic poisoning—successful management of ventricular fibrillation following massive overdose of imipramine. *Anaesth Intensive Care* 1997;25:542–5.
476. Lin SR. The effect of dextran and streptokinase on cerebral function and blood flow after cardiac arrest. An experimental study on the dog. *Neuroradiology* 1978;16:340–2.
477. Fischer M, Bottiger BW, Popov-Cenic S, Hossmann KA. Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat. *Intensive Care Med* 1996;22:1214–23.
478. Ruiz-Bailen M, Aguayo de Hoyos E, Serrano-Corcoles MC, Diaz-Castellanos MA, Ramos-Cuadra JA, Reina-Toral A. Efficacy of thrombolysis in patients with acute myocardial infarction requiring cardiopulmonary resuscitation. *Intensive Care Med* 2001;27:1050–7.
479. Janata K, Holzer M, Kurkciyan I, et al. Major bleeding complications in cardiopulmonary resuscitation: the place of thrombolytic therapy in cardiac arrest due to massive pulmonary embolism. *Resuscitation* 2003;57:49–55.
480. Kurkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. *Arch Intern Med* 2000;160:1529–35.
481. Lederer W, Lichtenberger C, Pechlaner C, Kroesen G, Baubin M. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. *Resuscitation* 2001;50:71–6.
482. Bozeman WP, Kleiner DM, Ferguson KL. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. *Resuscitation* 2006;69:399–406.
483. Stadlbauer KH, Krismer AC, Arntz HR, et al. Effects of thrombolysis during out-of-hospital cardiopulmonary resuscitation. *Am J Cardiol* 2006;97:305–8.
484. Fatovich DM, Dobb GJ, Clugston RA. A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). *Resuscitation* 2004;61:309–13.
485. Tiffany PA, Schultz M, Stueven H. Bolus thrombolytic infusions during CPR for patients with refractory arrest rhythms: outcome of a case series. *Ann Emerg Med* 1998;31:124–6.
486. Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. *N Engl J Med* 2002;346:1522–8.
487. Bottiger BW, Arntz HR, Chamberlain DA, et al. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. *N Engl J Med* 2008;359:2651–62.
488. Li X, Fu QL, Jing XL, et al. A meta-analysis of cardiopulmonary resuscitation with and without the administration of thrombolytic agents. *Resuscitation* 2006;70:31–6.
489. Fava M, Loyola S, Berton H, Dougnac A. Massive pulmonary embolism: percutaneous mechanical thrombectomy during cardiopulmonary resuscitation. *J Vasc Interv Radiol* 2005;16:119–23.
490. Lederer W, Lichtenberger C, Pechlaner C, Kinz J, Kroesen G, Baubin M. Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrest. *Resuscitation* 2004;61:123–9.
491. Zahorec R. Rescue systemic thrombolysis during cardiopulmonary resuscitation. *Bratisl Lek Listy* 2002;103:266–9.
492. Konstantinov IE, Saxena P, Koniuszko MD, Alvarez J, Newman MA. Acute massive pulmonary embolism with cardiopulmonary resuscitation: management and results. *Tex Heart Inst J* 2007;34:41–5 [discussion 5–6].
493. Scholz KH, Hilmer T, Schuster S, Wojcik J, Kreuzer H, Tebbe U. Thrombolysis in resuscitated patients with pulmonary embolism. *Dtsch Med Wochenschr* 1990;115:930–5.
494. Gramann J, Lange-Braun P, Bodemann T, Hochrein H. Der Einsatz von Thrombolytika in der Reanimation als Ultima ratio zur Überwindung des Herztodes. *Intensiv- und Notfallbehandlung* 1991;16:134–7.
495. Klefisch F, Gareis R, Störck T, Möckel M, Danne O. Praktische ultima-ratio thrombolyse bei therapierefraktärer kardiopulmonaler reanimation. *Intensivmedizin* 1995;32:155–62.
496. Böttiger BW, Martin E. Thrombolytic therapy during cardiopulmonary resuscitation and the role of coagulation activation after cardiac arrest. *Curr Opin Crit Care* 2001;7:176–83.
497. Spöhr F, Böttiger BW. Safety of thrombolysis during cardiopulmonary resuscitation. *Drug Saf* 2003;26:367–79.
498. Langhelle A, Tyvold SS, Lexow K, Hapnes SA, Sunde K, Steen PA. In-hospital factors associated with improved outcome after out-of-hospital cardiac arrest. A comparison between four regions in Norway. *Resuscitation* 2003;56:247–63.
499. Calle PA, Buylaert WA, Vanhaute OA. Glycemia in the post-resuscitation period. The Cerebral Resuscitation Study Group. *Resuscitation* 1989;17(Suppl.):S181–8 [discussion S99–206].
500. Longstreth Jr WT, Diehr P, Inui TS. Prediction of awakening after out-of-hospital cardiac arrest. *N Engl J Med* 1983;308:1378–82.
501. Longstreth Jr WT, Inui TS. High blood glucose level on hospital admission and poor neurological recovery after cardiac arrest. *Ann Neurol* 1984;15:59–63.
502. Longstreth Jr WT, Copass MK, Dennis LK, Rauch-Matthews ME, Stark MS, Cobb LA. Intravenous glucose after out-of-hospital cardiopulmonary arrest: a community-based randomized trial. *Neurology* 1993;43:2534–41.
503. Mackenzie CF. A review of 100 cases of cardiac arrest and the relation of potassium, glucose, and haemoglobin levels to survival. *West Indian Med J* 1975;24:39–45.
504. Mullner M, Sterz F, Binder M, Schreiber W, Deimel A, Laggner AN. Blood glucose concentration after cardiopulmonary resuscitation influences functional neurological recovery in human cardiac arrest survivors. *J Cereb Blood Flow Metab* 1997;17:430–6.
505. Skrifvars MB, Pettila V, Rosenberg PH, Castren M. A multiple logistic regression analysis of in-hospital factors related to survival at six months in patients resuscitated from out-of-hospital ventricular fibrillation. *Resuscitation* 2003;59:319–28.
506. Ditchey RV, Lindenfeld J. Potential adverse effects of volume loading on perfusion of vital organs during closed-chest resuscitation. *Circulation* 1984;69:181–9.
507. Voorhees WD, Ralston SH, Kougias C, Schmitz PM. Fluid loading with whole blood or Ringer's lactate solution during CPR in dogs. *Resuscitation* 1987;15:113–23.
508. Gentile NT, Martin GB, Appleton TJ, Moeggenberg J, Paradis NA, Nowak RM. Effects of arterial and venous volume infusion on coronary perfusion pressures during canine CPR. *Resuscitation* 1991;22:55–63.
509. Bender R, Breil M, Heister U, et al. Hypertonic saline during CPR: feasibility and safety of a new protocol of fluid management during resuscitation. *Resuscitation* 2007;72:74–81.
510. Bruel C, Parienti JJ, Marie W, et al. Mild hypothermia during advanced life support: a preliminary study in out-of-hospital cardiac arrest. *Crit Care* 2008;12:R31.
511. Kamarainen A, Virkkunen I, Tenhunen J, Yli-Hankala A, Silvast T. Prehospital induction of therapeutic hypothermia during CPR: a pilot study. *Resuscitation* 2008;76:360–3.
512. Krep H, Breil M, Sinn D, Hagendorff A, Hoeft A, Fischer M. Effects of hypertonic versus isotonic infusion therapy on regional cerebral blood flow after experimental cardiac arrest cardiopulmonary resuscitation in pigs. *Resuscitation* 2004;63:73–83.
513. Soar J, Foster J, Breitkreutz R. Fluid infusion during CPR and after ROSC—is it safe? *Resuscitation* 2009;80:1221–2.
514. Ong ME, Chan YH, Oh JJ, Ngo AS. An observational, prospective study comparing tibial and humeral intraosseous access using the EZ-IO. *Am J Emerg Med* 2009;27:8–15.
515. Gerritse BM, Scheffer GJ, Draaisma JM. Prehospital intraosseous access with the bone injection gun by a helicopter-transported emergency medical team. *J Trauma* 2009;66:1739–41.
516. Brenner T, Bernhard M, Helm M, et al. Comparison of two intraosseous infusion systems for adult emergency medical use. *Resuscitation* 2008;78:314–9.
517. Frascione RJ, Jensen JP, Kaye K, Salzman JG. Consecutive field trials using two different intraosseous devices. *Prehosp Emerg Care* 2007;11:164–71.
518. Banerjee S, Singhi SC, Singh S, Singh M. The intraosseous route is a suitable alternative to intravenous route for fluid resuscitation in severely dehydrated children. *Indian Pediatr* 1994;31:1511–20.
519. Brickman KR, Krupp K, Rega P, Alexander J, Guinness M. Typing and screening of blood from intraosseous access. *Ann Emerg Med* 1992;21:414–7.
520. Fiser RT, Walker WM, Seibert JJ, McCarthy R, Fiser DH. Tibial length following intraosseous infusion: a prospective, radiographic analysis. *Pediatr Emerg Care* 1997;13:186–8.
521. Ummenhofer W, Frei FJ, Urwyler A, Drewe J. Are laboratory values in bone marrow aspirate predictable for venous blood in paediatric patients? *Resuscitation* 1994;27:123–8.
522. Guy J, Haley K, Zuspan SJ. Use of intraosseous infusion in the pediatric trauma patient. *J Pediatr Surg* 1993;28:158–61.
523. Macnab A, Christenson J, Findlay J, et al. A new system for sternal intraosseous infusion in adults. *Prehosp Emerg Care* 2000;4:173–7.
524. Ellemunter H, Simma B, Trawoger R, Maurer H. Intraosseous lines in preterm and full term neonates. *Arch Dis Child Fetal Neonatal Ed* 1999;80:F74–5.
525. Delguercio LR, Feins NR, Cohn JD, Coomaraswamy RP, Wollman SB, State D. Comparison of blood flow during external and internal cardiac massage in man. *Circulation* 1965;31(Suppl. 1):171–80.
526. Wik L, Kramer-Johansen J, Myklebust H, et al. Quality of cardiopulmonary resuscitation during out-of-hospital cardiac arrest. *JAMA* 2005;293:299–304.
527. Kramer-Johansen J, Myklebust H, Wik L, et al. Quality of out-of-hospital cardiopulmonary resuscitation with real time automated feedback: a prospective interventional study. *Resuscitation* 2006;71:283–92.
528. Sutton RM, Maltese MR, Niles D, et al. Quantitative analysis of chest compression interruptions during in-hospital resuscitation of older children and adolescents. *Resuscitation* 2009;80:1259–63.
529. Sutton RM, Niles D, Nysaether J, et al. Quantitative analysis of CPR quality during in-hospital resuscitation of older children and adolescents. *Pediatrics* 2009;124:494–9.
530. Boczar ME, Howard MA, Rivers EP, et al. A technique revisited: hemodynamic comparison of closed- and open-chest cardiac massage during human cardiopulmonary resuscitation. *Crit Care Med* 1995;23:498–503.
531. Anthi A, Tzelepis GE, Alivizatos P, Michalis A, Palatianos GM, Geroulanos S. Unexpected cardiac arrest after cardiac surgery: incidence, predisposing causes, and outcome of open chest cardiopulmonary resuscitation. *Chest* 1998;113:15–9.
532. Pottle A, Bullock I, Thomas J, Scott L. Survival to discharge following Open Chest Cardiac Compression (OCCC). A 4-year retrospective audit in a cardiothoracic

- specialist centre - Royal Brompton and Harefield NHS Trust, United Kingdom. *Resuscitation* 2002;52:269–72.
533. Babbs CF. Interposed abdominal compression CPR: a comprehensive evidence based review. *Resuscitation* 2003;59:71–82.
  534. Babbs CF, Nadkarni V. Optimizing chest compression to rescue ventilation ratios during one-rescuer CPR by professionals and lay persons: children are not just little adults. *Resuscitation* 2004;61:173–81.
  535. Beyar R, Kishon Y, Kimmel E, Neufeld H, Dinnar U. Intrathoracic and abdominal pressure variations as an efficient method for cardiopulmonary resuscitation: studies in dogs compared with computer model results. *Cardiovasc Res* 1985;19:335–42.
  536. Voorhees WD, Niebauer MJ, Babbs CF. Improved oxygen delivery during cardiopulmonary resuscitation with interposed abdominal compressions. *Ann Emerg Med* 1983;12:128–35.
  537. Sack JB, Kesselbrenner MB, Bregman D. Survival from in-hospital cardiac arrest with interposed abdominal counterpulsation during cardiopulmonary resuscitation. *JAMA* 1992;267:379–85.
  538. Sack JB, Kesselbrenner MB, Jarrad A. Interposed abdominal compression-cardiopulmonary resuscitation and resuscitation outcome during asystole and electromechanical dissociation. *Circulation* 1992;86:1692–700.
  539. Mateer JR, Stueven HA, Thompson BM, Aprahamian C, Darin JC. Pre-hospital IAC-CPR versus standard CPR: paramedic resuscitation of cardiac arrests. *Am J Emerg Med* 1985;3:143–6.
  540. Lindner KH, Pfenninger EG, Lurie KG, Schurmann W, Lindner IM, Ahnefeld FW. Effects of active compression–decompression resuscitation on myocardial and cerebral blood flow in pigs. *Circulation* 1993;88:1254–63.
  541. Shultz JJ, Coffeen P, Sweeney M, et al. Evaluation of standard and active compression–decompression CPR in an acute human model of ventricular fibrillation. *Circulation* 1994;89:684–93.
  542. Chang MW, Coffeen P, Lurie KG, Shultz J, Bache RJ, White CW. Active compression–decompression CPR improves vital organ perfusion in a dog model of ventricular fibrillation. *Chest* 1994;106:1250–9.
  543. Orliaguet GA, Carli PA, Rozenberg A, Janniere D, Sauval P, Delpech P. End-tidal carbon dioxide during out-of-hospital cardiac arrest resuscitation: comparison of active compression–decompression and standard CPR. *Ann Emerg Med* 1995;25:48–51.
  544. Guly UM, Mitchell RG, Cook R, Steedman DJ, Robertson CE. Paramedics and technicians are equally successful at managing cardiac arrest outside hospital. *BMJ* 1995;310:1091–4.
  545. Tucker KJ, Galli F, Savitt MA, Kahsai D, Bresnahan L, Redberg RF. Active compression–decompression resuscitation: effect on resuscitation success after in-hospital cardiac arrest. *J Am Coll Cardiol* 1994;24:201–9.
  546. Malzer R, Zeiner A, Binder M, et al. Hemodynamic effects of active compression–decompression after prolonged CPR. *Resuscitation* 1996;31:243–53.
  547. Lurie KG, Shultz JJ, Callahan ML, et al. Evaluation of active compression–decompression CPR in victims of out-of-hospital cardiac arrest. *JAMA* 1994;271:1405–11.
  548. Cohen TJ, Goldner BG, Maccaro PC, et al. A comparison of active compression–decompression cardiopulmonary resuscitation with standard cardiopulmonary resuscitation for cardiac arrests occurring in the hospital. *N Engl J Med* 1993;329:1918–21.
  549. Schwab TM, Callahan ML, Madsen CD, Utecht TA. A randomized clinical trial of active compression–decompression CPR vs standard CPR in out-of-hospital cardiac arrest in two cities. *JAMA* 1995;273:1261–8.
  550. Stiell I, Hebert P, Wells G, et al. The Ontario trial of active compression–decompression cardiopulmonary resuscitation for in-hospital and prehospital cardiac arrest. *JAMA* 1996;275:1417–23.
  551. Mauer D, Schneider T, Dick W, Wilhelm A, Elich D, Mauer M. Active compression–decompression resuscitation: a prospective, randomized study in a two-tiered EMS system with physicians in the field. *Resuscitation* 1996;33:125–34.
  552. Nolan J, Smith G, Evans R, et al. The United Kingdom pre-hospital study of active compression–decompression resuscitation. *Resuscitation* 1998;37:119–25.
  553. Luiz T, Ellinger K, Denz C. Active compression–decompression cardiopulmonary resuscitation does not improve survival in patients with prehospital cardiac arrest in a physician-manned emergency medical system. *J Cardiothorac Vasc Anesth* 1996;10:178–86.
  554. Plaisance P, Lurie KG, Vicaut E, et al. A comparison of standard cardiopulmonary resuscitation and active compression–decompression resuscitation for out-of-hospital cardiac arrest. French Active Compression–Decompression Cardiopulmonary Resuscitation Study Group. *N Engl J Med* 1999;341:569–75.
  555. Baubin M, Rabl W, Pfeiffer KP, Benzer A, Gilly H. Chest injuries after active compression–decompression cardiopulmonary resuscitation (ACD-CPR) in cadavers. *Resuscitation* 1999;43:9–15.
  556. Rabl W, Baubin M, Broinger G, Scheithauer R. Serious complications from active compression–decompression cardiopulmonary resuscitation. *Int J Legal Med* 1996;109:84–9.
  557. Hoke RS, Chamberlain D. Skeletal chest injuries secondary to cardiopulmonary resuscitation. *Resuscitation* 2004;63:327–38.
  558. Plaisance P, Lurie KG, Payen D. Inspiratory impedance during active compression–decompression cardiopulmonary resuscitation: a randomized evaluation in patients in cardiac arrest. *Circulation* 2000;101:989–94.
  559. Plaisance P, Soleil C, Lurie KG, Vicaut E, Ducros L, Payen D. Use of an inspiratory impedance threshold device on a facemask and endotracheal tube to reduce intrathoracic pressures during the decompression phase of active compression–decompression cardiopulmonary resuscitation. *Crit Care Med* 2005;33:990–4.
  560. Wolcke BB, Mauer DK, Schoefmann MF, et al. Comparison of standard cardiopulmonary resuscitation versus the combination of active compression–decompression cardiopulmonary resuscitation and an inspiratory impedance threshold device for out-of-hospital cardiac arrest. *Circulation* 2003;108:2201–5.
  561. Aufderheide TP, Pirrallo RG, Provo TA, Lurie KG. Clinical evaluation of an inspiratory impedance threshold device during standard cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest. *Crit Care Med* 2005;33:734–40.
  562. Lurie KG, Barnes TA, Zielinski TM, McKnite SH. Evaluation of a prototypic inspiratory impedance threshold valve designed to enhance the efficiency of cardiopulmonary resuscitation. *Respir Care* 2003;48:52–7.
  563. Lurie KG, Coffeen P, Shultz J, McKnite S, Detloff B, Mulligan K. Improving active compression–decompression cardiopulmonary resuscitation with an inspiratory impedance valve. *Circulation* 1995;91:1629–32.
  564. Lurie KG, Mulligan KA, McKnite S, Detloff B, Lindstrom P, Lindner KH. Optimizing standard cardiopulmonary resuscitation with an inspiratory impedance threshold valve. *Chest* 1998;113:1084–90.
  565. Lurie KG, Voelckel WG, Zielinski T, et al. Improving standard cardiopulmonary resuscitation with an inspiratory impedance threshold valve in a porcine model of cardiac arrest. *Anesth Analg* 2001;93:649–55.
  566. Lurie KG, Zielinski T, McKnite S, Aufderheide T, Voelckel W. Use of an inspiratory impedance valve improves neurologically intact survival in a porcine model of ventricular fibrillation. *Circulation* 2002;105:124–9.
  567. Raedler C, Voelckel WG, Wenzel V, et al. Vasopressor response in a porcine model of hypothermic cardiac arrest is improved with active compression–decompression cardiopulmonary resuscitation using the inspiratory impedance threshold valve. *Anesth Analg* 2002;95:1496–502.
  568. Voelckel WG, Lurie KG, Zielinski T, et al. The effects of positive end-expiratory pressure during active compression decompression cardiopulmonary resuscitation with the inspiratory threshold valve. *Anesth Analg* 2001;92:967–74.
  569. Yannopoulos D, Aufderheide TP, Gabrielli A, et al. Clinical and hemodynamic comparison of 15:2 and 30:2 compression-to-ventilation ratios for cardiopulmonary resuscitation. *Crit Care Med* 2006;34:1444–9.
  570. Mader TJ, Kellogg AR, Smith J, et al. A blinded, randomized controlled evaluation of an impedance threshold device during cardiopulmonary resuscitation in swine. *Resuscitation* 2008;77:387–94.
  571. Menegazzi JJ, Salcido DD, Menegazzi MT, et al. Effects of an impedance threshold device on hemodynamics and restoration of spontaneous circulation in prolonged porcine ventricular fibrillation. *Prehosp Emerg Care* 2007;11:179–85.
  572. Langhelle A, Stromme T, Sunde K, Wik L, Nicolaysen G, Steen PA. Inspiratory impedance threshold valve during CPR. *Resuscitation* 2002;52:39–48.
  573. Herff H, Raedler C, Zander R, et al. Use of an inspiratory impedance threshold valve during chest compressions without assisted ventilation may result in hypoxaemia. *Resuscitation* 2007;72:466–76.
  574. Plaisance P, Lurie KG, Vicaut E, et al. Evaluation of an impedance threshold device in patients receiving active compression–decompression cardiopulmonary resuscitation for out of hospital cardiac arrest. *Resuscitation* 2004;61:265–71.
  575. Cabrini L, Beccaria P, Landoni G, et al. Impact of impedance threshold devices on cardiopulmonary resuscitation: a systematic review and meta-analysis of randomized controlled studies. *Crit Care Med* 2008;36:1625–32.
  576. Wik L, Bircher NG, Safar P. A comparison of prolonged manual and mechanical external chest compression after cardiac arrest in dogs. *Resuscitation* 1996;32:241–50.
  577. Dickinson ET, Verdile VP, Schneider RM, Salluzzo RF. Effectiveness of mechanical versus manual chest compressions in out-of-hospital cardiac arrest resuscitation: a pilot study. *Am J Emerg Med* 1998;16:289–92.
  578. McDonald JL. Systolic and mean arterial pressures during manual and mechanical CPR in humans. *Ann Emerg Med* 1982;11:292–5.
  579. Ward KR, Menegazzi JJ, Zelenak RR, Sullivan RJ, McSwain Jr NE. A comparison of chest compressions between mechanical and manual CPR by monitoring end-tidal PCO<sub>2</sub> during human cardiac arrest. *Ann Emerg Med* 1993;22:669–74.
  580. Wang HC, Chiang WC, Chen SY, et al. Video-recording and time-motion analyses of manual versus mechanical cardiopulmonary resuscitation during ambulance transport. *Resuscitation* 2007;74:453–60.
  581. Steen S, Liao Q, Pierre L, Paskevicius A, Sjoberg T. Evaluation of LUCAS, a new device for automatic mechanical compression and active decompression resuscitation. *Resuscitation* 2002;55:285–99.
  582. Rubertsson S, Karlsten R. Increased cortical cerebral blood flow with LUCAS; a new device for mechanical chest compressions compared to standard external compressions during experimental cardiopulmonary resuscitation. *Resuscitation* 2005;65:357–63.
  583. Axelsson C, Nestin J, Svensson L, Axelsson AB, Herlitz J. Clinical consequences of the introduction of mechanical chest compression in the EMS system for treatment of out-of-hospital cardiac arrest—a pilot study. *Resuscitation* 2006;71:47–55.
  584. Steen S, Sjoberg T, Olsson P, Young M. Treatment of out-of-hospital cardiac arrest with LUCAS, a new device for automatic mechanical compression and active decompression resuscitation. *Resuscitation* 2005;67:25–30.
  585. Larsen AI, Hjørnevik AS, Ellingsen CL, Nilsen DW. Cardiac arrest with continuous mechanical chest compression during percutaneous coronary

- intervention. A report on the use of the LUCAS device. *Resuscitation* 2007;75:454–9.
586. Bonnemeier H, Olivecrona G, Simonis G, et al. Automated continuous chest compression for in-hospital cardiopulmonary resuscitation of patients with pulseless electrical activity: a report of five cases. *Int J Cardiol* 2009;136:e39–50.
  587. Grogard HK, Wik L, Eriksen M, Brekke M, Sunde K. Continuous mechanical chest compressions during cardiac arrest to facilitate restoration of coronary circulation with percutaneous coronary intervention. *J Am Coll Cardiol* 2007;50:1093–4.
  588. Larsen AI, Hjørnevik A, Bonarjee V, Barvik S, Melberg T, Nilsen DW. Coronary blood flow and perfusion pressure during coronary angiography in patients with ongoing mechanical chest compression: a report on 6 cases. *Resuscitation* 2010;81:493–7.
  589. Smekal D, Johansson J, Huzevka T, Rubertsson S. No difference in autopsy detected injuries in cardiac arrest patients treated with manual chest compressions compared with mechanical compressions with the LUCAS device—a pilot study. *Resuscitation* 2009;80:1104–7.
  590. Deakin CD, Paul V, Fall E, Petley GW, Thompson F. Ambient oxygen concentrations resulting from use of the Lund University Cardiopulmonary Assist System (LUCAS) device during simulated cardiopulmonary resuscitation. *Resuscitation* 2007;74:303–9.
  591. Timmerman S, Cardoso LF, Ramires JA, Halperin H. Improved hemodynamic performance with a novel chest compression device during treatment of in-hospital cardiac arrest. *Resuscitation* 2004;61:273–80.
  592. Halperin H, Berger R, Chandra N, et al. Cardiopulmonary resuscitation with a hydraulic-pneumatic band. *Crit Care Med* 2000;28:N203–6.
  593. Halperin HR, Paradis N, Ornato JP, et al. Cardiopulmonary resuscitation with a novel chest compression device in a porcine model of cardiac arrest: improved hemodynamics and mechanisms. *J Am Coll Cardiol* 2004;44:2214–20.
  594. Hallstrom A, Rea TD, Sayre MR, et al. Manual chest compression vs use of an automated chest compression device during resuscitation following out-of-hospital cardiac arrest: a randomized trial. *JAMA* 2006;295:2620–8.
  595. Steinmetz J, Barnung S, Nielsen SL, Risom M, Rasmussen LS. Improved survival after an out-of-hospital cardiac arrest using new guidelines. *Acta Anaesthesiol Scand* 2008;52:908–13.
  596. Casner M, Andersen D, Isaacs SM. Preliminary report of the impact of a new CPR assist device on the rate of return of spontaneous circulation in out of hospital cardiac arrest. *PreHosp Emerg Med* 2005;9:61–7.
  597. Ong ME, Ornato JP, Edwards DP, et al. Use of an automated, load-distributing band chest compression device for out-of-hospital cardiac arrest resuscitation. *JAMA* 2006;295:2629–37.
  598. Paradis N, Young G, Lemeshow S, Brewer J, Halperin H. Inhomogeneity and temporal effects in AutoPulse Assisted Prehospital International Resuscitation—an exception from consent trial terminated early. *Am J Emerg Med* 2010;28:391–8.
  599. Tomte O, Sunde K, Lorentz T, et al. Advanced life support performance with manual and mechanical chest compressions in a randomized, multicentre manikin study. *Resuscitation* 2009;80:1152–7.
  600. Wirth S, Korner M, Treitl M, et al. Computed tomography during cardiopulmonary resuscitation using automated chest compression devices—an initial study. *Eur Radiol* 2009;19:1857–66.
  601. Holmstrom P, Boyd J, Sorsa M, Kuusma M. A case of hypothermic cardiac arrest treated with an external chest compression device (LUCAS) during transport to re-warming. *Resuscitation* 2005;67:139–41.
  602. Wik L, Kili S. Use of an automatic mechanical chest compression device (LUCAS) as a bridge to establishing cardiopulmonary bypass for a patient with hypothermic cardiac arrest. *Resuscitation* 2005;66:391–4.
  603. Sunde K, Wik L, Steen PA. Quality of mechanical, manual standard and active compression–decompression CPR on the arrest site and during transport in a manikin model. *Resuscitation* 1997;34:235–42.
  604. Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. *JAMA* 1962;182:548–55.
  605. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). *J Am Coll Cardiol* 2006;48:e247–346.
  606. Deakin CD, Morrison LJ, Morley PT, et al. 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 8: advanced life support. *Resuscitation*; doi:10.1016/j.resuscitation.2010.08.027, in press.
  607. Manz M, Pfeiffer D, Jung W, Lueritz B. Intravenous treatment with magnesium in recurrent persistent ventricular tachycardia. *New Trends Arrhythmias* 1991;7:437–42.
  608. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. *Circulation* 1988;77:392–7.
  609. Delacretaz E. Clinical practice. Supraventricular tachycardia. *N Engl J Med* 2006;354:1039–51.
  610. DiMarco JP, Miles W, Akhtar M, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil: assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group [published correction appears in *Ann Intern Med*. 1990; 113:996]. *Ann Intern Med* 1990;113:104–10.
  611. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006;114:e257–354.
  612. Sticherling C, Tada H, Hsu W, et al. Effects of diltiazem and esmolol on cycle length and spontaneous conversion of atrial fibrillation. *J Cardiovasc Pharmacol Ther* 2002;7:81–8.
  613. Shettigar UR, Toole JG, Appunni DO. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. *Am Heart J* 1993;126:368–74.
  614. Demircan C, Cikrikci HI, Engindeniz Z, et al. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. *Emerg Med J* 2005;22:411–4.
  615. Wattanasuwan N, Khan IA, Mehta NJ, et al. Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. *Chest* 2001;119:502–6.
  616. Davey MJ, Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. *Ann Emerg Med* 2005;45:347–53.
  617. Chiladakis JA, Stathopoulos C, Davlouros P, Manolis AS. Intravenous magnesium sulfate versus diltiazem in paroxysmal atrial fibrillation. *Int J Cardiol* 2001;79:287–91.
  618. Dauchot P, Gravenstein JS. Effects of atropine on the electrocardiogram in different age groups. *Clin Pharmacol Ther* 1971;12:274–80.
  619. Chamberlain DA, Turner P, Sneddon JM. Effects of atropine on heart-rate in healthy man. *Lancet* 1967;2:12–5.
  620. Bernheim A, Fatio R, Kiowski W, Weilenmann D, Rickli H, Rocca HP. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. *Transplantation* 2004;77:1181–5.
  621. Klumbies A, Paliege R, Volkmann H. Mechanical emergency stimulation in asystole and extreme bradycardia. *Z Gesamte Inn Med* 1988;43:348–52.
  622. Zeh E, Rahner E. The manual extrathoracic stimulation of the heart. Technique and effect of the precordial thump (author's transl). *Z Kardiol* 1978;67:299–304.
  623. Chan L, Reid C, Taylor B. Effect of three emergency pacing modalities on cardiac output in cardiac arrest due to ventricular asystole. *Resuscitation* 2002;52:117–9.
  624. Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. *N Engl J Med* 1991;325:1621–9.
  625. Wang HE, O'Connor RE, Megargel RE, et al. The use of diltiazem for treating rapid atrial fibrillation in the out-of-hospital setting. *Ann Emerg Med* 2001;37:38–45.
  626. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. *Am J Cardiol* 2000;86:950–3.
  627. Kalus JS, Spencer AP, Tsikouris JP, et al. Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. *Am J Health Syst Pharm* 2003;60:2308–12.
  628. Nolan JP, Neumar RW, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. *Resuscitation* 2008;79:350–79.
  629. Sunde K, Pytte M, Jacobsen D, et al. Implementation of a standardised treatment protocol for post resuscitation care after out-of-hospital cardiac arrest. *Resuscitation* 2007;73:29–39.
  630. Gaieski DF, Band RA, Abella BS, et al. Early goal-directed hemodynamic optimization combined with therapeutic hypothermia in comatose survivors of out-of-hospital cardiac arrest. *Resuscitation* 2009;80:418–24.
  631. Carr BG, Goyal M, Band RA, et al. A national analysis of the relationship between hospital factors and post-cardiac arrest mortality. *Intensive Care Med* 2009;35:505–11.
  632. Oddo M, Schaller MD, Feihl F, Ribordy V, Liaudet L. From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest. *Crit Care Med* 2006;34:1865–73.
  633. Knafelj R, Radsel P, Ploj T, Noc M. Primary percutaneous coronary intervention and mild induced hypothermia in comatose survivors of ventricular fibrillation with ST-elevation acute myocardial infarction. *Resuscitation* 2007;74:227–34.
  634. Nolan JP, Laver SR, Welch CA, Harrison DA, Gupta V, Rowan K. Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database. *Anaesthesia* 2007;62:1207–16.
  635. Keenan SP, Dodek P, Martin C, Priestap F, Norena M, Wong H. Variation in length of intensive care unit stay after cardiac arrest: where you are is as important as who you are. *Crit Care Med* 2007;35:836–41.
  636. Carr BG, Kahn JM, Merchant RM, Kramer AA, Neumar RW. Inter-hospital variability in post-cardiac arrest mortality. *Resuscitation* 2009;80:30–4.



637. Niskanen M, Reinikainen M, Kurola J. Outcome from intensive care after cardiac arrest: comparison between two patient samples treated in 1986–87 and 1999–2001 in Finnish ICUs. *Acta Anaesthesiol Scand* 2007;51:151–7.
638. Hovdenes J, Laake JH, Aaberge L, Haugaa H, Bugge JF. Therapeutic hypothermia after out-of-hospital cardiac arrest: experiences with patients treated with percutaneous coronary intervention and cardiogenic shock. *Acta Anaesthesiol Scand* 2007;51:137–42.
639. Soar J, Mancini ME, Bhanji F, et al. 2010 International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 12: education, implementation, and teams. *Resuscitation*; doi:10.1016/j.resuscitation.2010.08.030, in press.
640. Laver S, Farrow C, Turner D, Nolan J. Mode of death after admission to an intensive care unit following cardiac arrest. *Intensive Care Med* 2004;30:2126–8.
641. Laurent I, Monchi M, Chiche JD, et al. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. *J Am Coll Cardiol* 2002;40:2110–6.
642. Ruiz-Bailen M, Aguayo de Hoyos E, Ruiz-Navarro S, et al. Reversible myocardial dysfunction after cardiopulmonary resuscitation. *Resuscitation* 2005;66:175–81.
643. Cerchiari EL, Safar P, Klein E, Diven W. Visceral, hematologic and bacteriologic changes and neurologic outcome after cardiac arrest in dogs. The vascular post-resuscitation syndrome. *Resuscitation* 1993;25:119–36.
644. Adrie C, Monchi M, Laurent I, et al. Coagulopathy after successful cardiopulmonary resuscitation following cardiac arrest: implication of the protein C anticoagulant pathway. *J Am Coll Cardiol* 2005;46:21–8.
645. Adrie C, Adib-Conquy M, Laurent I, et al. Successful cardiopulmonary resuscitation after cardiac arrest as a “sepsis-like” syndrome. *Circulation* 2002;106:562–8.
646. Adrie C, Laurent I, Monchi M, Cariou A, Dhainau JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? *Curr Opin Crit Care* 2004;10:208–12.
647. Zwemer CF, Whitesall SE, D'Alecy LG. Cardiopulmonary-cerebral resuscitation with 100% oxygen exacerbates neurological dysfunction following nine minutes of normothermic cardiac arrest in dogs. *Resuscitation* 1994;27:159–70.
648. Richards EM, Fiskum G, Rosenthal RE, Hopkins I, McKenna MC. Hyperoxic reperfusion after global ischemia decreases hippocampal energy metabolism. *Stroke* 2007;38:1578–84.
649. Vereczki V, Martin E, Rosenthal RE, Hof PR, Hoffman GE, Fiskum G. Normoxic resuscitation after cardiac arrest protects against hippocampal oxidative stress, metabolic dysfunction, and neuronal death. *J Cereb Blood Flow Metab* 2006;26:821–35.
650. Liu Y, Rosenthal RE, Haywood Y, Miljkovic-Lolic M, Vanderhoeck JY, Fiskum G. Normoxic ventilation after cardiac arrest reduces oxidation of brain lipids and improves neurological outcome. *Stroke* 1998;29:1679–86.
651. Menon DK, Coles JP, Gupta AK, et al. Diffusion limited oxygen delivery following head injury. *Crit Care Med* 2004;32:1384–90.
652. Buunk G, van der Hoeven JG, Meinders AE. Cerebrovascular reactivity in comatose patients resuscitated from a cardiac arrest. *Stroke* 1997;28:1569–73.
653. Buunk G, van der Hoeven JG, Meinders AE. A comparison of near-infrared spectroscopy and jugular bulb oximetry in comatose patients resuscitated from a cardiac arrest. *Anaesthesia* 1998;53:13–9.
654. Roine RO, Launes J, Nikkinen P, Lindroth L, Kaste M. Regional cerebral blood flow after human cardiac arrest. A hexamethylpropyleneamine oxime single photon emission computed tomographic study. *Arch Neurol* 1991;48:625–9.
655. Beckstead JE, Tweed WA, Lee J, MacKeen WL. Cerebral blood flow and metabolism in man following cardiac arrest. *Stroke* 1978;9:569–73.
656. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. *Circulation* 2001;104:2158–63.
657. Pell JP, Sirel JM, Marsden AK, Ford I, Walker NL, Cobbe SM. Presentation, management, and outcome of out of hospital cardiopulmonary arrest: comparison by underlying aetiology. *Heart* 2003;89:839–42.
658. Zipes DP, Wellens HJ. Sudden cardiac death. *Circulation* 1998;98:2334–51.
659. Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. *N Engl J Med* 1997;336:1629–33.
660. Bendz B, Eritsland J, Nakstad AR, et al. Long-term prognosis after out-of-hospital cardiac arrest and primary percutaneous coronary intervention. *Resuscitation* 2004;63:49–53.
661. Keelan PC, Bunch TJ, White RD, Packer DL, Holmes Jr DR. Early direct coronary angioplasty in survivors of out-of-hospital cardiac arrest. *Am J Cardiol* 2003;91:1461–3. A6.
662. Quintero-Moran B, Moreno R, Villarreal S, et al. Percutaneous coronary intervention for cardiac arrest secondary to ST-elevation acute myocardial infarction. Influence of immediate paramedical/medical assistance on clinical outcome. *J Invasive Cardiol* 2006;18:269–72.
663. Garot P, Lefevre T, Eltchaninoff H, et al. Six-month outcome of emergency percutaneous coronary intervention in resuscitated patients after cardiac arrest complicating ST-elevation myocardial infarction. *Circulation* 2007;115:1354–62.
664. Nagao K, Hayashi N, Kanmatsuse K, et al. Cardiopulmonary cerebral resuscitation using emergency cardiopulmonary bypass, coronary reperfusion therapy and mild hypothermia in patients with cardiac arrest outside the hospital. *J Am Coll Cardiol* 2000;36:776–83.
665. Nielsen N, Hovdenes J, Nilsson F, et al. Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. *Acta Anaesthesiol Scand* 2009;53:926–34.
666. Wolfrum S, Pierau C, Radke PW, Schunkert H, Kurowski V. Mild therapeutic hypothermia in patients after out-of-hospital cardiac arrest due to acute ST-segment elevation myocardial infarction undergoing immediate percutaneous coronary intervention. *Crit Care Med* 2008;36:1780–6.
667. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001;345:1368–77.
668. Mullner M, Sterz F, Binder M, et al. Arterial blood pressure after human cardiac arrest and neurological recovery. *Stroke* 1996;27:59–62.
- 668a. Trzeciak S, Jones AE, Kilgannon JH, et al. Significance of arterial hypotension after resuscitation from cardiac arrest. *Crit Care Med* 2009;37:2895–903.
669. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med* 2002;346:557–63.
670. Angelos MG, Ward KR, Hobson J, Beckley PD. Organ blood flow following cardiac arrest in a swine low-flow cardiopulmonary bypass model. *Resuscitation* 1994;27:245–54.
671. Sakabe T, Tateishi A, Miyauchi Y, et al. Intracranial pressure following cardiopulmonary resuscitation. *Intensive Care Med* 1987;13:256–9.
672. Morimoto Y, Kemmotsu O, Kitami K, Matsubara I, Tedo I. Acute brain swelling after out-of-hospital cardiac arrest: pathogenesis and outcome. *Crit Care Med* 1993;21:104–10.
673. Nishizawa H, Kudoh I. Cerebral autoregulation is impaired in patients resuscitated after cardiac arrest. *Acta Anaesthesiol Scand* 1996;40:1149–53.
674. Sundgreen C, Larsen FS, Herzog TM, Knudsen GM, Boesgaard S, Aldershvile J. Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. *Stroke* 2001;32:128–32.
675. Ely EW, Trueman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003;289:2983–91.
676. De Jonghe B, Cook D, Appere-De-Vecchi C, Guyatt G, Meade M, Outin H. Using and understanding sedation scoring systems: a systematic review. *Intensive Care Med* 2000;26:275–85.
677. Snyder BD, Hauser WA, Loewenson RB, Leppik IE, Ramirez-Lassepas M, Gumnit RJ. Neurologic prognosis after cardiopulmonary arrest. III: seizure activity. *Neurology* 1980;30:1292–7.
678. Levy DE, Caronna JJ, Singer BH, Lapinski RH, Frydman H, Plum F. Predicting outcome from hypoxic-ischemic coma. *JAMA* 1985;253:1420–6.
679. Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. *Neurology* 1988;38:401–5.
680. Zandbergen EG, Hijdra A, Koelman JH, et al. Prediction of poor outcome within the first 3 days of postanoxic coma. *Neurology* 2006;66:62–8.
681. Ingvar M. Cerebral blood flow and metabolic rate during seizures. Relationship to epileptic brain damage. *Ann NY Acad Sci* 1986;462:194–206.
682. Caviness JN, Brown P. Myoclonus: current concepts and recent advances. *Lancet Neurol* 2004;3:598–607.
683. Losert H, Sterz F, Roine RO, et al. Strict normoglycaemic blood glucose levels in the therapeutic management of patients within 12 h after cardiac arrest might not be necessary. *Resuscitation* 2007.
684. Skrifvars MB, Saarinen K, Ikola K, Kuusma M. Improved survival after in-hospital cardiac arrest outside critical care areas. *Acta Anaesthesiol Scand* 2005;49:1534–9.
685. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001;345:1359–67.
686. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006;354:449–61.
687. Oksanen T, Skrifvars MB, Varpula T, et al. Strict versus moderate glucose control after resuscitation from ventricular fibrillation. *Intensive Care Med* 2007;33:2093–100.
688. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009;360:1283–97.
689. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med* 2009;35:1738–48.
690. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ* 2009;180:821–7.
691. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. *JAMA* 2008;300:933–44.
692. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. *Crit Care Med* 2007;35:2262–7.
693. Meyfroidt G, Keenan DM, Wang X, Wouters PJ, Veldhuis JD, Van den Berghe G. Dynamic characteristics of blood glucose time series during the course of critical illness: effects of intensive insulin therapy and relative association with mortality. *Crit Care Med* 2010;38:1021–9.
694. Padkin A. Glucose control after cardiac arrest. *Resuscitation* 2009;80:611–2.
695. Takino M, Okada Y. Hyperthermia following cardiopulmonary resuscitation. *Intensive Care Med* 1991;17:419–20.
696. Hickey RW, Kochanek PM, Ferimer H, Alexander HL, Garman RH, Graham SH. Induced hyperthermia exacerbates neurologic neuronal histologic damage after asphyxial cardiac arrest in rats. *Crit Care Med* 2003;31:531–5.
697. Takasu A, Saitoh D, Kaneko N, Sakamoto T, Okada Y. Hyperthermia: is it an ominous sign after cardiac arrest? *Resuscitation* 2001;49:273–7.
698. Zeiner A, Holzer M, Sterz F, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. *Arch Intern Med* 2001;161:2007–12.
699. Hickey RW, Kochanek PM, Ferimer H, Graham SH, Safar P. Hypothermia and hyperthermia in children after resuscitation from cardiac arrest. *Pediatrics* 2000;106:118–22.

700. Diringner MN, Reaven NL, Funk SE, Uman GC. Elevated body temperature independently contributes to increased length of stay in neurologic intensive care unit patients. *Crit Care Med* 2004;32:1489–95.
701. Gunn AJ, Thoresen M. Hypothermic neuroprotection. *NeuroRx* 2006;3:154–69.
702. Froehler MT, Geocadin RG. Hypothermia for neuroprotection after cardiac arrest: mechanisms, clinical trials and patient care. *J Neurol Sci* 2007;261:118–26.
703. McCullough JN, Zhang N, Reich DL, et al. Cerebral metabolic suppression during hypothermic circulatory arrest in humans. *Ann Thorac Surg* 1999;67:1895–9 [discussion 919–21].
704. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. *N Engl J Med* 2002;346:549–56.
705. Belliard G, Catez E, Charron C, et al. Efficacy of therapeutic hypothermia after out-of-hospital cardiac arrest due to ventricular fibrillation. *Resuscitation* 2007;75:252–9.
706. Castrejon S, Cortes M, Salto ML, et al. Improved prognosis after using mild hypothermia to treat cardiorespiratory arrest due to a cardiac cause: comparison with a control group. *Rev Esp Cardiol* 2009;62:733–41.
707. Bro-Jeppesen J, Kjaergaard J, Horsted TI, et al. The impact of therapeutic hypothermia on neurological function and quality of life after cardiac arrest. *Resuscitation* 2009;80:171–6.
708. Hachimi-Idrissi S, Corne L, Ebinger G, Michotte Y, Huyghens L. Mild hypothermia induced by a helmet device: a clinical feasibility study. *Resuscitation* 2001;51:275–81.
709. Bernard SA, Jones BM, Horne MK. Clinical trial of induced hypothermia in comatose survivors of out-of-hospital cardiac arrest. *Ann Emerg Med* 1997;30:146–53.
710. Busch M, Soreide E, Lossius HM, Lexow K, Dickstein K. Rapid implementation of therapeutic hypothermia in comatose out-of-hospital cardiac arrest survivors. *Acta Anaesthesiol Scand* 2006;50:1277–83.
711. Storm C, Steffen I, Scheffold JC, et al. Mild therapeutic hypothermia shortens intensive care unit stay of survivors after out-of-hospital cardiac arrest compared to historical controls. *Crit Care* 2008;12:R78.
712. Don CW, Longstreth Jr WT, Maynard C, et al. Active surface cooling protocol to induce mild therapeutic hypothermia after out-of-hospital cardiac arrest: a retrospective before-and-after comparison in a single hospital. *Crit Care Med* 2009;37:3062–9.
713. Arrich J. Clinical application of mild therapeutic hypothermia after cardiac arrest. *Crit Care Med* 2007;35:1041–7.
714. Holzer M, Mullner M, Sterz F, et al. Efficacy and safety of endovascular cooling after cardiac arrest: cohort study and Bayesian approach. *Stroke* 2006;37:1792–7.
715. Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. *Crit Care Med* 2009;37:1101–20.
716. Bernard S, Buist M, Monteiro O, Smith K. Induced hypothermia using large volume, ice-cold intravenous fluid in comatose survivors of out-of-hospital cardiac arrest: a preliminary report. *Resuscitation* 2003;56:9–13.
717. Virkkunen I, Yli-Hankala A, Silfvast T. Induction of therapeutic hypothermia after cardiac arrest in prehospital patients using ice-cold Ringer's solution: a pilot study. *Resuscitation* 2004;62:299–302.
718. Kliegel A, Losert H, Sterz F, et al. Cold simple intravenous infusions preceding special endovascular cooling for faster induction of mild hypothermia after cardiac arrest—a feasibility study. *Resuscitation* 2005;64:347–51.
719. Kliegel A, Janata A, Wandaller C, et al. Cold infusions alone are effective for induction of therapeutic hypothermia but do not keep patients cool after cardiac arrest. *Resuscitation* 2007;73:46–53.
720. Kilgannon JH, Roberts BW, Stauss M, et al. Use of a standardized order set for achieving target temperature in the implementation of therapeutic hypothermia after cardiac arrest: a feasibility study. *Acad Emerg Med* 2008;15:499–505.
721. Scott BD, Hogue T, Fixley MS, Adamson PB. Induced hypothermia following out-of-hospital cardiac arrest; initial experience in a community hospital. *Clin Cardiol* 2006;29:525–9.
722. Kim F, Olsufka M, Carlsson D, et al. Pilot study of rapid infusion of 2 L of 4 degrees C normal saline for induction of mild hypothermia in hospitalized, comatose survivors of out-of-hospital cardiac arrest. *Circulation* 2005;112:715–9.
723. Jacobshagen C, Pax A, Unsold BW, et al. Effects of large volume, ice-cold intravenous fluid infusion on respiratory function in cardiac arrest survivors. *Resuscitation* 2009;80:1223–8.
724. Spiel AO, Kliegel A, Janata A, et al. Hemostasis in cardiac arrest patients treated with mild hypothermia initiated by cold fluids. *Resuscitation* 2009;80:762–5.
725. Larsson IM, Wallin E, Rubertsson S. Cold saline infusion and ice packs alone are effective in inducing and maintaining therapeutic hypothermia after cardiac arrest. *Resuscitation* 2010;81:15–9.
726. Skulec R, Kovarnik T, Dostalova G, Kolar J, Linhart A. Induction of mild hypothermia in cardiac arrest survivors presenting with cardiogenic shock syndrome. *Acta Anaesthesiol Scand* 2008;52:188–94.
727. Hoedemaekers CW, Ezzahiti M, Gerritsen A, van der Hoeven JG. Comparison of cooling methods to induce and maintain normo- and hypothermia in intensive care unit patients: a prospective intervention study. *Crit Care* 2007;11:R91.
728. Kim F, Olsufka M, Longstreth Jr WT, et al. Pilot randomized clinical trial of prehospital induction of mild hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4 degrees C normal saline. *Circulation* 2007;115:3064–70.
729. Kamarainen A, Virkkunen I, Tenhunen J, Yli-Hankala A, Silfvast T. Prehospital therapeutic hypothermia for comatose survivors of cardiac arrest: a randomized controlled trial. *Acta Anaesthesiol Scand* 2009;53:900–7.
730. Kamarainen A, Virkkunen I, Tenhunen J, Yli-Hankala A, Silfvast T. Induction of therapeutic hypothermia during prehospital CPR using ice-cold intravenous fluid. *Resuscitation* 2008;79:205–11.
731. Hammer L, Vitrat F, Savary D, et al. Immediate prehospital hypothermia protocol in comatose survivors of out-of-hospital cardiac arrest. *Am J Emerg Med* 2009;27:570–3.
732. Aberle J, Kluge S, Prohl J, et al. Hypothermia after CPR through conduction and convection—initial experience on an ICU. *Intensivmed Notfallmed* 2006;43:37–43.
733. Feuchtl A, Gockel B, Lawrenz T, Bartelsmeier M, Stellbrink C. Endovascular cooling improves neurological short-term outcome after prehospital cardiac arrest. *Intensivmedizin* 2007;44:37–42.
734. Fries M, Stoppe C, Brucken D, Rossaint R, Kuhlen R. Influence of mild therapeutic hypothermia on the inflammatory response after successful resuscitation from cardiac arrest. *J Crit Care* 2009;24:453–7.
735. Benson DW, Williams Jr GR, Spencer FC, Yates AJ. The use of hypothermia after cardiac arrest. *Anesth Analg* 1959;38:423–8.
736. Yanagawa Y, Ishihara S, Norio H, et al. Preliminary clinical outcome study of mild resuscitative hypothermia after out-of-hospital cardiopulmonary arrest. *Resuscitation* 1998;39:61–6.
737. Damian MS, Ellenberg D, Gildemeister R, et al. Coenzyme Q10 combined with mild hypothermia after cardiac arrest: a preliminary study. *Circulation* 2004;110:3011–6.
738. Hay AW, Swann DG, Bell K, Walsh TS, Cook B. Therapeutic hypothermia in comatose patients after out-of-hospital cardiac arrest. *Anaesthesia* 2008;63:15–9.
739. Zeiner A, Holzer M, Sterz F, et al. Mild resuscitative hypothermia to improve neurological outcome after cardiac arrest. A clinical feasibility trial. *Hypothermia After Cardiac Arrest (HACA) Study Group. Stroke* 2000;31:86–94.
740. Uray T, Malzer R. Out-of-hospital surface cooling to induce mild hypothermia in human cardiac arrest: a feasibility trial. *Resuscitation* 2008;77:331–8.
- 740a. Castren M, Nordberg P, Svensson L, et al. Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness). *Circulation* 2010;122:729–36.
741. Felberg RA, Krieger DW, Chuang R, et al. Hypothermia after cardiac arrest: feasibility and safety of an external cooling protocol. *Circulation* 2001;104:1799–804.
742. Flint AC, Hemphill JC, Bonovich DC. Therapeutic hypothermia after cardiac arrest: performance characteristics and safety of surface cooling with or without endovascular cooling. *Neurocrit Care* 2007;7:109–18.
743. Heard KJ, Peberdy MA, Sayre MR, et al. A randomized controlled trial comparing the Arctic Sun to standard cooling for induction of hypothermia after cardiac arrest. *Resuscitation* 2010;81:9–14.
744. Merchant RM, Abella BS, Peberdy MA, et al. Therapeutic hypothermia after cardiac arrest: unintentional overcooling is common using ice packs and conventional cooling blankets. *Crit Care Med* 2006;34:S490–4.
745. Haugk M, Sterz F, Grassberger M, et al. Feasibility and efficacy of a new non-invasive surface cooling device in post-resuscitation intensive care medicine. *Resuscitation* 2007;75:76–81.
746. Al-Senani FM, Graffagnino C, Grotta JC, et al. A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolGard System and Icy catheter following cardiac arrest. *Resuscitation* 2004;62:143–50.
747. Pichon N, Amiel JB, Francois B, Dugard A, Etchecopar C, Vignon P. Efficacy of and tolerance to mild induced hypothermia after out-of-hospital cardiac arrest using an endovascular cooling system. *Crit Care* 2007;11:R71.
748. Wolff B, Machill K, Schumacher D, Schulzki I, Werner D. Early achievement of mild therapeutic hypothermia and the neurologic outcome after cardiac arrest. *Int J Cardiol* 2009;133:223–8.
749. Nagao K, Kikushima K, Watanabe K, et al. Early induction of hypothermia during cardiac arrest improves neurological outcomes in patients with out-of-hospital cardiac arrest who undergo emergency cardiopulmonary bypass and percutaneous coronary intervention. *Circ J* 2010;74:77–85.
750. Mahmood MA, Zweifler RM. Progress in shivering control. *J Neurol Sci* 2007;261:47–54.
751. Wadhwa A, Sengupta P, Durrani J, et al. Magnesium sulphate only slightly reduces the shivering threshold in humans. *Br J Anaesth* 2005;94:756–62.
752. Kuboyama K, Safar P, Radovsky A, et al. Delay in cooling negates the beneficial effect of mild resuscitative cerebral hypothermia after cardiac arrest in dogs: a prospective, randomized study. *Crit Care Med* 1993;21:1348–58.
753. Riter HG, Brooks LA, Pretorius AM, Ackermann LW, Kerber RE. Intra-arrest hypothermia: both cold liquid ventilation with perfluorocarbons and cold intravenous saline rapidly achieve hypothermia, but only cold liquid ventilation improves resumption of spontaneous circulation. *Resuscitation* 2009;80:561–6.
754. Staffey KS, Dendi R, Brooks LA, et al. Liquid ventilation with perfluorocarbons facilitates resumption of spontaneous circulation in a swine cardiac arrest model. *Resuscitation* 2008;78:77–84.
755. Polderman KH, Peerdeman SM, Girbes AR. Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury. *J Neurosurg* 2001;94:697–705.
756. Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. *Crit Care Med* 2007;35:2196–204.

757. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial I Study Group. *N Engl J Med* 1986;314:397–403.
758. Grafton ST, Longstreth Jr WT. Steroids after cardiac arrest: a retrospective study with concurrent, nonrandomized controls. *Neurology* 1988;38:1315–6.
759. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. *Arch Intern Med* 2009;169:15–24.
760. Gueugniaud PY, Gaussorgues P, Garcia-Darennes F, et al. Early effects of nimodipine on intracranial and cerebral perfusion pressures in cerebral anoxia after out-of-hospital cardiac arrest. *Resuscitation* 1990;20:203–12.
761. Roine RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation: a placebo-controlled, double-blind, randomized trial. *JAMA* 1990;264:3171–7.
762. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group. *N Engl J Med* 1991;324:1225–31.
763. Laurent I, Adrie C, Vinsonneau C, et al. High-volume hemofiltration after out-of-hospital cardiac arrest: a randomized study. *J Am Coll Cardiol* 2005;46:432–7.
764. Edgren E, Hedstrand U, Nordin M, Rydin E, Ronquist G. Prediction of outcome after cardiac arrest. *Crit Care Med* 1987;15:820–5.
765. Young GB, Doig G, Ragazzoni A. Anoxic-ischemic encephalopathy: clinical and electrophysiological associations with outcome. *Neurocrit Care* 2005;2:159–64.
766. Al Thenayan E, Savard M, Sharpe M, Norton L, Young B. Predictors of poor neurologic outcome after induced mild hypothermia following cardiac arrest. *Neurology* 2008;71:1535–7.
767. Wijdevicks EF, Parisi JE, Sharbrough FW. Prognostic value of myoclonus status in comatose survivors of cardiac arrest. *Ann Neurol* 1994;35:239–43.
768. Thomke F, Marx JJ, Sauer O, et al. Observations on comatose survivors of cardiopulmonary resuscitation with generalized myoclonus. *BMC Neurol* 2005;5:14.
769. Arnoldus EP, Lammers GJ. Postanoxic coma: good recovery despite myoclonus status. *Ann Neurol* 1995;38:697–8.
770. Celesia GG, Grigg MM, Ross E. Generalized status myoclonicus in acute anoxic and toxic-metabolic encephalopathies. *Arch Neurol* 1988;45:781–4.
771. Morris HR, Howard RS, Brown P. Early myoclonic status and outcome after cardiorespiratory arrest. *J Neurol Neurosurg Psychiatry* 1998;64:267–8.
772. Datta S, Hart GK, Opdam H, Gutteridge G, Archer J. Post-hypoxic myoclonic status: the prognosis is not always hopeless. *Crit Care Resusc* 2009;11:39–41.
773. English WA, Giffin NJ, Nolan JP. Myoclonus after cardiac arrest: pitfalls in diagnosis and prognosis. *Anaesthesia* 2009;64:908–11.
774. Wijdevicks EF, Hijdra A, Young GB, Bassetti CL, Wiebe S. Practice parameter: prediction of outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006;67:203–10.
775. Zandbergen EG, de Haan RJ, Hijdra A. Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage. *Intensive Care Med* 2001;27:1661–7.
776. Grubb NR, Simpson C, Sherwood R, et al. Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. *Heart* 2007.
777. Martens P. Serum neuron-specific enolase as a prognostic marker for irreversible brain damage in comatose cardiac arrest survivors. *Acad Emerg Med* 1996;3:126–31.
778. Meynaar IA, Straaten HM, van der Wetering J, et al. Serum neuron-specific enolase predicts outcome in post-anoxic coma: a prospective cohort study. *Intensive Care Med* 2003;29:189–95.
779. Rech TH, Vieira SR, Nagel F, Brauner JS, Scalco R. Serum neuron-specific enolase as early predictor of outcome after in-hospital cardiac arrest: a cohort study. *Crit Care* 2006;10:R133.
780. Reisinger J, Hollinger K, Lang W, et al. Prediction of neurological outcome after cardiopulmonary resuscitation by serial determination of serum neuron-specific enolase. *Eur Heart J* 2007;28:52–8.
781. Schoerhuber W, Kittler H, Sterz F, et al. Time course of serum neuron-specific enolase. A predictor of neurological outcome in patients resuscitated from cardiac arrest. *Stroke* 1999;30:1598–603.
782. Bottiger BW, Mobes S, Glatzer R, et al. Astroglial protein S-100 is an early and sensitive marker of hypoxic brain damage and outcome after cardiac arrest in humans. *Circulation* 2001;103:2694–8.
783. Fogel W, Krieger D, Veith M, et al. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest. *Crit Care Med* 1997;25:1133–8.
784. Martens P, Raabe A, Johnsson P. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia. *Stroke* 1998;29:2363–6.
785. Prohl J, Rother J, Kluge S, et al. Prediction of short-term and long-term outcomes after cardiac arrest: a prospective multivariate approach combining biochemical, clinical, electrophysiological, and neuropsychological investigations. *Crit Care Med* 2007;35:1230–7.
786. Stelzl T, von Bose MJ, Hög B, Fuchs HH, Flugel KA. A comparison of the prognostic value of neuron-specific enolase serum levels and somatosensory evoked potentials in 13 reanimated patients. *Eur J Emerg Med* 1995;2:24–7.
787. Tiainen M, Roine RO, Pettila V, Takkunen O. Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia. *Stroke* 2003;34:2881–6.
788. Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR. Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. *Resuscitation* 2005;65:49–55.
789. Roine RO, Somer H, Kaste M, Viinikka L, Karonen SL. Neurological outcome after out-of-hospital cardiac arrest. Prediction by cerebrospinal fluid enzyme analysis. *Arch Neurol* 1989;46:753–6.
790. Zingler VC, Krumm B, Bertsch T, Fassbender K, Pohlmann-Eden B. Early prediction of neurological outcome after cardiopulmonary resuscitation: a multimodal approach combining neurobiochemical and electrophysiological investigations may provide high prognostic certainty in patients after cardiac arrest. *Eur Neurol* 2003;49:79–84.
791. Rosen H, Sunnerhagen KS, Herlitz J, Blomstrand C, Rosengren L. Serum levels of the brain-derived proteins S-100 and NSE predict long-term outcome after cardiac arrest. *Resuscitation* 2001;49:183–91.
792. Dauberschmidt R, Zinsmeyer J, Mrochen H, Meyer M. Changes of neuron-specific enolase concentration in plasma after cardiac arrest and resuscitation. *Mol Chem Neuropathol* 1991;14:237–45.
793. Mussack T, Biberthaler P, Kanz KG, et al. Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. *Crit Care Med* 2002;30:2669–74.
794. Fries M, Kunz D, Gressner AM, Rossaint R, Kühlen R. Procalcitonin serum levels after out-of-hospital cardiac arrest. *Resuscitation* 2003;59:105–9.
795. Hachimi-Idrissi S, Van der Auwera M, Schietecatte J, Ebinger G, Michotte Y, Huyghens L. S-100 protein as early predictor of regaining consciousness after out of hospital cardiac arrest. *Resuscitation* 2002;53:251–7.
796. Piazza O, Cotena S, Esposito G, De Robertis E, Tufano R. S100B is a sensitive but not specific prognostic index in comatose patients after cardiac arrest. *Minerva Chir* 2005;60:477–80.
797. Rosen H, Rosengren L, Herlitz J, Blomstrand C. Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest. *Stroke* 1998;29:473–7.
798. Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Jochum M. S-100b, sE-selectin, and sP-selectin for evaluation of hypoxic brain damage in patients after cardiopulmonary resuscitation: pilot study. *World J Surg* 2001;25:539–43 [discussion 44].
799. Sodeck GH, Domanovits H, Sterz F, et al. Can brain natriuretic peptide predict outcome after cardiac arrest? An observational study. *Resuscitation* 2007;74:439–45.
800. Geppert A, Zorn G, Delle-Karth G, et al. Plasma concentrations of von Willebrand factor and intracellular adhesion molecule-1 for prediction of outcome after successful cardiopulmonary resuscitation. *Crit Care Med* 2003;31:805–11.
801. Adib-Conquy M, Monchi M, Goulenok C, et al. Increased plasma levels of soluble triggering receptor expressed on myeloid cells 1 and procalcitonin after cardiac surgery and cardiac arrest without infection. *Shock* 2007;28:406–10.
802. Longstreth Jr WT, Clayton KJ, Chandler WL, Sumi SM. Cerebrospinal fluid creatine activity and neurologic recovery after cardiac arrest. *Neurology* 1984;34:834–7.
803. Karkela J, Pasanen M, Kaukinen S, Morsky P, Harmoinen A. Evaluation of hypoxic brain injury with spinal fluid enzymes, lactate, and pyruvate. *Crit Care Med* 1992;20:378–86.
804. Rothstein T, Thomas E, Sumi S. Predicting outcome in hypoxic-ischemic coma. A prospective clinical and electrophysiological study. *Electroencephalogr Clin Neurophysiol* 1991;79:101–7.
805. Sherman AL, Tirschwell DL, Mickleson PJ, Longstreth Jr WT, Robinson LR. Somatosensory potentials. CSF creatine kinase BB activity, and awakening after cardiac arrest. *Neurology* 2000;54:889–94.
806. Longstreth Jr WT, Clayton KJ, Sumi SM. Cerebrospinal fluid and serum creatine kinase BB activity after out-of-hospital cardiac arrest. *Neurology* 1981;31:455–8.
807. Tirschwell DL, Longstreth Jr WT, Rauch-Matthews ME, et al. Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest. *Neurology* 1997;48:352–7.
808. Clemmensen P, Strandgaard S, Rasmussen S, Grande P. Cerebrospinal fluid creatine kinase isoenzyme BB levels do not predict the clinical outcome in patients unconscious following cardiac resuscitation. *Clin Cardiol* 1987;10:235–6.
809. Rosen H, Karlsson JE, Rosengren L. CSF levels of neurofilament is a valuable predictor of long-term outcome after cardiac arrest. *J Neurol Sci* 2004;221:19–24.
810. Tiainen M, Kovalainen TT, Takkunen OS, Roine RO. Somatosensory and brainstem auditory evoked potentials in cardiac arrest patients treated with hypothermia. *Crit Care Med* 2005;33:1736–40.
811. Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. *Neurology* 2009;72:744–9.
812. Rossetti AO, Logroscino G, Liaudet L, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. *Neurology* 2007;69:255–60.
813. Rossetti AO, Oddo M, Logroscino G, Kaplan PW. Prognostication after cardiac arrest and hypothermia: a prospective study. *Ann Neurol* 2010;67:301–7.
814. Oksanen T, Tiainen M, Skrifvars MB, et al. Predictive power of serum NSE and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. *Resuscitation* 2009;80:165–70.

815. Rundgren M, Karlsson T, Nielsen N, Cronberg T, Johnsson P, Friberg H. Neuron specific enolase and S-100B as predictors of outcome after cardiac arrest and induced hypothermia. *Resuscitation* 2009;80:784–9.
816. Fioux F, Losser MR, Bourgeois E, et al. Kidney retrieval after sudden out of hospital refractory cardiac arrest: a cohort of uncontrolled non heart beating donors. *Crit Care* 2009;13:R141.
817. Kootstra G. Statement on non-heart-beating donor programs. *Transplant Proc* 1995;27:2965.
818. Fondeville C, Hessheimer AJ, Ruiz A, et al. Liver transplant using donors after unexpected cardiac death: novel preservation protocol and acceptance criteria. *Am J Transplant* 2007;7:1849–55.
819. Morozumi J, Sakurai E, Matsuno N, et al. Successful kidney transplantation from donation after cardiac death using a load-distributing-band chest compression device during long warm ischemic time. *Resuscitation* 2009;80:278–80.
820. Perkins GD, Brace S, Gates S. Mechanical chest-compression devices: current and future roles. *Curr Opin Crit Care* 2010;16:203–10.
821. Engdahl J, Abrahamsson P, Bang A, Lindqvist J, Karlsson T, Herlitz J. Is hospital care of major importance for outcome after out-of-hospital cardiac arrest? Experience acquired from patients with out-of-hospital cardiac arrest resuscitated by the same Emergency Medical Service and admitted to one of two hospitals over a 16-year period in the municipality of Goteborg. *Resuscitation* 2000;43:201–11.
822. Liu JM, Yang Q, Pirralo RG, Klein JP, Aufderheide TP. Hospital variability of out-of-hospital cardiac arrest survival. *Prehosp Emerg Care* 2008;12:339–46.
823. Herlitz J, Engdahl J, Svensson L, Angquist KA, Silfverstolpe J, Holmberg S. Major differences in 1-month survival between hospitals in Sweden among initial survivors of out-of-hospital cardiac arrest. *Resuscitation* 2006;70:404–9.
824. Callaway CW, Schmicker R, Kampmeyer M, et al. Receiving hospital characteristics associated with survival after out-of-hospital cardiac arrest. *Resuscitation* 2010.
825. Davis DP, Fisher R, Aguilar S, et al. The feasibility of a regional cardiac arrest receiving system. *Resuscitation* 2007;74:44–51.
826. Spaite DW, Bobrow BJ, Vadeboncoeur TF, et al. The impact of prehospital transport interval on survival in out-of-hospital cardiac arrest: implications for regionalization of post-resuscitation care. *Resuscitation* 2008;79:61–6.
827. Spaite DW, Stiell IG, Bobrow BJ, et al. Effect of transport interval on out-of-hospital cardiac arrest survival in the OPALS Study: implications for triaging patients to specialized cardiac arrest centers. *Ann Emerg Med* 2009.
828. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. *Heart* 1999;82:426–31.
829. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory The PRAGUE study. *Eur Heart J* 2000;21:823–31.
830. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. *Eur Heart J* 2003;24:94–104.
831. Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. *N Engl J Med* 2008;358:231–40.
832. Abernathy 3rd JH, McGwin Jr G, Acker 3rd JE, Rue 3rd LW. Impact of a voluntary trauma system on mortality, length of stay, and cost at a level I trauma center. *Am Surg* 2002;68:182–92.
833. Clemmer TP, Orme Jr JF, Thomas FO, Brooks KA. Outcome of critically injured patients treated at Level I trauma centers versus full-service community hospitals. *Crit Care Med* 1985;13:861–3.
834. Culica D, Aday LA, Rohrer JE. Regionalized trauma care system in Texas: implications for redesigning trauma systems. *Med Sci Monit* 2007;13:SR9–18.
835. Hannan EL, Farrell LS, Cooper A, Henry M, Simon B, Simon R. Physiologic trauma triage criteria in adult trauma patients: are they effective in saving lives by transporting patients to trauma centers? *J Am Coll Surg* 2005;200:584–92.
836. Harrington DT, Connolly M, Biffi WL, Majercik SD, Cioffi WG. Transfer times to definitive care facilities are too long: a consequence of an immature trauma system. *Ann Surg* 2005;241:961–6 [discussion 6–8].
837. Liberman M, Mulder DS, Lavoie A, Sampalis JS. Implementation of a trauma care system: evolution through evaluation. *J Trauma* 2004;56:1330–5.
838. MacKenzie EJ, Rivara FP, Jurkovich GJ, et al. A national evaluation of the effect of trauma-center care on mortality. *N Engl J Med* 2006;354:366–78.
839. Mann NC, Cahn RM, Mullins RJ, Brand DM, Jurkovich GJ. Survival among injured geriatric patients during construction of a statewide trauma system. *J Trauma* 2001;50:1111–6.
840. Mullins RJ, Veum-Stone J, Hedges JR, et al. Influence of a statewide trauma system on location of hospitalization and outcome of injured patients. *J Trauma* 1996;40:536–45 [discussion 45–6].
841. Mullins RJ, Mann NC, Hedges JR, Worrall W, Jurkovich GJ. Preferential benefit of implementation of a statewide trauma system in one of two adjacent states. *J Trauma* 1998;44:609–16 [discussion 17].
842. Mullins RJ, Veum-Stone J, Helfand M, et al. Outcome of hospitalized injured patients after institution of a trauma system in an urban area. *JAMA* 1994;271:1919–24.
843. Mullner R, Goldberg J. An evaluation of the Illinois trauma system. *Med Care* 1978;16:140–51.
844. Mullner R, Goldberg J. Toward an outcome-oriented medical geography: an evaluation of the Illinois trauma/emergency medical services system. *Soc Sci Med* 1978;12:103–10.
845. Nathens AB, Jurkovich GJ, Rivara FP, Maier RV. Effectiveness of state trauma systems in reducing injury-related mortality: a national evaluation. *J Trauma* 2000;48:25–30 [discussion 1].
846. Nathens AB, Maier RV, Brundage SI, Jurkovich GJ, Grossman DC. The effect of interfacility transfer on outcome in an urban trauma system. *J Trauma* 2003;55:444–9.
847. Nicholl J, Turner J. Effectiveness of a regional trauma system in reducing mortality from major trauma: before and after study. *BMJ* 1997;315:1349–54.
848. Potoka DA, Schall LC, Gardner MJ, Stafford PW, Peitzman AB, Ford HR. Impact of pediatric trauma centers on mortality in a statewide system. *J Trauma* 2000;49:237–45.
849. Sampalis JS, Lavoie A, Boukas S, et al. Trauma center designation: initial impact on trauma-related mortality. *J Trauma* 1995;39:232–7 [discussion 7–9].
850. Sampalis JS, Denis R, Frechette P, Brown R, Fleischer D, Mulder D. Direct transport to tertiary trauma centers versus transfer from lower level facilities: impact on mortality and morbidity among patients with major trauma. *J Trauma* 1997;43:288–95 [discussion 95–6].
851. Nichol G, Aufderheide TP, Eigel B, et al. Regional systems of care for out-of-hospital cardiac arrest: a policy statement from the American Heart Association. *Circulation* 2010;121:709–29.
852. Nichol G, Soar J. Regional cardiac resuscitation systems of care. *Curr Opin Crit Care* 2010;16:223–30.
853. Soar J, Packham S. Cardiac arrest centres make sense. *Resuscitation* 2010;81:507–8.